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The focus of this dissertation is the study of two enzymes, DXR and HppE.  DXR 
catalyzes the first committed step in the MEP pathway, which is the pathway most 
eubacteria, archeabacteria, algae, and the plastids of plants use for the biosynthesis of 
isoprenoid.  Since mammals utilize the mevalonate pathway and isoprenoids are 
essential for survival, all enzymes in the MEP pathway are excellent antibiotic 
targets.  One antibiotic that has promise in the fight against malaria is the natural 
product fosmidomycin, whose antibiotic activity is due to its ability to bind and 
inhibit DXR.  With a deeper understanding of DXR’s catalyzed reaction, it will be 
possible to design a more sophisticated and potent antibiotic.  To probe the 
mechanism of DXR, two fluorinated substrate analogues, 3F-DXP and 4F-DXP, and 
a fluorinated product analogue, FCH2-MEP were designed and analyzed as possible 
substrates or inhibitors.  To further analyze the mechanism of DXR, a 2° [2H]-KIE 
study was conducted using the equilibrium perturbation method.  
 viii
The second enzyme this dissertation examines is HppE, which catalyzes the final 
step in the biosynthesis of the antibiotic, fosfomycin.   Fosfomycin is a clinically 
useful antibiotic for the treatment of limb-threatening diabetic foot infections and 
urinary tract infections.  Chemically speaking, HppE is unique for two reasons.  First, 
HppE’s epoxidation differs from Nature’s standard method of epoxide formation by 
alkene oxidation, where the epoxide oxygen is derived from molecular oxygen.  For 
HppE, the epoxide is formed through the dehydrogenation of a secondary alcohol; 
thus the epoxide oxygen is derived from the substrate.  Second, HppE is a unique 
member of the mononuclear non-heme iron-dependent family of enzymes.  HppE 
differs from all other mononuclear non-heme iron-dependent enzymes by requiring 
NADH and an external electron mediator for turnover but not requiring α-KG, pterin, 
ascorbate, or an internal iron-sulfur cluster.  After a study was published on the 
activity of zinc-reconstituted HppE from Streptomyces wedmorensis, the proposed 
iron and NADH dependent mechanism of HppE was reevaluated and was 
reconfirmed.  The HppE from Pseudomonas syringae (Ps-HppE) was also purified 
and was characterized biochemically and spectroscopically.  The results of [2H] and 








Table of Contents 
List of Tables ....................................................................................................... xiii 
List of Figures ...................................................................................................... xiv 
 
Chapter 1  Background and Significance.................................................................1 
1.1. The Importance of Isoprenoids .............................................................1 
1.1.1.   Mevalonate Pathway .................................................................2 
1.1.2.   Discovery of the MEP Pathway.................................................3 
1.1.2.1.  1-Deoxy-D-Xylulose 5-Phosphate Synthase (DXS) .......4 
1.1.2.2.  1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase 
  (DXR) ...........................................................................6 
1.1.2.3.  IspD, IspE and IspF.........................................................7 
1.1.2.4.  IspG.................................................................................9 
1.1.2.5.  IspH...............................................................................11 
1.2. Fosfomycin .........................................................................................12 
1.2.1.   Antibiotic activity of fosfomycin.............................................12 
1.2.2.   Fosfomycin Biosynthetic Pathway ..........................................15 
1.2.2.1.  The initial steps of the Fosfomycin Biosynthesis:  
 Fom1, Fom2 and FomC ..............................................15 
1.2.2.2.  Fom3: A new methyl transferase ..................................16 
1.2.2.3.  HppE:  A novel non-heme iron dependent enzyme ......17 
1.3. Thesis Statement .................................................................................28 
1.4. References............................................................................................31 
Chapter 2  Mechanistic Investigations of DXR with Fluorinated Analogues .......39 
2.1. Introduction..........................................................................................39 
2.2. Materials and Methods.........................................................................45 
2.2.1.   General.....................................................................................45 
2.2.2.   Cloning, Over-expression and Purification of DXR................45 
 x
2.2.3.   Cloning, Overexpression and Purification of DXS..................46 
2.2.4.   Active Site Titration of DXR...................................................46 
2.2.5.   3F-DXP and 4F-DXP Inhibition Study....................................47 
2.2.6.   Assays To Investigate Slow-Binding Inhibition ......................49 
2.2.7.   FCH2-MEP Inactivation Analysis............................................51 
2.2.8.   Test For Fluoride Elimination By 19F NMR............................52 
2.2.9.   Test Oxidation of FCH2-MEP By NADP+...............................52 
2.2.10.  FCH2-MEP Inhibition Studies ................................................53 
2.2.11.  FRET Binding Assay ..............................................................53 
2.2.12.  Synthesis of Fluorinated Analogues .......................................53 
2.3. Results and Discussion ........................................................................56 
2.3.1.   Synthesis of Fluorinated Analogues ........................................56 
2.3.2.   Inhibition Analysis of 3F-DXP and 4F-DXP...........................58 
2.3.3.   Analysis of FCH2-MEP as a DXR Inactivator.........................64 
2.3.4.   FRET Binding Analysis...........................................................66 
2.4. Conclusions..........................................................................................69 
2.5. References............................................................................................73 
Chapter 3  Secondary Kinetic Isotope Effect Study on DXR................................79 
3.1. Introduction..........................................................................................79 
3.2. Materials and Methods.........................................................................84 
3.2.1.   General.....................................................................................84 
3.2.2.   Removal of His-tag, Over-expression and Purification  
 of DXR.....................................................................................85 
3.2.3.   Synthesis of 3[2H]-DXP and 4[2H]-DXP.................................86 
3.2.4.   Determining kcat and KM for DXP, 3[2H]-DXP and  
 4[2H]-DXP ...............................................................................87 
3.2.5.   Determining Keq for the DXR Reaction Using DXP,  
 3[2H]-DXP and 4[2H]-DXP .....................................................87 
3.2.6.   Equilibrium Perturbation Experiment......................................88 
3.2.7.   Kinetic Simulations of Equilibrium Perturbation  
 Experiments ................................................................................88 
 xi
3.3. Results and Discussion .......................................................................91 
3.3.1.   Non-Competitive KIE Analysis...............................................91 
3.3.2.   Equilibrium Perturbation Experiments ....................................93 
3.4. Conclusions..........................................................................................99 
3.5. References..........................................................................................100 
Chapter 4  Reconfirmation HppE is an Iron and NAD(P)H Dependent  
 Epoxidase....................................................................................................103 
4.1. Introduction........................................................................................103 
4.2. Materials and Methods.......................................................................107 
4.2.1.   General...................................................................................107 
4.2.2.   Purification of HppE with and without Bound Metals ..........108 
4.2.3.   Bioautography Assay .............................................................109 
4.2.4.   31P NMR Spectroscopy Assay ...............................................110 
4.2.5.   NADH Stoichiometry ............................................................111 
4.2.6.   Binding Affinity of Flavin Derivatives..................................111 
4.2.7.   HPLC Activity Assay ............................................................112 
4.3. Results and Discussion ......................................................................113 
4.3.1.   Enzyme Activity Determined by Bioautography Assay........113 
4.3.2.   Enzyme Activity Determined by NMR Spectroscopy...........116 
4.3.3.   Enzyme Activity Determined by the HPLC Assay................117 
4.3.4.   NADH Dependence of HppE Activity ..................................118 
4.3.5.   Binding of Flavin Cofactors...................................................119 
4.3.6.   Electron Mediators.................................................................122 
4.4. Conclusions........................................................................................124 
4.5. References..........................................................................................126 
Chapter 5  PURIFICATION, CHARACTERIZATION AND A KINETIC ISOTOPE EFFECT 
ANALYSIS 
  OF THE HPPE FROM PSEUDOMONAS SYRINGAE ..........................................130 
5.1. Introduction........................................................................................130 
5.2. Materials and Methods.......................................................................138 
 xii
5.2.1.   General...................................................................................138 
5.2.2.   Materials ................................................................................138 
5.2.3.   Synthesis of Deuterium Labeled HPP Analogues .................140 
5.2.4.   Construction of Expression Plasmid for the Ps-HppE  
 Gene .......................................................................................140 
5.2.5.   Growth of E. coli BL21(DE3)/pLH01 Cells..........................140 
5.2.6.   Purification of Recombinant Apo- Ps-HppE .........................141 
5.2.7.   Molecular Mass Determination..............................................142 
5.2.8.   NBT Staining of Ps-HppE .....................................................142 
5.2.9.   Enzyme Activity Assays ........................................................143 
5.2.10.  Primary [2H] Kinetic Isotope Effect .....................................143 
5.2.11.  NMR Characterization of the Ps-HppE’s Products ..............144 
5.2.12.  Effects of Metal Ions on the Activity of Ps-HppE................144 
5.2.13.  The Dependence of Ps-HppE Activity on Oxygen...............145 
5.2.14.  DFT Calculations of Bond Dissociation Energies ................145 
5.2.15.  EPR Spectroscopy.................................................................146 
5.2.16.  [18O] Kinetic Isotope Effects Measurements ........................147 
5.2.17.  Calculation of 18O Equilibium Isotope Effects .....................148 
5.3. Results and Discussion ......................................................................150 
5.3.1.   Cloning, Overexpression, and Purification of Ps-HppE........150 
5.3.2.   Sequence Analysis .................................................................151 
5.3.3.   Reconstitution of Epoxidase Activity ....................................152 
5.3.4.   Activity for (S)-HPP and (R)-HPP.........................................155 
5.3.5.   EPR Characterization of Ps-HppE.........................................159 
5.3.6.   Post-Translational Hydroxylation of Ps-HppE......................161 





List of Tables 
Table 2-1: Summary of numerical results from computer simulations..............62 
Table 2-2: Summary of analytical results from fitting to Equations 2-1  
 and 2-3 ..............................................................................................67 
Table 3-1: Summary of non-competitive KIE measurements............................92 
Table 3-2: Results from computer simulations ..................................................98 
Table 3-3: Summary of Keq and KIE data from equilibrium perturbation 
experiments .......................................................................................98 
Table 4-1: Binding affinity of HppE for flavin derivatives..............................120 
Table 4-2: Rates of HppE-catalyzed epoxidation using different electron  
 mediators.........................................................................................123 
Table 5-1: Calculated EIEs for the reduction of molecular oxygen.................134 
Table 5-2: Vibration frequencies of molecular oxygen and reduced forms.....136 
Table 5-3: Vibrational frequencies (cm–1) of O2, H2O, and Fe/O2 species ......150 
Table 5-4: Rate constants for reactions at 1.5:1 FMN to HppE ratio...............155 
Table 5-5: Summary of 1° [2H]-KIE results at a different FMN to Ps-HppE 
  ratios...............................................................................................158 
Table 5-6: Summary of experimental [18O]-KIEs ............................................164 
Table 5-7: Calculated [18O]-EIEs using vibrational frequencies......................164 
Table 5-8: Summary of BDEs of the different hydrogen atoms abstracted  
 by a metal-superoxide .....................................................................169 
 xiv
List of Figures 
Figure 1-1: Isoprenoid building blocks..................................................................1 
Figure 1-2: Examples of terpenoids.......................................................................2 
Figure 1-3: Mevalonate-dependent pathway for isoprenoid biosynthesis .............3 
Figure 1-4: MEP pathway for isoprenoid biosynthesis .........................................4 
Figure 1-5: The DXS reaction ...............................................................................5 
Figure 1-6: Mechanism for DXS ...........................................................................5 
Figure 1-7: The DXR reaction...............................................................................6 
Figure 1-8: Proposed mechanisms for DXR..........................................................7 
Figure 1-9: The IspD reaction................................................................................7 
Figure 1-10: Proposed IspD mechanism..................................................................8 
Figure 1-11: The IspE reaction ................................................................................9 
Figure 1-12: The IspF reaction ................................................................................9 
Figure 1-13: The IspG reaction................................................................................9 
Figure 1-14: Proposed IspG mechanism................................................................10 
Figure 1-15: The IspH reaction..............................................................................11 
Figure 1-16: Proposed mechanism  for IspH.........................................................12 
Figure 1-17: Peptidoglycan structures ...................................................................13 
Figure 1-18: Proposed mechanism for MurA........................................................14 
Figure 1-19: Inactivation mechanism of MurA by fosfomycin.............................14 
Figure 1-20: Fosfomycin biosynthetic pathway ....................................................15 
Figure 1-21: Proposed mechanism for Fom1 ........................................................16 
Figure 1-22: Proposed mechanism for Fom3 ........................................................17 
Figure 1-23: P450 olefin epoxidation ....................................................................18 
Figure 1-24: Proposed mechanism for lipoxygenases ...........................................19 
 xv
Figure 1-25: Proposed mechanism for IPNS .........................................................22 
Figure 1-26: Proposed mechanism for α-KG dependent enzymes ........................23 
Figure 1-27: Proposed mechanism for tyrosine hydroxylase ................................24 
Figure 1-28: Proposed mechanism of ACCO........................................................25 
Figure 1-29: Proposed mechanisms for HppE with (S)-HPP ................................27 
Figure 1-30: Proposed mechanism of HppE with (R)-HPP...................................28 
Figure 2-1: Reaction catalyzed by DXR..............................................................39 
Figure 2-2: Structure of fosmidomycin ...............................................................40 
Figure 2-3: Proposed mechanisms for DXR........................................................41 
Figure 2-4: Structures of 3F-DXP  and 4F-DXP .................................................42 
Figure 2-5: Proposed inactivation mechanism of FCH2-MEP.............................44 
Figure 2-6: Kinetic mechanism used for computer simulations ..........................51 
Figure 2-7: Synthetic scheme for 3F-DXP ..........................................................54 
Figure 2-8: Synthetic scheme for 4F-DXP ..........................................................55 
Figure 2-9: Synthetic scheme for FCH2-MEP .....................................................56 
Figure 2-10: Non-linear progress curves with 3F-DXP and 4F-DXP ...................58 
Figure 2-11: Dixon plot of 3F-DXP steady-state phase of inhibition....................59 
Figure 2-12: 3F-DXP steady-state phase of inhibition fit to Equation 2-3............59 
Figure 2-13: 4F-DXP steady-state phase of inhibition fit to Equation 2-3............60 
Figure 2-14: Kinetic mechanisms for slow-binding inhibition..............................60 
Figure 2-15: Plot of kobs from Equation 2-2 versus [fosmidomycin].....................62 
Figure 2-16: Progress curves for 3F-DXP inhibition.............................................63 
Figure 2-17: Progress curves for fosmidomycin inhibition ...................................64 
Figure 2-18: Dixon plot showing the inhibition by FCH2-MEP............................65 
Figure 2-19: NADPH-DXR FRET Scans..............................................................66 
 xvi
Figure 2-20: FRET titration of MEP, 3F-DXP, and 4F-DXP................................67 
Figure 2-21: Compounds whose binding to DXR was analyzed by FRET...........69 
Figure 3-1: Proposed Mechanisms for DXR .......................................................80 
Figure 3-2: Structures of 3[2H]-DXP and 4[2H]-DXP.........................................81 
Figure 3-3: Reaction coordinate diagram displaying the origin of 2° KIE..........82 
Figure 3-4: Structure of 1F-DXP.........................................................................83 
Figure 3-5: Synthetic scheme of 3[2H]-DXP.......................................................86 
Figure 3-6: Synthetic scheme of 4[2H]-DXP.......................................................86 
Figure 3-7: Kinetic scheme used for computer simulations ................................89 
Figure 3-8: Progress curves for DXP, 3[2H]-DXP and 4[2H]-DXP ....................93 
Figure 3-9: Curves for determining Keq for the DXR reaction............................95 
Figure 3-10: Data from equilibrium perturbation experiment ...............................97 
Figure 4-1: Reaction catalyzed by HppE...........................................................103 
Figure 4-2: Proposed NAD(P)H and Iron dependent mechanisms for HppE....105 
Figure 4-3: Oxygen rebound mechanism...........................................................106 
Figure 4-4: Proposed hydride transfer mechanism for HppE ............................107 
Figure 4-5: Bioautography assay results of unfiltered reaction samples ...........114 
Figure 4-6: Bioautography assay results of filtered reaction samples ...............115 
Figure 4-7: Bioautography assay results of filtered reactions carried out in  
 dark and in sunlight.........................................................................116 
Figure 4-8: HPLC chromatogram of the HppE-catalyzed conversion of (S)-HPP 
 to fosfomycin ..................................................................................117 
Figure 4-9: The NADH-dependence of the conversion of (S)-HPP to 
 fosfomycin ......................................................................................118 
Figure 4-10: Proposed pterin-dependent hydroxylase-like mechanism for the  
 xvii
 HppE reaction .................................................................................119 
Figure 4-11: Binding curves of FMN to HppE(Zn2+) and HppE(Fe2+) ...............121 
Figure 4-12: Binding curves of FAD to HppE(Zn2+) and HppE(Fe2+)................122 
Figure 4-13: Structure of the electron mediators analyzed..................................123 
Figure 5-1: Fosfomycin biosynthetic pathway ..................................................131 
Figure 5-2: Proposed NAD(P)H and Iron dependent mechanisms for HppE....133 
Figure 5-3: Reaction coordinate diagram displaying the origin of the 
 18O KIE. ..........................................................................................135 
Figure 5-4: Molecular orbital diagram for O2 and •O2¯ .....................................136 
Figure 5-5: Synthetic scheme for (R)-2-[2H]-HPP ............................................139 
Figure 5-6: Synthetic scheme for (1R,2S)-1-[2H]-HPP .....................................139 
Figure 5-7: Synthetic scheme for (S)-1,1-[2H]2-HPP.........................................140 
Figure 5-8: SDS-PAGE gel of as-purified (apo) Ps-HppE................................151 
Figure 5-9: Protein sequence alignment of Ps-HppE and Sw-HppE. ................152 
Figure 5-10: Proposed nucleophilic displacement-hydride transfer mechanism  
 for HppE..........................................................................................154 
Figure 5-11: The HppE catalyzed reaction with (R)-HPP as the substrate..........155 
Figure 5-12: Plot of the product from the reaction of (R)-HPP with Ps-HppE at  
 varying ratios of FMN to Ps-HppE.................................................157 
Figure 5-13: EPR spectra of HppE-Fe(II) nitrosyl complexes for Ps-HppE and  
 Sw-HppE with and without substrate..............................................160 
Figure 5-14: Electronic absorption spectrum of reconstituted Ps-HppE.............162 
Figure 5-15: Ps-HppE after SDS-PAGE and transfered to nitrocellulose  
 membrane that is stained showing presence of DOPA...................163 
Figure 5-16: 18O-Isotope fractionation plots for (S)-HPP and (S)-1,1-[2H]2-HPP  
 xviii
 to determine [18O]-KIEs..................................................................163 
Figure 5-17: Proposed mechanism of isopenicillin N-synthase (IPNS) ..............167 







Chapter 1: Background and Significance 
1.1. THE IMPORTANCE OF ISOPRENOIDS 
Terpenoids are a large family of natural products comprised of over 35,000 
distinct compounds.1  They are widely distributed in nature and are rich in vital biological 
activities, including light harvesting pigments,2 growth hormones,3 and signal 
transduction.4  The terpenoid building block is a 5-carbon unit known as isoprene (1), 
which derives from either isopentenyl diphosphate (IPP, 2) or dimethylallyl diphosphate 
(DMAPP, 3), see Figure 1-1.  Despite the wide variety of terpenoid structures, they all 
consist of a multiple of five carbons.  This allows terpenoids to be classified based on 
their five carbon multiplicity.  For example, monoterpenes have 10 carbons; 
sequiterpenes have 15 carbons; diterpenes have 20 carbons; and sesterterpenes have 25 
carbons. A few examples of the various types of terpenoid structures are presented in 














Isoprene (1) Isopentenyl diphosphate (2)
Dimethylallyl diphosphate (3)  








Patchouli alcohol (5) Lanosterol (6)
β−Carotene (7)  
Figure 1-2: Examples of terpenoids. 
 
1.1.1. Mevalonate Pathway. 
While conducting labeling studies in the 1960’s to investigate the biosynthesis of 
cholesterol, Bloch and Lynen discovered the mevalonate pathway for isoprenoid 
biosynthesis.5,6  They determined that every carbon of cholesterol is derived from acetate, 
and after detailed analysis, the biosynthetic pathway shown in Figure 1-3 was 
established.  The pathway begins with the Claisen condensation of two molecules of 
acetyl-CoA (7) to form acetoacetyl-CoA (8).  A third acetyl-CoA reacts with the 
acetoacetyl-CoA through an aldol condensation reaction, followed by removal of one of 
the CoA’s by hydrolysis to yield (3S)-3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) (9).  
HMG-CoA is then reduced with NADPH by HMG-CoA reductase to produce 
mevalonate (10), which in humans is the rate-limiting step in the mevalonate pathway.7  
Inhibitors to HMG-CoA reductase, such as pravastatin, are widely prescribed drugs for 
lowering cholesterol levels.8  Mevalonate is then phosphorylated twice at the primary 
hydroxyl group to add the pyrophosphate functional group, and the secondary hydroxyl 
 3
group is activated by phosphorylation.  Subsequent dehydration and decarboxylation in a 
concerted process yields IPP (2).  The final enzyme in the pathway is IPP isomerase, 





















DMAPP (3) IPP (2) Mevalonate (10)
Acetyl-CoA (7) Acetoacetyl-CoA (8) HMG-CoA (9)
 
Figure 1-3: Mevalonate-dependent pathway for isoprenoid biosynthesis. 
 
1.1.2. Discovery of the MEP Pathway. 
For many years, it was believed that all organisms utilize the mevalonate pathway 
for the biosynthesis of the isoprenoid building blocks, IPP and DMAPP.  However, in 
1993 a pathway independent of mevalonate was discovered in the labs of Rhomer and 
Arigoni.9-11  Rhomer’s discovery arose by observing that the labeling pattern in 
hopanoids using various [13C1]glucose isotopomers and [13C]acetate isotopomers as 
precursors was inconsistent with what the mevalonate dependent pathway predicted.9  
Similar observation was also made by Arigoni and researchers in their labeling studies on 
ginkgolide formation in seedlings of the Ginkgo biloba and on ubiquinone biosynthesis in 
 4
E. coli.10,11  After further investigations by them and a few others, the pathway depicted 
in Figure 1-4 has been established as the non-mevalonate pathway for the synthesis of 
IPP (2) and DMAPP (3) in selected sources.  Since 2C-methyl-D-erythritol 4-phosphate 
(14, MEP) is the product of the first committed step of the pathway, this pathway is 
commonly referred as the MEP pathway.  Since the MEP pathway is absent in mammals 
but is essential for many pathogens, including Plasmodium falciparum12 and 
Mycobacterium tuberculosis,13 all enzymes in this pathway are potential antibiotic 












































































Figure 1-4: MEP pathway for isoprenoid biosynthesis. 
 













DXP (13)Pyruvate (11) G3P (12)  
Figure 1-5: The DXS reaction. 
 
The first step in the MEP pathway is catalyzed by 1-deoxy-D-xylulose 5-
phosphate (DXP) synthase (DXS).  In the reaction, pyruvate (11) condenses with 
glyceraldehydes-3-phosphate (G3P, 12) to produce DXP (13), see Figure 1-5.  The DXS 
reaction is thiamine pyrophosphate (TPP) dependent, and the proposed mechanism is 
























































Figure 1-6: Mechanism for DXS. 
 
The reaction begins with the nucleophilic attack of the ylid carbon of the 
thiazolium ring on to the carbonyl carbon of pyruvate, followed by decarboxylation.  The 
resulting carbanion (12), stabilized thought resonance into the thiazolium ring, does 
nucleophilic addition at the carbonyl of G3P (12).  The TPP adduct (22) is then cleaved 
 6
in a retroaldol-like manner to yield DXP (13) and TPP.  As mentioned above, the first 
committed product of the pathway is MEP and not DXP, which is due to DXP also being 
used in the biosynthetic pathways of thiamine and pyridoxal.15,16 
 













DXP (13) MEP (14)  
Figure 1-7: The DXR reaction. 
 
The first committed reaction of the MEP pathway is catalyzed by DXP 
reductoisomerase (DXR).17  During this reaction, DXP (13) undergoes rearrangement to 
MEP with the concomitant oxidation of the reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) to NADP+, see Figure 1-7.  It is has been shown that DXP first 
rearranges to an aldehyde intermediate, and the reaction is driven forward by the 
reduction of the aldehyde intermediate by NADPH.18  As shown in Figure 1-8, there are 
two proposed mechanisms for the DXR reaction, an α-ketol rearrangement and a 
retroaldol/aldol rearrangement.  The α-ketol rearrangement (route A) is similar to the 
mechanism catalyzed by ketol acid reductoisomerase, a key enzyme in the biosynthesis 
of branched chain amino acids.19  This reaction is initiated by the deprotonation of the C-
3 hydroxyl group followed by a 1,2-migration to yield the aldehyde intermediate (23).  
The second mechanism proceeds with a retroaldol/aldol rearrangement to produce the 
same intermediate, methylerythrose phosphate (23, route B).  Here the enzyme first 
catalyzes the cleavage of the C3-C4 bond through a retroaldol mechanism to yield a 
three-carbon (24) and a two-carbon phosphate (25) intermediate.  These intermediates 
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then condense through an aldol reaction to form a new C-C bond in 23, which is 
subsequently reduced by NADPH.  To distinguish between these two proposed 

















































Figure 1- 8: Proposed mechanisms for DXR. 
 























14 15  
Figure 1-9: The IspD reaction. 
The third step in the pathway is the cytidylynation of MEP (14) by IspD to yield 
4-(cytidine 5’-diphospho)-2-C-methyl-D-erythritol (15, CDP-ME), see Figure 1-9.20  The 
reaction is believed to proceed through an associative mechanism with nucleophilic 
attack of the phosphate of MEP on the α-phosphate of cytidine 5’-triphosphate (CTP) to 
yield the pentacoordinate phosphate intermediate (27), see Figure 1-10.  Depending on 
 8
the lifetime of this intermediate, it might technically be the transition state in the reaction.  
Upon the collapse of this pentacoordinate phosphate intermediate, pyrophosphate and 
CDP-ME (15) are formed.  However, a disociative mechanism is also possible, where the 
pyrophosphate group breaks away from CTP before the nucleophilic attack by MEP, 
leaving the α-phosphate group of CTP as a metaphosphate.  The metaphosphate 




































































Figure 1-10: Proposed IspD mechanism. 
 
The forth step in the MEP pathway is the phosphorylation of the C2-hydroxyl 
group of CDP-ME (15) by ATP, catalyzed by IspE, to generate 2-phospho-4-(cytidine 
5’diphospho)-2-C-methyl-D-erythritol (16, CDP-ME2P), see Figure 1-11.21,22  IspE 
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Figure 1-11: The IspE reaction. 
 
The fifth enzyme in the pathway, IspF, catalyzes the cyclization of CDP-ME2P 
(16) to generate 2-C-methyl-d-erythritol 2,4-cyclodiphosphate (17, MECDP) and the 
release of cytidine monophosphate (CMP), see Figure 1-12.23,24  IspF is believed to 
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Figure 1-13: The IspG reaction. 
 
The sixth step in the pathway is catalyzed by IspG, and it converts MECDP (17) 
to 4-hydroxy-2-methylbut-2-enyl 1-phosphate (18, HMBPP), see Figure 1-13.25  
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Sequence analysis revealed the presence of three conserved cysteine residues (C270, 
C273 and C306).  When each of these residues were separately mutated to serine, the 
resulting IspG had no activity.26  UV/vis and Mössbauer spectroscopy studies showed 
that these three cysteine residues are ligands of a [4Fe-4S] cluster.27  Since IspG contains 
a [4Fe-4S] cluster, several mechanisms involving radical chemistry have been proposed.  
To date, there is no real experimental evidence to distinguish and/or eliminate any of the 
proposed mechanisms.  However, a theoretical investigation has been performed in which 
the energies of the proposed intermediates in the different mechanisms were calculated to 
see which mechanism is most probable.28  This study best supports the mechanism 
depicted in Figure 1-14.  The mechanism begins with the heterolytic cleavage of the C-O 
bond of MECDP (17), probably through the aid of an active site general acid to form the 
tertiary C3 carbocation intermediate (28).  An external reductase then channels a single 
electron through the [4Fe-4S] cluster to reduce the carbocation to a C3-radical (29).  This 
is followed by a second single electron transfer through the [4Fe-4S] cluster to reduce 29 
to a carbanion (30).  The carbanion intermediate then undergoes dehydration to yield 
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Figure 1-15: The IspH reaction. 
 
The final reaction in the MEP pathway is the reductive deoxygenation of HMBPP 
(18) catalyzed by IspH to yield IPP (2) and DMAPP (3), see Figure 1-15.29  Through 
characterization by UV/vis and EPR spectroscopy, it was determined that, like IspG, 
IspH also contains a [4Fe-4S] cluster.30,31  Different mechanisms have been proposed for 
IspH, yet there are no studies to date that can differentiate between the different proposed 
mechanisms.  The mechanism displayed in Figure 1-16, which utilizes similar chemistry 
as IspG, is however the most probable.30  The mechanism begins with the elimination of 
the C4-hydroxyl group, possibly assisted through an iron of the [4Fe-4S] cluster acting as 
a Lewis acid catalyst, to produce the carbocation intermediate (31).  Two single electron 
transfers mediated by the [4Fe-4S], would reduce the carbocation intermediate ultimately 
to a carbanion species (33).  This carbanion intermediate can then be protonated at C3 to 













































Figure 1-16: Proposed mechanism  for IspH. 
 
1.2. FOSFOMYCIN 
1.2.1. Antibiotic activity of fosfomycin. 
Bacteria live in hypotonic environments.  To protect themselves against this 
enviroment, they are surrounded by rigid cell walls to prevent them from swelling and 
bursting due to the osmotic pressure.  Part of the rigidity of the cell wall derives from the 
peptidoglycan framework that encases the cell, which consists of covalently linked 
polysaccharide and polypeptide chains.  As seen in Figure 1-17, the peptidoglycan is 
found in Gram-positive and Gram-negative bacteria; however, the exact structure of the 
























































A B  
Figure 1-17: Peptidoglycan structures for Gram-positive (A) and Gram-negative (B) 
bacteria. 
 
As can be seen in two peptidoglycan structures in Figure 1-17, both Gram-
positive (A) and Gram-negative (B) bacteria have the same three carbon linker, displayed 
in red, that connects the polysaccharide and polypeptide chains.  These three carbons 
derive from phosphoenolpyruvate (34, PEP), and they are transferred to uridine 
diphosphate-N-acetylglucosamine (35, UDP-GlcNAc) to form enolpyruvyl-UDP-N-
acetylglucosamine (37, EP-UDP-GlcNAc).  This reaction is catalyzed by MurA and is the 
first committed step of the peptidoglycan biosynthetic pathway.32  The proposed 
mechanism of MurA is shown in Figure 1-18.33  The reaction begins with nucleophilic 
addition of the C3-hydroxyl group of UDP-GlcNAc to the C2 of PEP, which is assisted 
by the protonation of PEP by Cys115.  The resulting tetrahedral (36) intermediate breaks 




































































Figure 1-19: Inactivation mechanism of MurA by fosfomycin. 
 
The antibiotic fosfomycin (38) inactivates MurA by acting as a PEP analogue, 
and the proposed mechanism for the inactivation is depicted in Figure 1-19.34  MurA 
catalyzes the nucleophilic ring opening of the epoxide by Cys115, which results in a 
































Figure 1-20: Fosfomycin biosynthetic pathway. 
 
1.2.2.1.        The initial steps of the Fosfomycin Biosynthesis: Fom1, Fom2 and FomC. 
Fosfomycin is a natural product that is made by several species of Pseudomonas 
and Streptomyces,35,36 and its biosynthetic gene cluster from Streptomyces wedmorensis, 
Streptomyces fradiae and the partial cluster from Pseudomonas syringae have been 
isolated.37-39  The entire biosynthetic pathway has been elucidated and is presented in 
Figure 1-20.  The pathway begins with Fom1, a PEP mutase, which converts PEP (34) to 
phosphonopyruvic acid (40, PnPy) through the proposed mechanism depicted in Figure 
1-21.40  This product belongs to a growing family of C-P bond containing natural 
products, many of which have interesting biological activities.41  The reaction is believed 
to proceed through a dissociative mechanism that is initiated by the cleavage of the P-O 
bond to form a metaphosphate (44) and an enolate (45) intermediate.  The enolate 
intermediate then rotates around the C1-C2 bond, which aligns C3 to react with the 
metaphosphate ion to form the new C3-P bond in 40.  This reaction is reversible, with the 
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equilibrium favoring PEP over PnPy greater than 500 to 1.42  To drive the reaction 
forward, PnPy (40) is decarboxylated to phosphonoacetaldehyde (41, PnAA) by the PnPy 
decarboxylase, Fom2.43  The third step of the pathway is the reduction of the carbonyl of 

























44 45 40  
Figure 1-21: Proposed mechanism for Fom1. 
 
1.2.2.2. Fom3: A new methyl transferase.  
The fourth step in the biosynthetic pathway is the methylation of HEP (42) to (S)-
2-hydroxypropylphosphonic acid (43, (S)-HPP) by Fom3.44  Through labeling studies, it 
is known that the methyl groups is derived from methylcobalamin (MeCbl).45  Sequence 
analysis of Fom3 revealed the presence of a cobalamin binding motif and predicted the 
enzyme to be a member of the radical-SAM (S-adenosyl methionine) family of proteins.39  
A mechanism for Fom3 has been proposed based on known chemistry of radical-SAM 
proteins.44  The mechanism begins with the reductive cleavage of the C5’-S bond in SAM 
to generate methionine and 5’-deoxyadenosyl radical (see 48).  The adenosyl radical 
abstracts a C2 hydrogen atom from HEP (42) producing the C2 radical intermediate (see 
49), which would react with the methyl group of MeCbl (see 50).  In order to begin the 
following turnover, Fom3 has to be reactivated by reducing the [4Fe-4S] cluster, 
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recharging the cobalamin to MeCbl, and binding a new SAM (see 46).  This does differ 
from the standard radical-SAM proteins where the [4Fe-4S] and the SAM are regenerated 
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Figure 1- 22: Proposed mechanism for Fom3. 
 
1.2.2.3. HppE:  A novel non-heme iron dependent enzyme. 
The final step in the biosynthetic pathway is the epoxidation of (S)-HPP (43) to 
fosfomycin (38).  This reaction is catalyzed by Fom4, which has been named (S)-HPP 
epoxidase (HppE).  The mechanistic analysis of HppE is the second primary focus of this 
dissertation research.  The reaction catalyzed by HppE is an epoxidation reaction; 
however, it differs from Nature’s standard strategy for epoxide formation.  In nature, 
most epoxide rings are generated via oxidation of the corresponding alkenes by either 
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heme-dependent cytochrome P450s47,48 or non-heme iron-dependent monooxygenases.49  
A general P450 olefin epoxidation mechanism is shown in Figure 1-23.  A reactive 
oxygen species known as Compound 1 (51) oxidizes the olefin by a single electron to 
form a new C-O bond (see 52).  The iron-oxygen bond is then cleaved homolytically, and 
through oxygen rebound the epoxide ring is formed.50  The non-heme iron dependent 
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Figure 1-23: P450 olefin epoxidation. 
 
Previous isotope labeling experiments with HppE demonstrated that no oxygen 
atom from O2 is incorporated into fosfomycin.  Instead, the oxygen atom of the epoxy 
ring in fosfomycin (38) is derived from the secondary hydroxyl group of (S)-HPP 
(43).52,53  Thus the conversion of (S)-HPP to fosfomycin by HppE is effectively a 
dehydrogenation reaction, not an oxygenation reaction. 
HppE is a unique member of the mononuclear non-heme iron dependent enzymes.  
This family of enzymes is categorized into two groups, iron(II) and iron(III) dependent 
enzymes.51  The iron in iron(III) enzymes is ferric in the resting state, while the iron(II) 
enzyme’s iron is ferrous in the resting state of the enzymes.  The significance of this 
difference is that iron(III) can not bind and activate molecular oxygen, while iron(II) can.  
The role of the iron in iron(III) enzymes is to activate the substrate through a single 
electron oxidation, generating a substrate radical and ferrous iron.  The substrate radical, 
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which now has a doublet spin state, can react with molecular oxygen, which has a triplet 
spin state.  An example of an iron(III) enzyme are lipoxygenases, whose mechanism is 
depicted in Figure 1-24.  Lipoxygenases catalyze the oxidation of unsaturated fatty acids 
to produce fatty acid hydroperoxides at 1,4-pentadienyl positions.  The bulk of the 
mechanistic analysis on lipoxygenases has been conducted on soybean lipoxygenase.  
The physiological substrate of soybean lipoxygenase is linoleic acid, 9,12-(Z,Z)-
octadecadienoic acid (55), which is converted to 13-(S)-hydroperoxy-9,11-(Z,E)-
octadecadienoic acid (58, 13-(S)-HPOD).54  The   reaction proceeds via an initial rate-
limiting hydrogen abstraction by the FeIII-OH cofactor to generate a substrate radical (56) 
and   FeII-OH2.55  The substrate radical rapidly reacts with molecular oxygen and the 
equivalent of a hydrogen atom is transferred back to the peroxo intermediate (57) to 
produce the hydroperoxide product (58) and to regenerate the resting ferric-hydroxide 























Figure 1-24: Proposed mechanism for lipoxygenases. 
 
Iron(II) enzymes, which includes HppE, bind and activate oxygen.  The reactive 
oxygen species typically carries out a two electron oxidation of the substrate.  Iron(II) 
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enzymes catalyze a wide variety of reactions, including hydroxylation of aliphatic C-H 
bonds, epoxidation of C-C double bonds, cis-dihydroxylation of arene double bonds, 
heterocyclic ring formation, and oxidative aromatic ring cleavage.56  Despite the broad 
range of reaction types, all iron(II) enzymes share the same structural motif known as the 
2-His-1-carboxylate facial triad.  The name of this motif derives from the active site iron 
being bound by three endogenous protein ligands arranged at the vertices of one 
triangular face of an octahedron.  Two of the ligands are histidines, and the other is either 
an aspartate or a glutamate.  The three remaining coordination sites are available for 
exogenous ligands, such as solvent molecules, the substrate/co-substrate, and molecular 
oxygen.  The iron is usually six-coordinated in the resting state and relatively unreactive 
towards molecular oxygen.  It is after substrate/co-substrate binding that the iron changes 
to five-coordinated, which provides a coordination site for binding of O2.  The 
substrate/co-substrate binding generally increases the binding affinity of O2.  With O2 
binding taking place only after the binding of substrate and/or co-substrate also greatly 
enhances the coupling of the reduction of O2 to the oxidation of the substrate.  This 
binding event brings together the substrate and activated oxygen together in close 
proximity for the ensuing reaction.51 
The reactive oxygen species generated in the reaction can be either Fe(III)-
superoxide (Fe(III)-OO•), Fe(III)-hydroperoxide (Fe(III)-OOH) or Fe(IV)-oxo 
(Fe(IV)=O), with Fe(IV)-oxo being the most reactive and widely used.51  To date there is 
no direct evidence of a mononuclear non-heme iron dependent enzyme that utilizes 
Fe(III)-superoxide as the reactive species; however, it is widely accepted that the reactive 
species for the first oxidation reaction catalyzed by isopenicillin N synthase (IPNS) is 
Fe(III)-superoxide.57  There are no reported mononuclear non-heme iron dependent 
enzymes which use Fe(III)-hydroperoxide as the reactive species despite its involvement 
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in flavin-dependent hydroxylases.58  In contrast, it is well documented for mononuclear 
non-heme iron dependent enzymes that utilize Fe(IV)-oxo as the reactive species.  The 
list includes the α-ketoglutarate (α-KG) dependent TauD59 and CytC3,60 tyrosine 
hydroxylase,61 and 1-aminocyclopropane-1-carboxylic acid (ACC) oxidase (ACCO).62  
The IPNS reaction begins with the binding of the substrate, δ-(L-α-aminoadipoyl)-
L-cysteinyl-D-valine (60, ACV).63,64  The thiolate group of ACV coordinates to the iron 
to produce a five-coordinate iron site, leaving the sixth site open for oxygen binding.  
Molecular oxygen then binds to the iron(II) at the vacant coordination site, where it is 
reduced by an inner-sphere electron transfer from iron(II) to yield Fe(III)-superoxide (see 
61).  It also has been demonstrated through calculations that the coordination of the 
thiolate enhances the binding of O2 by stabilizing Fe(III)-superoxide.57  The reactive 
species for the first oxidative ring closure to form the β-lactam ring is believed to be 
Fe(III)-superoxide; however, this has not been experimentally verified.  The Fe(III)-
superoxide is proposed to abstract a hydrogen atom from the cysteine β-carbon to form 
the substrate radical (62) and Fe(III)-hydroperoxide.  The intermediate is further oxidized 
by a second single electron transfer to the iron to form the thioketone (63) and Fe(II)-
hydroperoxide.  The O-O bond of the peroxide is then cleaved heterolytically to generate 
Fe(IV)-oxo and hydroxide, which abstracts the valine N-H proton.  Concerted with 
Fe(IV)-oxo formation, the valine nitrogen performs a nucleophilic attack on the cysteine 
β-carbon to form the β-lactam ring (64).  The strong oxidant, Fe(IV)-oxo, can now 
abstract the unactivated hydrogen atom from the valine β-carbon (see 64).  Similar in 
fashion to the oxygen rebound mechanism of cytochrome P450 reaction, the resulting 
substrate radical (65) reacts with the thiolate to close the thiazolidine ring (66) with 






















































































Figure 1-25: Proposed mechanism for IPNS. 
 
The oxygen activation mechanism depicted in Figure 1-26 to generate the 
reactive Fe(IV)-oxo is shared by believed all known α-KG dependent enzymes.51  The six 
coordinated Fe(II) center begins the reaction to bind α-KG by displacing two ligands (see 
68).  At this stage, the iron is still six coordinated and is relatively unreactive toward 
molecular oxygen.  The substrate then binds to the active site but does not coordinate to 
the iron (see 69).  When this occurs, a water ligand dissociates leaving a coordination site 
open for oxygen binding.  By limiting oxygen binding to after the substrate binds reduces 
the uncoupled reactions.  Once molecular oxygen now binds to the open coordination 
site, it is reduced to Fe(III)-superoxide (70).  This activates the distal oxygen for 
nucleophilic attack at the α-keto carbon.  The resulting bridged intermediate (71) is 
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believed to undergo a concerted decarboxylation of α-KG and a heterolytic cleavage of 
the O-O bond, forming the Fe(IV)-oxo reactive species (72).  The reactive Fe(IV)-oxo 
abstracts a hydrogen atom from the substrate (see 73), and the substrate radical is either 
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Figure 1-26: Proposed mechanism for α-KG dependent enzymes. 
 
A second type of iron(II) enzymes whose reactive species has been verified to be 
Fe(IV)-oxo are the pterin-dependent aromatic amino acid hydroxylases, specifically 
tyrosine hydroxylase.61  As the case for the α-KG enzymes, when tyrosine binds to the 
active site of tyrosine hydroxylase (75), it does not coordinate to the iron (see 76).  
However, binding of tyrosine triggers the release of a water ligand to change the iron 
from six coordinated to five coordinated, which produces a vacant coordination site for 
binding of molecular oxygen.  When oxygen binds in the active site, it first reacts with 
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the iron to form Fe(III)-superoxide before forming a putative Fe(II)-O-O-pterin adduct 
(77).65  The peroxy-adduct then cleaves heterolytically to form 4a-hydroxypterin and 
Fe(IV)-oxo (see 78).61  The Fe(IV)-oxo does not perform hydrogen atom abstraction, but 
instead facilitates the electrophilic attack of the aromatic ring to generate a carbocation 


































































































Figure 1-27: Proposed mechanism for tyrosine hydroxylase. 
 
A third type of iron(II) enzyme where the reactive species has been determined to 
be Fe(IV)-oxo is ACCO, which oxidatively breaks down ACC into ethylene, hydrogen 
cyanide and CO2.66  ACCO does not utilize α-KG or reduced pterin for the reductive 
activation of O2; instead, ascorbate plays the reductant role.  The substrate binding order 
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has not been fully deduced, but it is believed that ascorbate and ACC bind before O2 (see 
82 and 83).67  When O2 binds to the ferrous center, Fe(III)-superoxide forms (see 84), 
which is reduced by a single electron transfer from ascorbate to generate Fe(III)-
hydroperoxide (see 85).  A second single electron transfer from ascorbate and cleavage of 
the O-O bond produces the reactive species, Fe(IV)-oxo (see 86).62  The Fe(IV)-oxo then 
performs a single electron oxidation of the amine to form a cation amine radical (87), 
which subsequently breaks down in a manner yet to be determined to yield ethylene, 


























































Figure 1-28: Proposed mechanism of ACCO. 
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HppE is unique with respect to all other mononuclear non-heme iron-dependent 
enzymes regarding the required components for activity.  The HppE reaction is 
independent of ascorbate, α-KG, pterin, or an internal iron-sulfur cluster.  Instead, the 
HppE reaction requires two external electrons from NAD(P)H to complete the four 
electron reduction/activation of O2 ; the other two electrons are supplied by (S)-HPP (43).  
An external reductase is required to mediate single electron transfer into the iron active 
site; however, a putative HppE reductase is yet to be discovered.  For in vitro activity 
assays of HppE, a promiscuous reductase from a separate biosynthetic pathway, such as 
CDP-6-deoxy-L-threo-D-glycero-4-hexulose-3-dehydrase reductase (E3), or a chemical 
electron mediator, such as flavin mononucleotide (FMN), are substituted for the putative 
HppE reductase. 
The mechanism of HppE epoxidation has been proposed to parallel the alkane 
hydroxylation catalyzed by cytochrome P45048 and non-heme iron-dependent 
oxygenases.51,68  The reaction likely begins with hydrogen abstraction from the C-1 
position of 43 by an activated oxygen species.  In a manner similar to the oxygen rebound 
mechanism for cytochrome P450s, the C-1 centered radical intermediate can then cyclize 
to form fosfomycin (38) and the reduced iron center.  As shown in Figure 1-29, the 
reactive oxygen species can be one of three species.  One of them is Fe(III)-superoxide 
(91), which forms upon dioxygen binding to the ferrous iron center (90), similar to what 
has been proposed for the initial H-atom abstraction in isopenicillin N synthase 
(IPNS).57,64  The Fe(III)-superoxide species can be reduced by one electron and 
protonated to form Fe(III)-hydroperoxide (93), which can also abstract the C-1 hydrogen 
atom.  The Fe(III)-hydroperoxide species can be further reduced by a second single 
electron transfer with concurrent cleavage of the O-O bond to form Fe(IV)-oxo (94), as 
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described above for the α-KG dependent enzymes59,60 and for ACCO.62  This reactive 















































































Figure 1-29: Proposed mechanisms for HppE with (S)-HPP (43). 
 
The HppE reaction is stereo- and regiospecific.69  When HppE reacts with (S)-
HPP (43), the C1 pro-R hydrogen atom is abstracted in the course of fosfomycin 
production.  When (R)-HPP (97) is substituted for (S)-HPP (43), the C2 hydrogen atom is 
abstracted and a new ketone product is produced, 2-oxopropylphosphonic acid (105).  As 
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depicted in Figure 1-30, the proposed mechanisms for the reaction with (R)-HPP mirror 













































































Figure 1-30: Proposed mechanism of HppE with (R)-HPP (97). 
 
1.3. THESIS STATEMENT 
  The focus of this dissertation is the study of two enzymes, DXR and 
HppE.  DXR catalyzes the first committed step in the MEP pathway, which is the 
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pathway most eubacteria, archeabacteria, algae, and the plastids of plants use for the 
biosynthesis of isoprenoid.  Since mammals utilize the mevalonate pathway and 
isoprenoids are essential for survival, enzymes in the MEP pathway are excellent 
antibiotic targets.  Every year there are around 300 million new malaria infections and 
1-3 million deaths as a result of the disease, which is caused by the parasite 
Plasmodium falciparum.  One antibiotic that has promise in the fight against malaria 
is the natural product fosmidomycin, which has been demonstrated to cure mice 
infected with malaria.12  Fosmidomycin’s antibiotic activity is due to its ability to 
bind tightly and inhibit DXR.  With a deeper understanding of DXR’s catalyzed 
reaction, it will be possible to design a more sophisticated and potent antibiotic.  
Chapter 2 describes the design and inhibition analysis of two fluorinated substrate 
analogues, 3F-DXP and 4F-DXP, and a fluorinated product analogue, FCH2-MEP.  
The synthetic schemes for the substrate analogues were designed by Dr. Alexander 
Wong, and they were synthesized by Dr. Wong with the assistance of Ms. Vidusha 
Devasthali.  In order to complete the investigation, more 3F-DXP was required, 
which I started and Dr. Gang Dong completed.  The product analogue, FCH2-MEP, 
was synthesized by Dr. Xiaotao Pu.  Chapter 3 described a 2° [2H]-KIE study, which 
was conducted by the equilibrium perturbation method.  The labeled DXP analogues 
for the study were synthesized by Dr. Xiaotao Pu.    
The second enzyme this dissertation examines is HppE, which catalyzes the final 
step in the biosynthesis of the antibiotic, fosfomycin.   Fosfomycin (38) is a clinically 
useful antibiotic70 for the treatment of limb-threatening diabetic foot infections71 and 
lower urinary tract infections.  It has been shown to be effective against 
ciprofloxacin-resistant E. coli,72 as well as methicillin-resistant73 and vancomycin-
resistant74 strains of Staphylococcus aureus.  Chemically speaking, HppE is unique 
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for two reasons.  First, HppE’s epoxidation differs from Nature’s standard method of 
epoxide formation by alkene oxidation, where the epoxide oxygen is derived from 
molecular oxygen.47-49  For HppE, the epoxide is formed through the dehydrogenation 
of a secondary alcohol; thus the epoxide oxygen is derived from the substrate.  
Second, HppE is a unique member of the mononuclear non-heme iron-dependent 
family of enzymes.  HppE differs from all other mononuclear non-heme iron-
dependent enzymes by requiring NADH and an external electron mediator for 
turnover but not requiring α-KG, pterin, ascorbate, or an internal iron-sulfur cluster.  
In Chapter 4, the proposed iron and NADH dependent mechanism of HppE from 
Streptomyces wedmorensis is reevaluated after a study is published on the activity of 
zinc-reconstituted HppE.  This investigation was conducted in collaboration with Dr. 
Feng Yan.  Chapter 5 describes the purification, biochemical and spectroscopic 
characterization of the HppE from Pseudomonas syringae (Ps-HppE), and the results 
of [2H] and [18O]-KIE studies on Ps-HppE are also reported.  The EPR experiments 
were conducted in collaboration with Prof. Aimin Liu at the University of Mississippi 
Medical Center in Jackson, Mississippi.  The deuterium labeled compounds for the 
[2H]-KIE studies were synthesized by Dr. Sung-Ju Moon.  The bond dissociation 
energies were calculated by Dr. Steven O. Mansoorabadi, and the [18O]-KIE studies 
were conducted in collaboration with Dr. Liviu M. Mirica in the lab of Prof. Judith P. 
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Chapter 2: Mechanistic Investigations of DXR with Fluorinated 
Analogues 
2.1. INTRODUCTION 
Terpenoids are a large family of natural products comprised of over 35,000 
distinct compounds.1  They are widely distributed in nature and are rich in biological 
activities, including light harvesting pigments,2 growth hormones,3 and signal 
transduction.4  The terpenoid building block is a 5-carbon unit known as isoprene, which 
has long been established to be derived from acetate via the mevalonate pathway.5  
However, a new isoprene biosynthetic pathway has recently been discovered in 
eubacteria, archeabacteria, algae, and in the plastids of plants where the isoprenoid unit is 
formed independently of mevalonate.6-8  This non-mevalonate pathway operates in 
eubacteria, archeabacteria, algae, and the plastids of plants but is absent in mammals.4-6 
The initial precursors of the pathway are pyruvate and glyceraldehyde-3-
phosphate, which condense to form 2-C-1-deoxy-d-xylulose-5-phosphate (DXP, 1).9,10  
DXP is also required for the biosynthesis of the pyridoxal ring of vitamin B6 and is 
incorporated into the thiazole ring of vitamin B1.11-13  Therefore, the conversion of DXP 
to methyl-D-erythritol 4-phosphate (MEP, 2) catalyzed by DXP reductoisomerase (DXR) 















1 2  
Figure 2-1: Reaction catalyzed by DXR. 
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Since this pathway is absent in mammals but is essential for many pathogens, 
including Plasmodium falciparum15 and Mycobacterium tuberculosis,16 all enzymes in 
this pathway are potential antibacterial targets.17  This has been demonstrated by the 
action of the antibiotic fosmidomycin (3),18,19 which inhibits isoprenoid biosynthesis by 
binding to DXR.20,21  In clinical trials, fosmidomycin has been shown to clinically and 
parasitologically cure patients after 7 days of treatment.22  As the design of a more 
specific inhibitor for this enzyme depends on a detailed understanding of its mode of 







Figure 2-2: Structure of fosmidomycin (3). 
 
The reaction catalyzed by DXR is the isomerization of DXP (1) to 
methylerythrose phosphate (4), followed by the reduction of the aldehyde by NADPH 
yielding MEP (2).  As shown in Figure 2-3, there are two plausible mechanisms for the 
rearrangement step catalyzed by DXR.  The first mechanism is an α-ketol rearrangement 
(route A), which is similar to the mechanism catalyzed by ketol acid reductoisomerase, a 
key enzyme in the biosynthesis of branched chain amino acids.24  In route A, 
deprotonation of the C-3 hydroxyl group followed by a 1,2-migration to yield the 
aldehyde intermediate, methylerythrose phosphate (4), is the key step in the mechanism.  
The second mechanism proceeds through a retroaldolization/aldolization to produce the 
same intermediate, methylerythrose phosphate (4, Scheme 2, route B).  Here the enzyme 
first catalyzes the cleavage of the C3-C4 bond through a retroaldol reaction to yield a 
three carbon (5) and a two carbon phosphate intermediates (6); these intermediates then 
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Figure 2-3: Proposed mechanisms for DXR. 
 
The Escherichia coli enzyme, the specific DXR studied herein, has been shown to 
proceed via an ordered mechanism in which NADPH binds before DXP, and NADP+ is 
released after the discharge of MEP.25  However, a random mechanism has recently been 
determined for the Mycobacterium tuberculosis enzyme.16  Due to the significant 
differences in Km of the substrates in the forward and reverse reaction, a preferred order 
of binding exists in the latter case rendering its mechanism effectively similar to that of 
the E. coli enzyme.  Early studies have also established that the C-1 pro-S hydrogen in 
MEP (2) is derived from H-3 of DXP (1),26,27 and the hydride transfer from NADPH is 
pro-S specific.16,26,28  In addition, several crystal structures of DXR from various 
organisms  have been determined.29-34  Despite the advances made thus far in 
understanding of the catalytic properties of DXR, it remains elusive whether catalysis is 
best described by route A or route B.  In an attempt to gain more insight into this 
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intriguing catalysis, two fluorinated substrate analogues were prepared, 3F-DXP (7) and 
4F-DXP (8), and were examined for their competence as substrates or inhibitors upon 


















Figure 2-4: Structures of 3F-DXP (7) and 4F-DXP (8). 
 
A key difference between the two proposed mechanisms is the involvement of the 
two hydroxyl groups. The C3-hydroxyl group is essential for catalysis in both 
rearrangement mechanisms.  If this hydroxyl group is replaced by a fluorine (such 7) no 
chemistry can take place according to the α-ketol rearrangement. In contrast, this 
compound can still undergo the initial retroaldol reaction in the retroaldol/aldol 
rearrangement but will not be able to catalyze the subsequent aldol condensation to form 
the new C2-C4 bond.  Due to the expected endergonic nature of the initial retroaldol 
reaction, the equilibrium would favor the DXP analogue, resulting in no observable 
chemistry.  The two mechanisms differ significantly in the involvement of the C4-
hydroxyl group in the rearrangement reaction.  For the α-ketol rearrangement, the C4-
hydroxyl group has no direct role in catalysis.  Thus, when this hydroxyl group is 
replaced by a fluorine (8), the rearrangement reaction and the following reduction 
reaction should still proceed to generate the corresponding product.  In the 
retroaldol/aldol rearrangement reaction, the C4-hydroxyl group is crucial for the initial 
retroaldol reaction.  During the cleavage of the C3-C4 bond, the C4-hydroxyl group is 
believed to be deprotonated in order to neutralize the resulting C4-carbocation.  When the 
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C4-hydroxyl group is removed, the inability to stabilize the resulting C4-carbocation will 
prevent the reaction from taking place. 
To further probe this interesting reaction, we envisioned that a fluoromethyl 
analogue of MEP, a phosphate mono-((2S,3S)-3-fluoromethyl-2,4-dihydroxy-3-methyl-
butyl) ester (FCH2-MEP, 9), may be a DXR inactivator whose mode of action could also 
shed light on the catalytic mechanism of DXR.  Thus far, all of the inhibitors that have 
been tested for DXR are either DXP (1) or fosmidomycin (3) analogues.25,35-42  
Interestingly, while the DXR reaction is reversible, there are no report of MEP (2) 
analogues as inhibitors for this enzyme.25  There is also no compound known to 
irreversibly inactivate DXR in a mechanistically relevant manner.  To explore this new 
avenue for elucidating the mechanism of DXR and for controlling its catalyzed reaction, 
compound 9 was designed as a possible MEP-based suicide inhibitor.  If DXR proceeds 
via the α-ketol rearrangement mechanism (Scheme 2, route A), compound 9 may simply 
act as a competitive inhibitor against MEP (2) when the DXR reaction is run in the 
reverse direction (2 → 1).  The primary alcohol would be oxidized by NADP+ to the 
aldehyde intermediate, and then no further chemistry would be able to take place.  In 
contrast, if a retroaldol/aldol mechanism (Scheme 2, route B) is followed, compound 9 
may covalently modify DXR and irreversibly inactivate its activity.   
The possible scenarios of inactivation of DXR by 9 are depicted in Figure 2-5.  
When the reaction is run in the DXP (1) formation direction, FCH2-MEP (9) will be first 
oxidized to the corresponding aldehyde (10), which then proceeds through the same 
retroaldol mechanism, as MEP would, to cleave the C2-C3 bond.  Because the 
subsequent aldol condensation cannot occur in this case, the resulting 4-C fragment 11 
may instead undergo fluoride elimination to yield the Michael acceptor 13.43  As shown 
in path A, this intermediate may trap an active site nucleophile resulting in the inactive, 
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covalently modified enzyme, 14.44  Alternatively, a 1,4-reduction of 13 by NADPH 
(generated in situ) to give 15 followed by aldol condensation with 12 could generate 16 





































































Figure 2-5: Proposed inactivation mechanism of FCH2-MEP. 
 
Herein, we present our investigation of 3F-DXP (7) and 4F-DXP (8), which led to 
the conclusion that both are not substrates of DXR but instead are slow-binding 
inhibitors.  Also reported is the characterization of action of FCH2-MEP (9).  This 
compound was found not to be an inactivator of DXR but a weak inhibitor.  To 
investigate the binding of these inhibitors, a FRET binding assay was developed that can 
be readily modified for high-throughput inhibitor screening. 
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2.2. MATERIALS AND METHODS 
2.2.1. GENERAL. The pET24(+) vector and the overexpression host strain 
Escherichia coli BL21(DE3) were purchased from Novagen Inc. (Madison, WI).  Cloned 
DNA polymerase Pfu and GeneClean DNA purification kits were obtained from 
Stratagene (La Jolla, CA) and Bio 101 Inc. (La Jolla, CA), respectively.  Primers used in 
PCR amplification were customarily prepared by Integrated DNA Technologies, Inc. 
(Coralville, IA) and used without further purification.  Restriction endonucleases were 
purchased from Invitrogen (Carlsbad, CA).  All electrophoretic reagents were obtained 
from Bio-Rad (Hercules, CA).  Culture media were products of Difco (Detroit, MI), and 
the Ni-NTA agarose resin was purchased from Qiagen (Valencia, CA).  Fosmidomycin 
was acquired from Toronto Research Chemicals (North York, ON Canada).  All 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), or Fisher Scientific 
(Pittsburgh, PA).  DXP and MEP were made through enzymatic synthesis as 
published,46,47 except were purified by cellulose chromatography using water and THF as 
the solvent system.  The concentrations of DXP and MEP were determined through a 
published DXR assay.25 
 
2.2.2. CLONING, OVER-EXPRESSION AND PURIFICATION OF DXR. The E. coli 
DXR was cloned into the pET24(+) vector by Ms. Vidusha Devasthali so that the enzyme 
was expressed with a C-terminal hexa-histidine tag.  This resulting plasmid was used to 
transform E. coli BL21(DE3).  An overnight culture of the recombinant strain grown in 
Luria-Bertani (LB) medium supplemented with kanamycin (50 μg/mL) at 37 oC was used 
to inoculate a 1 L culture of the same medium and antibiotic.  These cultures were 
incubated at 37 oC until the OD600 reached 0.45, followed by induction with 1.0 mM 
isopropyl β-D-thiogalactoside (IPTG) and 3.5 h of additional incubation at 37 oC.  The 
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cells were harvested by centrifugation (6000g, 10 min).  Purification of this C-terminal 
His6-tagged protein by Ni-NTA agarose resin was performed at 4 °C according to the 
procedures recommended by the manufacturer, except the elution buffer was 100 mM 
imidazole.  The concentrated purified protein was aliquotted, flash frozen in 30% 
glycerol, and stored at – 80 °C. 
 
2.2.3. CLONING, OVEREXPRESSION AND PURIFICATION OF DXS. DXS was 
required for the enzymatic synthesis of DXP, and it was amplified from isolated E. coli 
genomic DNA by polymerase chain reaction (PCR) using the forward primer (DXS-1): 
5'-GGGAAACATATGAGTTTTGATATTGCC-3', and the reverse primer (DXS-2): 5'-
GCGCTC-GAGTGCCAGCCAGGCCTT-3'.  The PCR-amplified DNA fragment was 
digested with NdeI and XhoI, and ligated into the NdeI/XhoI sites of the transcription 
vector, pET24(+), that had been treated with CIAP to give a recombinant plasmid.  This 
plasmid was used to transform E. coli BL21(DE3).  An overnight culture of the 
recombinant strain grown in Luria-Bertani (LB) medium supplemented with kanamycin 
(50 μg/mL) at 37 oC was used to inoculate a 1 L culture of the same medium.  The culture 
was incubated at 37 oC until the OD600 reached 0.55, followed by induction with 0.5 mM 
IPTG and 3.5 h of additional incubation at 37 oC.  The cells were harvested by 
centrifugation (6000g, 10 min).  Purification of this C-terminal His6-tagged protein by Ni-
NTA agarose resin was performed at 4 °C according to the procedures recommended by 
the manufacturer. The concentrated purified protein was aliquotted, flash frozen, and 
stored at – 80 °C. 
 
2.2.4. ACTIVE SITE TITRATION OF DXR. The concentration of active DXR was 
determined via active site titration using NADPH as the titrant.  The FRET signal used in 
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these studies is from an active site tryptophan (Trp212) and the bound NADPH.  A 2 mL 
100 mM Tris•HCl (pH 7.6) solution containing 2 mM MgCl2 and 3.13 μM DXR (based 
on Bradford assay) was titrated against a 400 μM NADPH solution.  The binding of 
NADPH to DXR was monitored by the increase in fluorescence of NADPH upon binding 
to the active site.  The titration measurements were conducted with the Fluorolog-3 from 
Horiba Jobin Yvon (Edison, NJ).  The excitation and emission wavelengths were 340 and 
458 nm, respectively; and the excitation and emission slit widths were set at 1 and 5 nm, 
respectively.  To correct for the background fluorescence of free NADPH, a control 
titration without DXR was performed and subtracted from the titration with DXR.  This 
data was then fit, using Grafit 5.0.1, to Equation 2-1 with Fo, ∞F , Eo and KD as 
parameters, where Fo is the starting fluorescence, ∞F  is the final fluorescence, Eo is the 
total DXR concentration, and So is the total NADPH concentration. 
 
Equation 2-1 

















This fit led a DXR concentration of 1.85 ± 0.23 μM, which was then used to 
determine the stock DXR concentration.  This fit also allowed us to deduce a KD of 0.45 
± 0.15 μM for NADPH, which is very similar to its reported Km of 0.5 μM.25 
 
2.2.5. 3F-DXP AND 4F-DXP INHIBITION STUDY. Enzyme assays were performed at 37 
°C following a literature procedure.25  The reaction mixture contained 200 μL of 
degassed 100 mM Tris•HCl buffer (pH 7.6), 1 mM MgCl2, 1 mg/mL bovine serum 
albumin (BSA), 0.15 mM NADPH, 23 nM DXR, and varied concentrations of DXP.  The 
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reaction was initiated by the addition of DXR followed by monitoring the rate of NADPH 
consumption at 340 nm (ε340 = 6.22 mM-1•cm-1).  The kcat and Km for DXP were 
determined to be 21.3 s-1 and 200 μM, respectively, which differ from the literature 
values of 107 s-1 and 115 μM.25  The low activity is believed to be due to the presence of 
the C-terminal His6 tag, where the literature values are for the non-tagged enzyme.  For 
the inhibition studies, varied amounts of inhibitor were added to the above reaction 
mixture minus the DXR, and the resulting solution was incubated at 37 °C in a quartz 
cuvette for 15 min.  The inhibitor concentrations were determined by NMR by comparing 
the integration of the C-1 methyl signal of 3F-DXP and 4F-DXP to that of a methanol 
internal standard of known concentration.  The rate of NADPH consumption was plotted 
as the rate of formation of NADP+, and the plot was fitted to Equation 2-2, where νi is 
the initial velocity, νss is the steady-state velocity, and kobs is the rate constant going from 
νi to νss.48   
 
Equation 2 
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To determine the respective steady-state Ki values, the νss values from Equation 




















2.2.6.  ASSAYS TO INVESTIGATE SLOW-BINDING INHIBITION. Assays were carried 
out at 24 °C in degassed and N2 saturated 100 mM Tris•HCl buffer (pH 7.6) containing 2 
mM MgCl2, 1 mg/mL BSA, 0.1 mM DTT, 150 μM NADPH, and 975 μM DXP, with 
varying concentrations of inhibitor (0.0-1.46 mM for 3F-DXP and 0.0-7.8 μM for 
fosmidomycin).  The presence of 0.1 mM DTT in the assay mixture enhanced the 
linearity of the reaction curve when no inhibitor was present.  The reactions were 
initiated by the addition of enzyme to a final concentration of 25 nM.  The reaction was 
followed by monitoring the rate of NADPH consumption at 340 nm. 
The rate of NADPH consumption was plotted as the rate of NADP+ formation, 
and the plot was fitted to Equation 2-2.48  To obtain the rates constants for the initial 
inhibition simulations, the plot of kobs versus inhibitor concentration was fitted to 
Equation 2-4 for a one-step binding model and to Equation 2-5 for a two-step binding 
model, where I is the concentration of inhibitor, S is the concentration of DXP, Ki is the 
inhibition constant for the initial binding complex, Km,s is the Km for DXP, and k6 and k-6 
are the rate constants of the forward and reverse reactions associated with the step of 

























































Using the information deduced from graphical analysis of the inhibition behavior 
of 3F-DXP and fosmidomycin, their slow binding nature was further studied by the 
global simulations of the progress curves to a one-step and a two-step binding 
mechanism.  The initial simulations were performed using the Z-lab program on the 
family of progress curves recorded at different inhibitor concentrations to deduce the 
starting rate constants.  These rate constants were then used to globally fit the family of 
progress curves to determine the errors in the rate constants using Dynafit, and to 
evaluate which binding model yields a better fit.49  The kinetic mechanism in Figure 2-6 
was used for the simulations, except for the omission of the seventh step, a 
conformational change, when the one-step binding model was considered.  Both the 
ordered substrate binding mechanism with NADPH binding before DXP, similar to that 
of the E. coli DXR,25 and a random substrate binding mechanism, analogous to that 
concluded for the M. tuberculosis enzyme,16 were used for the simulations. The 
simulations produced similar results irrespective to whether substrate binding is ordered 
or random; thus for simplification, only the simulations based on an order substrate 
binding mechanism is described herein. 
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DXR + NADPH DXR  NADPH                    (1)
DXR  NADPH  DXP          (2)DXR  NADPH + DXP
DXR  NADP  MEP             (3)DXR  NADPH  DXP
DXR  NADP + MEP           (4)DXR  NADP  MEP
DXR + NADP                     (5)DXR  NADP
DXR  NADPH  I                 (6)DXR  NADPH + I















Figure 2- 6: Kinetic mechanism used for computer simulations. 
 
In the simulations, it was assumed that substrate binding and product release are 
not significantly rate-limiting. The rate constants for steps 1 through 5 were fixed in the 
simulations, and the rate constants for steps 6 and 7 were allowed to float.  Since the rate 
constants for steps 1 through 5 are not explicitly known, their values were approximated 
based on experimentally determined parameters.  The ratio of rate constants for substrate 
and product binding/dissociation were set to their determined Kd (step 1, 0.5 μM) or Km 
(step 2, 200 μM; step 4, 200 μM; step 5, 25 μM) values for steps 1, 2, 4 and 5.  The 
forward and reverse rate constants for step 3 were set to the determined kcat values for the 
forward (8.15 s-1) and reverse reactions (6.47 s-1) at 24°C.  The concentration of DXP was 
fixed at 975 μM.  The concentrations of DXR and NADPH were allowed to locally float. 
 
2.2.7. FCH2-MEP INACTIVATION ANALYSIS. To test if FCH2-MEP could 
inactivate DXR, 500 nM DXR was incubated at room temperature for 16 h in 100 mM 
 52 
Tris•HCl buffer (pH 7.6) containing 2 mM MgCl2, 1 mg/mL BSA, 300 μM NADP+, and 
1.8 mM FCH2-MEP.  An identical solution mixture without FCH2-MEP was incubated 
for 16 h as a control.  An aliquot (10 μL) of each incubation mixture was assayed for 
activity by adding it to a solution (190 μL) of 150 μM NADPH, 285 μM DXP, 2 mM 
MgCl2, and 1 mg/mL BSA in 100 mM Tris•HCl buffer, pH 7.6.  The concentration of 
MEP was determined as previously described. 
 
2.2.8. TEST FOR FLUORIDE ELIMINATION BY 19F NMR. To determine if DXR 
could catalyze the elimination of a fluoride ion from FCH2-MEP (9), 10 mM FCH2-MEP 
was mixed in a NMR tube with 2 mM MgCl2, and 10 mM NADP+ in 100 mM Tris•HCl 
buffer in D2O (pD 7.8).  The 19F NMR spectrum of this sample was recorded.  DXR was 
then added to the mixture to a final concentration of 60 μM, and the solution was 
incubated at room temperature for 15 h.  The 19F NMR spectrum of this sample was 
recorded at the end of incubation. 
 
2.2.9. TEST OXIDATION OF FCH2-MEP BY NADP+. To determine if DXR can 
carry out the initial oxidation of the primary hydroxyl group of FCH2-MEP (9) to 
generate the aldehyde intermediate (10), the formation of NADPH upon mixing FCH2-
MEP, NADP+, MgCl2 and DXR was investigated.  A solution of 8.5 mM FCH2-MEP, 1 
mM NADP+, 2 mM MgCl2 and 1 mg/mL BSA in 100 mM Tris•HCl buffer pH 7.6 was 
placed in a cuvette, and the absorbance of the solution at 340 nm was determined.  DXR, 
with a final concentration of 77 μM, was then added to the cuvette, and the solution was 
monitored at 340 nm for the production of NADPH. 
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2.2.10. FCH2-MEP INHIBITION STUDIES. The assays were run at 25 °C in degassed 
and N2 saturated 100 mM Tris•HCl buffer (pH 7.6) containing 2 mM MgCl2, 1 mg/mL 
BSA, and 400 µM NADP+, 96 μM MEP, and at varying concentrations of FCH2-MEP (9, 
0-2.9 mM).  The reactions were initiated by the addition of enzyme to a final 
concentration of 50 nM. All reactions were monitored by following the rate of production 
of NADPH at 340 nm.  The concentrations of MEP and DXR were determined as 
previously described. 
 
2.2.11. FRET BINDING ASSAY. The FRET signal used in these studies is the same 
signal in the active site titration studies.  For the FRET titration assays, the excitation 
wavelength was set at 280 nm, and the emission was set to 444 nm with slit widths of 1 
and 3 nm, respectively.  Temperature was set to 25 °C by using an electronic temperature 
controller.  The ligands were titrated into a 2 mL solution of 5 μM DXR, 10 μM NADPH 
and 2 mM MgCl2 in 100 mM Tris•HCl pH 7.6.  The solution was stirred during the entire 
titration with a micro stirbar.  The data for the ligands that produced a change in the 
FRET signal upon binding was fit to the Equation 2-1 to determine the respective Kd. 
For the stopped-flow experiment, one syringe was loaded with 50 μM DXR, 10 
μM NADPH and 2 mM MgCl2 in degassed and N2 saturated 100 mM Tris•HCl buffer 
(pH 7.6), and the other syringe was loaded with 365 μM DXP and 2 mM MgCl2 in the 
same Tris buffer.  The excitation wavelength was set at 280 nm, and a cutoff filter was 
used to block the emissions of wavelengths shorter than 360 nm.  The slit widths were 3 
nm for both excitation and emission.  The temperature was set to 24 °C.   
 
2.2.12. SYNTHESIS OF FLUORINATED ANALOGUES. The 3F-DXP (7) and 4F-DXP 
(8) were first synthesized by Dr. Alex Wong, who was assisted by Ms. Vidusha 
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Devasthali, and their schemes are displayed in Figures 2-7 and 2-8, respectively.  For the 
slow-binding experiments, more 3F-DXP was needed, so I repeated the first two-thirds of 
the synthesis, and Dr. Gang Dong completed the 3F-DXP synthesis.  The synthesis of 
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1. 1,3-propanediol, benzene, p-TsOH




































Figure 2-7: Synthetic scheme for 3F-DXP (7). 
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1. Ac2O, DMSO, rt
2. MeLi, CuI
    THF, -78 oC
     2 steps 80%
1. OXONE, Na2HPO4
         MeOH, rt
2. LiAlH4, THF, 0 oC
       2 steps 40%
1. Tf2O, pyr
    CH2Cl2, 0 oC
 2. TBAF, THF, rt
    2 steps 86%
1. HOAc, H2O, rt
2. NaIO4, aq EtOH, rt
3. NaBH4, aq EtOH, rt





2. NaIO4, aq EtOH, rt
3. NaBH4, aq EtOH, rt





Figure 2-9: Synthetic scheme for FCH2-MEP (9). 
 
2.3. RESULTS AND DISCUSSION 
2.3.1. ANALYSIS OF 3F-DXP AND 4F-DXP AS POSSIBLE SUBSTRATES OF DXR.
 When 3F-DXP (0 to 5 mM) was incubated with 150 nM DXR in the presence 
2mM MgCl2 and 150 μM NADPH in 100 mM Tris pH 7.6, no turnover was observed 
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based on the lack of NADPH oxidation.23  Under the same conditions, 4F-DXP was 
tested as a possible substrate of DXR, and it too failed to be turned-over by DXR.23  
Therefore, the substitution of either the C3-hydroxyl group or the C4-hydroxyl of DXP 
with fluorine results in the loss of activity with respect to DXR.   
These observations are consistent with two independent studies, in which 3-
deoxy-DXP and 4-deoxy-DXP were examined as possible substrates of E. coli DXR.50,51  
It was determined that both are not substrates but mixed-type inhibitors for DXR with Kis 
of 800 μM and 120 μM, respectively.50  Since the KM for DXP was determined in that 
study to be 97 μM, the Ki for 4-deoxy-DXP is similar in magnitude to the KM for DXP, 
yet the Ki for 3-deoxy-DXP is eight-fold higher than the KM for DXP.  The high Ki for 3-
deoxy-DXP and the fact that both analogues exhibit mixed-type inhibition, not standard 
competitive inhibition, raised questions regarding how these analogues bind to DXR.  If 
the removal of a hydroxyl groups prevents proper binding, one may not be able to draw 
any conclusions to the mechanism of DXR based on these studies.  Interestingly, a 
separate analysis of 3-deoxy-DXP and 4-deoxy-DXP with DXR from Synechocystis 
PCC6803 indicated that both analogues are competitive inhibitors with Kis of 150 and 30 
μM, respectively.51  The Ki for 3-deoxy-DXP is roughly equal to their measured KM for 
DXP, while the Ki for 4-deoxy-DXP is roughly six-fold lower than DXP’s KM.  This 
implies that for the DXR from Synechocystis PCC6803, both hydroxyl groups are not 
important for binding but are crucial for chemistry.  This conclusion is in favor of the 
retroaldol/aldol mechanisms over the α-ketol mechanism for the rearrangement reaction 
catalyzed by DXR.  To determine how the substitution of fluorine for each hydroxyl 





2.3.2. Inhibition Analysis of 3F-DXP and 4F-DXP. 
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Figure 2-10: Non-linear progress curves with 3F-DXP (A) and 4F-DXP (B). 
 
As seen in Figure 2-10, both 3F-DXP and 4F-DXP are inhibitors of DXR.  
Interestingly, these nonlinear progress curves are characteristic of slow-binding 
inhibition.52  For slow-binding inhibitors, the nonlinear progress curves result from initial 
weak inhibition which slowly converts to strong, steady-state level of inhibition. 
When the mode of inhibition for 3F-DXP was analyzed for the steady-state phase 
(νss determined from Equation 2-2) of the reaction curve, it was determined from the 
Dixon plot in Figure 2-11 to exhibit competitive inhibition.   To determine the Ki of 3F-
DXP, the νss versus [3F-DXP] curves for each DXP concentration were fitted separately 
to the standard equation for competitive inhibitors, Equation 2-3, which yielded a Ki of 
126 ± 21 μM.  The pattern for 4F-DXP appears to be the same, but due to its moderate 
instability, there was too much noise between the curves to determine for sure.  When the 
steady-state phase for each DXP concentration was analyzed separately, and assuming 
competitive inhibition, a Ki of 224 ± 65 μM was determined for 4F-DXP; due to the 
moderate instability of 4F-DXP, this value represents the upper limit of the true Ki. 
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[3F-DXP] (uM)















Figure 2-11: Dixon plot of 3F-DXP steady-state phase of inhibition (▲) 100 μM DXP, (■)  
  75 μM DXP, (●) 50 μM DXP. 
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Figure 2-12: 3F-DXP steady-state phase of inhibition fit to Equation 2-3, with DXP at 50  















Figure 2-13: 4F-DXP steady-state phase of inhibition fit to Equation 2-3, with DXP at 75  
  μM. 
 

















Figure 2-14: Kinetic mechanisms for slow-binding inhibition. 
 
As depicted in Figure 2-14, there are two possible kinetic mechanism for an 
inhibitor to display slow-binding inhibition.  In mechanism A, the inhibitor binds in a 
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single step, with the rate to equilibrium steady-state inhibition being equal to the sum of 
k3[I] and k-3.  Therefore, if the inhibitor has a slow on and off rate, it will exhibit slow-
binding inhibition.  In mechanism B, the inhibitor binds weakly in a rapid equilibrium to 
form E•I.  The enzyme-inhibitor complex then undergoes a slow but favorable 
conformational change to E•I*, which results in tighter inhibition. 
To distinguish between the two possible kinetic mechanisms for slow-binding 
inhibition as shown in Figure 2-14, the inhibition experiment for 3F-DXP was repeated 
at saturating DXP and NADPH to ensure a linear reaction curve over the time scale of the 
assay.  This experiment was not conducted on 4F-DXP due to its moderate instability.  
To determine how the slow-binding nature of 3F-DXP relates to the previously studied 
slow-binding inhibitor, fosmidomycin,25,53,54 these experiments were conducted on 
fosmidomycin as well.  The progress curves were fit to Equation 2-2, and the kobs was 
plotted versus the concentration of inhibitor.  If the slow-binding inhibition is the result 
of a one-step binding mechanism with a slow on and off rates, as shown in Figure 2-14 
A, then the plot of kobs versus inhibitor concentration should yield a linear relationship.  If 
the inhibitors bind in a two-step mechanism as depicted in Figure 2-14 B, there will be a 
hyperbolic relationship between kobs and inhibitor concentration.  For fosmidomycin, the 
relationship was linear (see Figure 2-15), which implies a one-step binding mechanism.  
However, for 3F-DXP, it was not possible to discriminate between the two possible 
models.  Due to moderate error, the data could be fit to both a linear and a curved line.   
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Figure 2-15: Plot of kobs from Equation 2-2 versus [fosmidomycin] and fit to Equation 2-4. 
 
The slow-binding nature of 3F-DXP and fosmidomycin was further explored 
through global kinetic computer simulations of the progress curves, see Figure 2-16 and 
2-17.  The resulting rate constants and Ki’s of the simulations are reported in Table 2-1. 
 
Table 2-1: Summary of numerical results from computer simulations. 
One-Step Two-Step 
 k6  
(μM-1s-1) 
k-6 (s-1) Ki k6  
(μM-1s-1)
k-6 (s-1) Ki k7 (s-1) k-7 (s-1) Ki* 
3F-DXP 4.84e-5 ± 
8e-7   
3.88e-3 ± 
8e-5  




0.5 ± 0.6 3.81e-3 ± 
9e-5 
80 ± 4000 
μM 




39 ± 1 nM 6 ± 35 330 ± 110 55 ± 300
μM 
3 ± 17 2.4e-3 ± 
1e-4 





Figure 2-16: A) Progress curves for 3F-DXP inhibition with corresponding simulation 
curves from one-step binding mechanism, and B) plot of residuals. 
 
These simulations concluded that a one-step binding mechanism yielded a better 
fit to the family of progress curves for both 3F-DXP and fosmidomycin.  If 3F-DXP and 
fosmidomycin both bind in a two-step mechanism, their initial weak Kis should be 11 
mM and 55 μM, respectively.  With these initial Ki values, the plots of kobs versus 
inhibitor concentration for both inhibitors will appear linear in the experimental 
concentration range for both binding mechanisms.  Therefore, the plot of kobs versus 
inhibitor concentration can not be used to distinguish a one-step binding mechanism from 
a two-step binding mechanism for these two inhibitors.  It is through the global fit of the 






Figure 2-17: A) Progress curves for fosmidomycin inhibition with corresponding 
simulation curves from one-step binding mechanism, and B) plot of 
residuals. 
2.3.3. Analysis of FCH2-MEP as a DXR Inactivator. 
To test if FCH2-MEP (9) could inactivate DXR, FCH2-MEP was incubated with 
DXR, NADP+, and MgCl2 overnight at room temperature.55  An identical incubation 
without 9 was run in parallel as a control.  An aliquot of each incubation mixture was 
assayed for activity by adding it to a solution containing NADPH, DXP, and MgCl2.  No 
loss in activity was observed as compared to the control.  Evidently, this compound is not 
an irreversible inactivator for DXR. 
To determine if DXR could catalyze the elimination of a fluoride ion from FCH2-
MEP, FCH2-MEP was mixed in a NMR tube with MgCl2 and NADP+, and the 19F NMR 
spectrum of this sample was recorded.55  DXR was then added to this mixture, and the 
solution was incubated at room temperature overnight.  The 19F NMR spectrum of this 
sample was again recorded, and no new peak in the 19F NMR spectrum was detected.  It 
was determined that no fluoride elimination was not due to DXR's inability to catalyze 
the retroaldol reaction on 10, but due to its inability to oxidize FCH2-MEP to 10 using 
A B
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NADP+.55  This is evident by the lack of NADPH production upon mixing FCH2-MEP 
with DXR, NADP+ and MgCl2.   
The fact that FCH2-MEP is neither a suicide inhibitor nor a substrate for DXR 
renders it unfit to distinguish the two proposed rearrangement mechanisms for DXR. The 
inability of DXR to catalyze the initial oxidation of FCH2-MEP, which is a prerequisite 
for both rearrangement mechanisms, may be ascribed to the increased steric bulk of the 
fluoromethyl group that may impede the required preorganization of FCH2-MEP in the 
active site for the oxidation to occur.  Interestingly, incubation of FCH2-MEP in the 
presence of MEP revealed that it is a weak inhibitor against DXR.  As shown in Figure 
2-18, when the reaction was run in the reverse direction with MEP (96 μM, which is 
roughly half its Km value) as the substrate, the addition of excess FCH2-MEP (2.9 mM) 
led to 45% inhibition of the reaction. 
[FCH2-MEP] (mM)












Figure 2-18: Dixon plot showing the inhibition by FCH2-MEP on the formation of DXP 
catalyzed by DXR.  The incubtion mixture contained 40 nM DXR, 400 μM 
NADP+, 2 mM MgCl2, and 96 μM MEP in 100 mM Tris•HCl buffer, pH 7.6. 
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2.3.4. FRET Binding Analysis. To explore the binding of the fluorinated analogues 
to DXR, a binding assay was developed by following the change of the FRET signal from 
Trp212 and the bound NADPH.  To confirm that a FRET signal exists for the 
DXR•NADPH•Mg2+ complex, a fluorescence scan of an NADPH and MgCl2 solution 
was conducted while exciting at 280 nm.  DXR was added to the solution and the scan 
was repeated, which produced the FRET signal displayed in Figure 2-19. 
 
wavelength (nm)












Figure 2-19: FRET Scans - Dashed line: 2 mM MgCl2, 55 μM NADPH in 100 mM Tris 
pH 7.6; Dotted line: the same solution but with 50 μM DXR; Solid line: 
difference spectrum showing the FRET peak at 440 nm. 
 
When MEP, 4F-DXP and fosmidomycin were titrated into a solution of DXR, 
NADPH and MgCl2, an increase in the FRET signal was observed, see Figure 2-20.  This 
change in FRET signal upon the addition of MEP, 4F-DXP and fosmidomycin was used 
to determine their respective Kd’s to the DXR•NADPH complex, and these values are 
listed in Table 2-2.  However, when 3F-DXP, FCH2-MEP or DMAPP (DMAPP is an 
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A B
inhibitor of DXR in the low mM range) was titrated into a solution of DXR, NADPH and 
MgCl2, no change in the FRET signal was observed. 
 
Table 2-2: Summary of analytical results from fitting to Equations 2-1 and 2-3. 
 Ki Kd 
3F-DXP 126 ± 21 μM ND 
4F-DXP 224 ± 65 μM 200 ±12 μM 
Fosmidomycin 23 ±10 nM 28 ± 4 nM 
DXP 130 ± 40 μM ND 
MEP 165 ± 28 μM 132 ± 6 μM 
 
[Ligand] (uM)






























Figure 2-20: FRET titration of A: (●) MEP and (■) 3F-DXP; B: 4F-DXP. 
 
When 3F-DXP, FCH2-MEP or DMAPP was added to a solution of DXR, 
NADPH, MEP and MgCl2, a decrease in the FRET signal is observed due to competitive 
binding against MEP for the active site.  To determine if DXP induces an increase in the 
FRET signal upon binding to the active site, the binding assay was adaptive for analysis 
via stopped-flow under single-turnover conditions.  A solution of DXP and MgCl2 was 
mixed with a solution of DXR, NADPH and MgCl2, and an initial increase in the FRET 
signal was observed followed by the loss of the FRET signal due to the oxidation of 
NADPH during catalysis.   
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The fact that 3F-DXP, FCH2-MEP and DMAPP do not induce a change in the 
FRET signal while the other compounds tested here do, implies that these three 
compounds do not bind to the active site of DXR.  Since 3F-DXP is a slow-binding 
inhibitor, and closely resembles DXP and 4F-DXP, it is reasonable to assume that it binds 
to the active site.  Similarly, FCH2-MEP and DMAPP are related to the compounds that 
produce a change in the FRET signal upon binding.  Since they can compete with MEP 
for the binding site and have been shown to be inhibitors for DXR, they should also bind 
to the active site of DXR.  From the crystal structure studies, it is clear that fosmidomycin 
binds to the active site magnesium ion in a bidentate manner through the hydroxamate 
moiety.  It is believed that DXP also binds in an analogous bidentate form involving the 
C2 carbonyl and the C3 hydroxyl group.56,57  When the compounds that produced a 
change in the FRET signal upon binding were compared to those that are innert, it 
became apparent that all the compounds that produced a change contained both 
functional groups required for bidentate binding to the magnesium ion, as shown in 
Figure 2-21.  The compounds that failed to produce a change in the FRET signal are 
missing either one or both of the functional groups required for bidentate binding.  Since 
3F-DXP binds in a slow one-step mechanism, likely due to a slow conformational change 
that occurs concurrently with inhibitor binding, and does not produce a change in the 
FRET signal, the change in FRET signal observed for DXP, 4F-DXP, MEP and 
fosmidomycin unlikely arises from a conformational change.  The reason for the increase 
in the FRET signal is believed to be due to the desolvation of the active site triggered by 
the elimination of the two water molecules bound to the magnesium when the 


















































Figure 2-21: Structures of the compounds whose binding to DXR•NADPH•Mg2+ was 
analyzed by FRET assay. The compounds that produce an increase in the 
FRET signal upon binding have their proposed Mg2+ ligands circled.  The 
compounds that do not produce a change in the FRET signal upon bindng 
have the missing Mg2+ ligand boxed. 
 
2.4. CONCLUSION 
To discriminate between the α-ketol mechanism and the retroaldol/aldol 
mechanism for the rearrangement reaction catalyzed by DXR, 3F-DXP and 4F-DXP were 
synthesized and analyzed as possible substrates.  It was determined that neither analogue 
is a substrate and that both are inhibitors with Ki’s similar to the KM of DXP.  These 
results are in agreement with the analysis from the study on 3-deoxy-DXP and 4-deoxy-
DXP, which concluded that both hydroxyl groups are important for catalysis yet not 
crucial for binding.37  Interestingly, in that same study, the authors report that 4-epi-DXP 
is also not a substrate and has a Ki similar to the KM of DXP; thus the stereochemistry of 
at least the C4 hydroxyl group is also important for catalysis and not binding.  The ability 
of both 4F-DXP and DXP to produce the same increase in the FRET signal upon binding 
implies that both bind in the same manner.  This further supports the conclusion that the 
importance of the C4-hydroxyl group is for chemistry and not for proper binding, and the 
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reaction favors the retroaldol/aldol rearrangement mechanism over the α-ketol 
rearrangement mechanism. 
When the study with 3F-DXP and 4F-DXP was first conducted, they were both 
found to be noncompetitive inhibitors of DXR.23  After reexamining the data, it was 
determined that 3F-DXP and 4F-DXP in fact slow-binding inhibitors for DXR.  The 
overlooking of the slow-binding inhibition resulted from using the initial weak binding 
phase to determine the initial velocity at low inhibitor concentrations, and using the final 
steady-state phase to determine the initial velocity at high inhibitor concentrations.  It is 
possible that a similar situation also occurred in the determination of 3-deoxy-DXP and 
4-deoxy-DXP as mixed type inhibitors for DXR that was also cloned from E. coli.40  
However, when 3-deoxy-DXP and 4-deoxy-DXP were analyzed against DXR cloned 
from Synechocystis PCC6803, no slow-binding inhibition was reported and both behaved 
as competitive inhibitors.37  
Based on the global analysis, both 3F-DXP and fosmidomycin are slow-binding 
inhibitors due to their respective slow on and off rates, not due to a slow conformational 
change following an initial rapid binding.  From crystal structure data, it is known that a 
conformation change does occur for the ternary DXR•NADPH•DXP/inhibitor enzyme 
complex, in which residues 206-216 move to enclose the active site upon forming the 
ternary complex.57  It is likely that this conformational change happens in a concerted 
manner along with DXP/inhibitor binding, which produces the slow on and off rates.58  
The requirements for slow-binding inhibition are not completely clear.  Among the 
compounds investigated here, only 3F-DXP, 4F-DXP and fosmidomycin exhibited slow-
binding inhibition; FCH2-MEP, DXP, MEP and DMAPP did not.  According to these 
results, two possible requirements for slow-binding inhibition become apparent.  One is 
the absence of either the 3-OH group or the 4-OH group but not both.  These hydroxyl 
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groups form hydrogen bonds with active site residues,57 which can provide part of the 
driving force for the binding/conformational change.  Thus, removal of one hydrogen 
bond donor/acceptor could raise the energy barrier for this conformational change that 
accompanies binding, resulting in slow-binding inhibition.  Removal of both hydrogen 
bond donor/acceptors could increase the energy barrier high enough to prevent the 
conformational change from occurring.  Consistent with this notion, fosmidomycin and 
4F-DXP are both missing the 4-OH group, and 3F-DXP is missing the 3-OH group.  
Mercklé et al. also reported that N-acetyl-1-amino-3-phosphonopropane, which lacks 
both 3-OH and 4-OH groups, does not show slow-binding inhibition.54  FCH2-MEP is 
only missing the 3-OH group, yet it is not slow-binding inhibitor.  This can be explained 
by its violation of the second possible requirement for slow-binding inhibition, no steric 
hindrance.  The increased steric bulk of the fluoromethylene group than the hydroxyl 
group prevents FCH2-MEP from proper binding to facilitate the conformational change.  
This can help account for the weak inhibition of FCH2-MEP, which is only effective in 
the mM range.  The size restrictions imposed on binding is also evident from the lack of 
turnover of Et-DXP ((2R,3S)-2,3-dihydroxy-4-oxohexyl dihydrogen phosphate), where 
the methyl group in DXP was replaced by an ethyl moiety.41  However, Et-DXP can still 
bind to and weakly inhibit DXR with an IC50 of 6.2 mM, but no slow-binding inhibition 
was reported for Et-DXP.  The impact of steric hindrance on binding and the absence of 
slow-binding inhibition is also evident for the carbamate fosmidomycin analogues 
designed by Mercklé et al. to rigidify the slow-binding inhibitor.54  Even though these 
analogues were well designed, they only showed inhibition in the high μM to low mM 
concentration range, and none of the analogues exhibited slow-binding inhibition.  This is 
believed to be due to the increase in steric bulkiness resulting from the modifications of 
fosmidomycin to increase its rigidity. 
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In an attempt to further differentiate between the two proposed mechanisms, 
FCH2-MEP was synthesized and analyzed as a possible mechanism-based inhibitor.  
Although this analogue was unable to inactivate DXR as originally proposed, it was 
determined to be a weak inhibitor of DXR.  It is possible that the cytidylated form of 
FCH2-MEP (equivalent to CDP-ME), which could be made synthetically or possibly by 
IspD, could be a viable inhibitor for IspE, which is also an excellent antibiotic drug target 
(see Figure 1-4).  The inability of DXR to oxidize FCH2-MEP to the aldehyde 
intermediate and the weak inhibition of FCH2-MEP towards DXR are most likely due to 
the steric hindrance caused by the substitution of a fluoromethylene group for a hydroxyl 
group. 
To investigate the binding of the fluorinated analogues, the FRET binding assay 
was developed.  The high sensitivity and simplicity of this binding assay make it ideal for 
high-throughput screening purpose.  A high-throughput screening assay for binding has 
previously been developed for DXR; however, this assay requires washing steps, 
streptavidin coated plates, biotinylated DXR, europium-conjugated streptavidin and a 
biotinylated peptide to serve as the competing DXR ligand.59  With the FRET assay 
described herein, a screening system can be envisioned requiring no washing steps and 
only native DXR, NADPH, MgCl2 and possibly MEP as a competing ligand. 
The results presented in this chapter provide a useful guide for the design of 
future inhibitors of DXR, which must consider the size restriction imposed by the active-
site of DXR.  However, due to the difficulty in rationally designing an inhibitor that does 
not violate DXR’s strict size exclusion, a high-throughput screening of chemical libraries 
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Chapter 3: Secondary Kinetic Isotope Effect Study on DXR 
3.1. INTRODUCTION 
Terpenoids are a large family of natural products comprised of over 35,000 
distinct compounds.1  They are widely distributed in nature and are rich in biological 
activities, including light harvesting pigments,2 growth hormones,3 and molecules 
involved in signal transduction.4  The terpenoid building block is a 5-carbon unit known 
as isoprene, which has long been established to be derived from acetate via the 
mevalonate pathway.5  However, a new isoprene biosynthetic pathway has recently been 
discovered in eubacteria, archeabacteria, algae, and in the plastids of plants where the 
isoprenoid unit is formed independently of mevalonate.6-8  Since this pathway is absent in 
mammals but is essential for many pathogens, including Plasmodium falciparum9 and 
Mycobacterium tuberculosis,10 all enzymes in this pathway are potential antibacterial 
targets.11  
The first committed step of the nonmevalonate pathway is catalyzed by DXR, 
which catalyzes the rearrangement and NADPH mediated reduction of DXP (1) to MEP 
(3).  Since MEP is the first metabolite specific to this pathway, this pathway is also 
known as the MEP pathway.  There are two proposed mechanisms for the rearrangement 
reaction, a concerted α-ketol rearrangement and a stepwise retroaldol/aldol 
rearrangement.  In the α-ketol rearrangement, deprotonation of the C-3 hydroxyl group 
followed by a 1,2-migration to yield the aldehyde intermediate, methylerythrose 
phosphate (2), which is subsequently reduced by NADPH.  In the retroaldol/aldol 
rearrangement mechanism, DXR first cleaves the C3-C4 bond of 1 through a retroaldol 
mechanism to yield a three carbon (4) and a two carbon phosphate intermediates (5); 
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these intermediates then condense through an aldol reaction to form a new C-C bond 
















































Figure 3-1: Proposed Mechanisms for DXR. 
 
A key difference between these two proposed mechanisms is the chemistry that 
occurs at C3 versus C4.  In Chapter 2, it was described how the hydroxyl groups at C3 
and C4 were separately replaced with a fluorine atom to probe the involvement of each 
hydroxyl group in the rearrangement reaction.12  Neither of these fluoro analogues is a 
substrate for DXR, but both are slow-binding inhibitors.12,13  These results are consistent 
with the retroaldol/aldol mechanism, since both hydroxyl groups are involved in the 
rearrangement reaction.  If the reaction proceeds with the α-ketol rearrangement 
mechanism, which only utilizes the C3-hydroxyl group, the 4-fluoro-analogue should be 
a substrate. 
To further investigate this important reaction, we designed and synthesized 3[2H]-
DXP (6) and 4[2H]-DXP (7) to study the secondary kinetic isotope effect experiment (2° 
KIE) of the DXR reaction.  The results may provide insight to distinguish between the 
two proposed rearrangement mechanisms.  A KIE of a is observed when there is a 
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difference in the zero-point energies (ZPE) of a C-H bond and the corresponding C-D 
bond in the reactant state versus in the transition state.  Differences in mass moments of 
inertia (MMI) and excited vibrational states (EXC) also contribute to the KIE.  However, 
for deuterium KIE’s, the difference in ZPE dominates the KIE.  If the reaction under 
investigation involves the cleavage of the C-H/D bond, a 1° KIE greater than unity is 
predicted.  If bond cleavage occurs next the labeled C-H bond in the reaction, a 2° KIE 
may be observed.  If the KIE is greater than unity, it is a normal KIE, and if the resulting 
KIE is less than unity, it is known as an inverse KIE.  Secondary KIE’s can be further 
devided into α and β effects.  An α effect occurs when the H/D is bonded to the carbon 
center where the reaction takes place, and in a β effect, the H/D is attached to a carbon 
adjacent to the carbon center where the reaction occurs.  The isotope effect study 

















Figure 3-2: Structures of 3[2H]-DXP (6) and 4[2H]-DXP (7). 
 
As stated above, a KIE arises predominantly from the difference in the ZPE of a 
C-H bond and a C-D bond in the reactant state versus in the transition state.  For a 2° α-
KIE, this difference is mostly due to changes in the hybridization state between the 
substrate and transition state.  When a carbon atom changes from sp3 to sp2 hybridization, 
a number of vibrational modes (stretches, in-plane and out-of-plane bending) change.  
The changes in streches and in-plane bending are too small to create a significant isotope 
effect.  However, the out-of-plane bending vibration for a sp3 carbon is 1350 cm-1, while 
that for a sp2 carbon is 800 cm-1.  This difference is large enough to produce a significant 
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isotope effect.  The larger force constant for the out-of-plane bending vibration of the sp3 
centered C-H/D bond implies a stiffer bond vibration and thus a more narrow potential 
energy well.  As seen in Figure 3-3, the narrower energy well produces a larger 
difference in the ZPEs between the sp3 C-H/D bonds than the difference between the sp2 


















Figure 3-3: Reaction coordinate diagram displaying the origin of the normal 2° KIE for 
a sp3 carbon that rehybridizes to a sp2 centered carbon. 
 
The hybridization state of the transition state lies between the hybridization state 
of the substrate and product.  If a carbon rehybridizes from sp3 to sp2, the transition state 
will have an s-character greater than an sp3 center but less than an sp2 center.  The 
amount of rehybridization that has occurred in the transition state is determined by 
whether the transition state occurs early or late.  Either way, the transition state will have 
a smaller force constant than the sp3 reactant state; thus it will have a smaller difference 
between the C-H/D ZPEs.  This smaller difference in the ZPEs at the transition state will 
increase the activation energy of the deuterium labeled reaction, resulting in a normal 2° 
 83
KIE.  Whether the transition state is early or late will impact the size of the intrinsic 
isotope effect.  If a reaction has an early transition state, it will be more reactant-like than 
product-like; thus little rehybridization would have occurred for that stage of the reaction.  
This will produce a small difference in the C-H/D ZPEs between the reactant state and 
transition state, which will give a small, normal intrinsic isotope effect.  The later the 
transition state of the reaction, the larger the difference of the C-H/D ZPEs between the 
reactant state and transition state will be, and thus the larger the intrinsic isotope effect 
will be, with a theoretical maximum value of 1.4.14  A reaction undergoing a 









Figure 3-4: Structure of 1F-DXP (8). 
 
In a report from Fox et al., 1F-DXP (8) was synthesized and analyzed as a 
possible substrate.  The fluorine addition to the methyl group is expected to accelerate the 
retroaldol reaction by stabilizing the negative charge on the resulting three carbon 
intermediate.  Indeed, the kcat for 1F-DXP was determined to be roughly twice that of 
DXP.15  To investigate whether the reduction step is rate-limiting, the 1° KIE was 
examined with 4S-[2H]-NADPH and DXP under single-turnover conditions.  A KIE of 
1.02 ± 0.02 was determined.  The experiment was repeated with 1F-DXP substituted for 
DXP, and a 1° KIE of 1.34 ± 0.01 was determined.  The KIE of unity with DXP implies 
that the hydride transfer step is not rate-limiting; however, the hydride-transfer step 
becomes partially rate-limiting when 1F-DXP (8) is substituted for DXP (1).  For the 
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hydride-transfer step to become partially rate-limiting, the step that is rate-limiting in the 
DXR reaction would have to become faster with a rate comparable to that of the hydride-
transfer step.  Since the addition of the fluorine at C1 is expected to accelerate the 
retroaldol reaction, the rearrangement step must be rate-limiting when DXP (1) is used as 
the substrate.  Thus, an observed 2° KIE should result only from the rearrangement 
reaction, specifically from the retroaldol reaction. 
In the α-ketol rearrangement, the C3 rehybridizes from sp3 to sp2, while the C4 
remains sp3 through out the reaction coordinate.  Therefore, if DXR utilizes the α-ketol 
rearrangement mechanism, 3[2H]-DXP should produce a normal 2° KIE, and 4[2H]-DXP 
should have a 2° KIE of unity.16  In the retroaldol/aldol rearrangement reaction, the C3 
rehybridizes from sp3 to sp2 in the retroaldol reaction and remains sp2 through out the 
aldol condensation reaction.  The C4 changes from sp3 to sp2 in the retroaldol reaction 
and changes back to sp3 in the aldol condensation reaction; however, it is believed that 
the retroaldol reaction will be significantly more rate-limiting than the aldol condensation 
reaction.  Thus if DXR follows the retroaldol/aldol rearrangement mechanism, 3[2H]-
DXP and 4[2H]-DXP should both produce a normal 2° KIE.16 
 
3.2. MATERIALS AND METHODS 
3.2.1. GENERAL. The pET24(+) vector was purchased from Novagen (Madison, 
WI).  Cloned DNA polymerase Pfu was obtained from Stratagene (La Jolla, CA).  
Primers used in PCR amplification were customarily prepared by Integrated DNA 
Technologies (Coralville, IA) and used without further purification.  All electrophoretic 
reagents were obtained from Bio-Rad (Hercules, CA), and culture media were products 
of Difco (Detroit, MI).  All other chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO) or Fisher Scientific (Pittsburgh, PA).  DXP and MEP were made through 
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enzymatic synthesis as published,17,18 except were purified by cellulose chromatography 
using water and THF as the solvent system.  The concentrations of DXP, 3[2H]-DXP, 
4[2H]-DXP and MEP were determined according to a literature proceedure.19 
 
3.2.2. REMOVAL OF HIS-TAG, OVER-EXPRESSION AND PURIFICATION OF DXR.
 The DXR used in this work is the native (non-tagged) form of the enzyme; in the 
studies described in Chapter 2, a C-terminal His-tagged DXR.12,13,20  The C-terminal His-
tag was removed by inserting a stop codon after the dxr sequence and before the coding 
sequence for the His-tag.  This was performed by site-directed mutagenesis using the 
QuickChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). The 
oligonucleotides used for mutagenesis were customarily synthesized by Integrated DNA 
Technology (Coralville, IA).  The mutagenesis primers used were dxrn1 
(5’GGTGATGCGTCTCGCAAGCTGACTCGAGCACC) and dxrn2 
(5’GGTGGTGGTGGTGCTCGAGTCAGCTTGCGAGA). The constructed mutant 
plasmids were amplified in E. coli strain DH5α and purified with QIAprep spin miniprep 
kit (Qiagen, Valencia, CA). Once the mutation was verified by DNA sequencing 
performed by the core facility in the Institute for Cellular and Molecular Biology of the 
University of Texas at Austin, the mutant plasmids were used to transform E. coli BL21 
Star™ (DE3) (Invitrogen, Carlsbad, CA) for protein expression. 
An overnight culture of the recombinant strain grown in LB media supplemented 
with kanamycin (50 μg/mL) at 37 oC was used to inoculate six 1 L cultures of the same 
medium and antibiotic.  These cultures were grown at 37 oC until the OD600 reached 0.65, 
followed by induction with 0.1 mM IPTG and 3.5 h of additional incubation at 37 oC.  
The cells were harvested by centrifugation (7000g, 8 min).  DXR was purified according 
to a literature procedure.19  The purified protein was concentrated, mixed with glycerol to 
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a final concentration of 30%, aliquotted, flash frozen, and stored at –80 °C.  The 
concentration of DXR was determined by the method of fluorescence active-site titration 
with NADPH as described in Chapter 2.12 
 
3.2.3. SYNTHESIS OF 3[2H]-DXP AND 4[2H]-DXP. The deuterium labeled DXP, 
3[2H]-DXP (6) and 4[2H]-DXP (7), were synthesized according to the synthetic schemes 
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Figure 3-6: Synthetic scheme of 4[2H]-DXP (7). 
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3.2.4. DETERMINING KCAT AND KM FOR DXP, 3[2H]-DXP AND 4[2H]-DXP.
 Enzyme assays were performed in duplicate and according to a literature 
procedure.19  The reactions were carried out at 24 °C.  The reaction mixture contained 
100 μL of degassed and N2 saturated 100 mM Tris•HCl buffer (pH 7.6), 2 mM MgCl2, 1 
mg/mL BSA, 0.15 mM NADPH, 30 nM DXR, and varied (20 μM-2328 μM) 
concentrations of DXP, 3[2H]-DXP and 4[2H]-DXP.  The reaction was initiated by the 
addition of DXR and was monitored by the consumption of NADPH at 340 nm.  The 
kinetic parameters of kcat and Km were determined using Grafit 5.0.1. 
 
3.2.5. DETERMINING KEQ FOR THE DXR REACTION USING DXP, 3[2H]-DXP AND 
4[2H]-DXP. The equilibrium constant for the reaction with DXP, 3[2H]-DXP and 
4[2H]-DXP was determined by measuring the change in [NADPH] from before the 
addition of DXR to after the addition of DXR till the reaction mixture reached 
equilibrium.  The assays were carried out at a fixed concentrations of MgCl2 (2 mM), 
NADPH (75 μM), DXP (67 μM), 3[2H]-DXP (57 μM), 4[2H]-DXP (70 μM), and at 
varying concentrations of NADP+ (0-1.7 mM) in 500 μL of 100 mM Tris pH 7.6 that was 
degassed and N2 saturated.  To drive the reaction to equilibrium, DXR was added to a 
final concentration of 1.7 μM.  The assays were carried out at 24 °C in duplicate.  To 
determine the Keq for each reaction the data was fit to Equation 3-1 using Grafit 5.0.1, 
where [NADPH]o, [DXP]o, and [NADP+]o are the respective starting concentrations 
before the addition of DXR.  In the equation, [X] is the difference between [NADPH]o 
and the concentration of NADPH once equilibrium is reached.  In the data fitting, Keq was 














3.2.6. EQUILIBRIUM PERTURBATION EXPERIMENT. The equilibrium perturbation 
experiments were conducted according to literature procedures.21-23  The concentrations 
used in the experiment were based on a similar study on alcohol dehydrogenase.23  The 
perturbations were carried out in triplicate and at 24 °C.  A stock solution containing 
MgCl2, NADPH, 3/4[2H]-DXP, MEP and NADP+ was made, and a 1 mL aliquot of this 
stock solution was diluted to 3 mL for each perturbation experiment.  The final 
concentrations for the 3[2H]-DXP perturbation experiments were 165 μM NADPH, 1 
mM 3[2H]-DXP, 1.1 mM MEP, 3.1 mM NADP+ and 2 mM MgCl2.  For the 4[2H]-DXP 
perturbation experiments, the final concentrations were 148.5 μM NADPH, 900 μM 
4[2H]-DXP, 990 μM MEP, 2.79 mM NADP+ and 1.8 mM MgCl2.  Before the addition of 
enzyme, the sample in the cuvette was incubated in the UV/Vis cell holder, which is 
connected to a water circulator to allow the temperature of the sample to equilibrate and 
to ensure the sample produce an acceptable baseline reading.  The concentration of DXR 
in each perturbation experiment varied from 300-450 nM. 
 
3.2.7. KINETIC SIMULATIONS OF EQUILIBRIUM PERTURBATION EXPERIMENTS.
 The E. coli DXR has been shown to have an ordered substrate binding 
mechanism, with NADPH binding before DXP.19  In contrast, studies of M. tuberculosis 
DXR concluded that it binds substrate in random order, but with a preference to bind 
NADPH before DXP.10  In computer simulations described here, the ordered substrate 
binding mechanism was used.  It was assumed that product release is also ordered with 
MEP dissociating before NADP+.  A fully random kinetic mechanism was tested by 
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simulation but did not produce significantly different results.  Therefore, for 
simplification, only the ordered mechanism is considered herein.  The kinetic mechanism 
used in the simulation is shown in Figure 3-7. 
 
DXR + NADPH DXR  NADPH                    (1)
DXR  NADPH  DXP          (2)DXR  NADPH + DXP
DXR  NADP  MEP             (3)DXR  NADPH  DXP
DXR  NADP + MEP          (4)DXR  NADP  MEP











DXR  NADPH  d-DXP       (6)DXR  NADPH + d-DXP
DXR  NADP  d-MEP         (7)DXR  NADPH  d-DXP







Figure 3-7: Kinetic scheme used for computer simulations. 
 
In the simulations, all the rate constants were allowed to float but with a few 
restrictions.  One restriction is that there is no isotope effect on binding.  The simulation 
was carried out by having the rate constant for binding of DXP and [2H]-DXP set equal to 
each other so that they floated together.  This condition was also applied to true for the 
dissociation of DXP and [2H]-DXP and for the binding/dissociation of MEP and [2H]-
MEP.  The Kd of 750 nM for NADPH to DXR was previously determined in the active 
site titration experiment.  In the simulations, the rate constants for NADPH binding and 
dissociation were floated together so that the equilibrium for binding equaled the Kd 
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value for NADPH.  Since the Kds for DXP, MEP and NADP+ are not known, their rate 
constants for binding and dissociation were allowed to float independent of each other.  
To further restrict the simulation, the ratio of the equilibrium for chemistry of the 
unlabeled reaction, Step 3, and that for the labeled reaction, Step 7, was set to their 
respective equilibrium isotope effect (See Table 3-3).  This was performed by fixing the 
ratio of chemistry for the unlabeled reaction, Step 3, to the ratio of the kcat for the forward 
and reverse reactions.  The ratio for chemistry in the labeled reaction was then fixed so 
that the equilibrium isotope effect equaled the experimentally determined value.   
The binding and dissociation rates for all compounds and the equilibrium binding 
values for DXP, MEP or NADP+ derived from computer simulations are not to be 
considered as accurate.  The values obtained by simulations depend on the initial starting 
values.  All of the starting binding rates were set less than the diffusion controlled limit to 
ensure that the returned values were also under the limit.  If different values for the 
binding and dissociation rates were used to start the simulation, the program would give 
different rates and equilibrium values at the end.  If the Kd for DXP was lowered, then the 
Kd for either NADP+ or MEP would also lower so that the starting reactant concentrations 
entered into the program were at equilibrium.  In the simulations, the exact equilibrium 
binding value for each reactant is not important, only the relationship among the four 
reactants is important.  The binding and dissociation rates did affect the KIE values but 
not in a significant manner.  Depending on the starting binding and dissociation rates, the 
KIE for 3[2H]-DXP ranged from 1.02 to 1.05 and the KIE for 4[2H]-DXP ranged from 
1.09 to 1.14.  The simulation results from Table 3-2 were used to calculate the KIEs 
reported in Table 3-3. 
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3.3. RESULTS AND DISCUSSION 
3.3.1. NON-COMPETITIVE KIE ANALYSIS. The kcat and KM for DXP, 3[2H]-DXP 
and 4[2H]-DXP were determined under identical conditions and according to the 
procedure described above.  These values and their corresponding (non-competitive) 
dkcat’s and dkcat/KM’s are reported in Table 3-1.  While this investigation was underway, a 
similar study was reported by Wong et al., and their reported KIEs are also listed in 
Table 3-1 for comparison.24  Our dkcat values are in support of the retroaldol/aldol 
mechanism; however, the dkcat/Km values do not completely agree with expected results 
for either mechanism.  The normal C4 KIE is consistent with the retroaldol/aldol 
mechanism and derives from the initial retroaldol cleavage reaction where the C4 carbon 
rehybridizes from sp3 to sp2.  The inverse C3 KIE could only arise for both proposed 
mechanisms from the sp2 to sp3 rehybridization of C3 carbon when the rearranged 
aldehyde intermediate is reduced by NADPH.  This would result if the reduction step is 
rate-limiting, which is inconsistent with the findings of Fox et al.15  If the reduction step 
is rate-limiting, the C4 KIE should be close to unity. 
In the study carried out by Wong et al.,24 the reported KIE’s were determined in a 
similar non-competitive manner.  Their data was interpreted in favor of the 
retroaldol/aldol rearrangement mechanism; however, there are a few problems with their 
KIE values as well.  First, both values for dVmax are smaller than the theoretical minimum 
for a 2° KIE of ~0.71.  Second, the dVmax and dVmax/KM KIE’s for C3 and C4 are inverse.  
As discussed in the previous paragraph, a C3 inverse KIE is possible only if the reduction 
step is rate-limiting.  However, this has been determined not to be the rate-limiting step.15  
Also, if the reduction step is the rate-limiting step of the DXR reaction, the C4 KIE 
should be close to unity.  Again, this is not true.  The reported C4 KIE for both dVmax and 
dVmax/KM is inverse, which could only result from the aldol condensation in the proposed 
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retroaldol/aldol mechanism and is impossible for the α-ketol rearrangement mechanism.  
Thus, if the data are correct, the aldol condensation reaction sould be the rate-limiting 
step for DXR, even though the retroaldol cleavage is more likely the rate-limiting step for 
the retroaldol/aldol rearrangement mechanism.  Again, the C3 KIE should have a value 
close to unity, if the aldol condensation is the rate-limiting step.  Clearly the latter is 
inconsistent with what was observed. 
 
Table 3-1: Summary of non-competitive KIE measurements. 
Substrate kcat (s-1) KM (μM) dkcat dkcat/KM dVmax (a) dVmax/KM (a) 
DXP 16.1 ± 0.7 166 ± 20 -- -- -- -- 
3[2H]-DXP 13.2 ± 0.7 116 ± 20 1.21 ± 0.08 0.85 ± 0.19 0.56 0.92 
4[2H]-DXP 13.7 ± 0.5 154 ± 17 1.17 ± 0.05 1.12 ± 0.17 0.62 0.86 
(a)  KIE results from study by Wong et al.24 
 
After close inspection of the data obtained by our assays, it became apparent that 
not all of the progress curves for the 3[2H]-DXP and 4[2H]-DXP assays were linear, see 
Figure 3-8.  This is different from what was found when the enzymatically synthesized 
DXP was used in the assays.  The nonlinear progress curves are characteristic of a slow-
binding inhibitor,25 and slow-binding inhibitors for DXR have been reported and 
discussed in Chapter 2.13,19  The presumed slow-binding inhibitor is likely the DXP 
enantiomer resulting from the dihydroxylation step in the synthesis of both labeled 
substrates.26  This is supported by the observation that DXP with the stereochemistry of 
its C4-hydroxyl group inverted is not a substrate for DXR.27  This observation raised 




































Figure 3-8: Steady-state progress curves for DXP, 3[2H]-DXP and 4[2H]-DXP in 
determining dkcat and dkcat/Km for 3[2H]-DXP and 4[2H]-DXP.  Reaction 
conditions A) 100 mM Tris pH 7.6, 2 mM MgCl2, 150 μM NADPH, 30 nM 
DXR, and 118 μM DXP (●) or 116 μM 3[2H]-DXP (▲); B) 100 mM Tris pH 
7.6, 2 mM MgCl2, 150 μM NADPH, 30 nM DXR, and 2295 μM DXP (●) or 
2328 μM 4[2H]-DXP (▲). 
 
3.3.2. EQUILIBRIUM PERTURBATION EXPERIMENTS. In order to avoid any 
complications due to the contamination of an inhibitor, we decided to employ the 
equilibrium perturbation method to determine the KIE.  Since this is a competitive 
technique, the contaminant will not have an effect on the size of the KIE.21,22  DXR is an 
excellent system for this method due its reaction being freely reversible and the easiness 
to follow the course of the reaction by monitoring the formation/consumption of NADPH 
at 340 nm.  The experiment is initiated by adding DXR to a solution of NADPH, 3/4[2H]-
DXP, NADP+ and MEP at chemical equilibrium but not isotopic equilibrium.  If there is 
a normal KIE (labeled substrate being slower than unlabeled substrate), there will be a 
temporary increase in the concentration of NADPH due to the forward reaction being 
slower than the reverse reaction.  If there is an inverse isotope effect, then there will be a 
temporary decrease in the concentration of NADPH due to the forward reaction being 
faster than the reverse reaction.  To determine the concentrations of NADPH, 3/4[2H]-
DXP, NADP+ and MEP required for the mixture to be at chemical equilibrium at the 
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beginning of the perturbation experiment and to aid in the simulations to determine the 
KIE’s, the equilibrium constants for the reaction with DXP, 3[2H]-DXP and 4[2H]-DXP 
and the corresponding equilibrium isotope effects were determined from the data in 





















































Figure 3-9: Curves for determining Keq for the reaction with A) DXP, B) 3[2H]-DXP, and 
C) 4[2H]-DXP.  [X] is from Equation 3-1, and represents the change in 
[NADPH] upon addition of DXR. 
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For 3[2H]-DXP and 4[2H]-DXP a temporary increase in the concentration of 
NADPH was observed before returning to equilibrium, corresponding to a normal 2° KIE 
for both compounds, see Figure 3-10.  To solve for the KIEs, an equation was derived 
based on Cleland’s methodology; however, to solve the differential equation, we had to 
assume that NADPH is in large excess of 3/4[2H]-DXP and MEP.  Reaction conditions 
where this assumption is valid would produce a perturbation smaller than the detection 
limit of a UV/Vis instrument.  To avoid this problem, conditions were used that produced 
a measurable perturbation in our experiment and the KIE was determined using a kinetic 































Figure 3-10: Data from equilibrium perturbation experiment and the respective curve fit 
from computer simulations:  A)  165 μM NADPH, 1 mM 3[2H]-DXP, 1.1 
mM MEP, 3.1 mM NADP+ and 2 mM MgCl2; B)  148.5 μM NADPH, 900 μM 
4[2H]-DXP, 990 μM MEP, 2.79 mM NADP+ and 1.8 mM MgCl2. 
 
The data was fit by computer simulation as described in the experimental section, 
and the resulting rate constants are listed in Table 3-2, and the corresponding KIE’s are 
listed in Table 3-3.  The normal KIE values for both compounds strongly favor the 
retroaldol/aldol rearrangement mechanism over the α-ketol rearrangement mechanism.  
These values are smaller than the 2° KIE values determined for muscle aldolase, 
suggesting either a step other than chemistry is partially rate-limiting, or the retroaldol 




of the KIE for 4[2H]-DXP is slightly larger than 3[2H]-DXP.  This would result from the 
C3 having less s-character in the transition state than C4, which could result from the 
negative charge on C3 not fully delocalized on to the C2-carbonyl in the transition state. 
 
Table 3-2: Results from computer simulations. 
3[2H]-DXP (b) 4[2H]-DXP (b)  
Float All Fix Binding Float All Fix Binding 
k1 73 ± 3  73  72 ± 4  72 
k-1 55 ± 2 55 54 ± 3 54 
k2 2.15 ± 0.06 2.15 6.9 ± 0.3 6.9 
k-2 463 ± 13 463 946 ± 40 946 
k3 19.2 ± 0.5 19.6 ± 0.2 19.8 ± 0.5 19.8 ± 0.3 
k-3 9.1 ± 0.2 9.4 ± 0.1 9.4 ± 0.2 9.4 ± 0.1 
k4 2410 ± 130 2410 1660 ± 90 1660 
k-4 11.8 ± 0.4 11.8 5.9 ± 0.3 5.9 
k5 127 ± 5 127 91 ± 4 91 
k-5 16.5 ± 0.7 16.5 25 ± 1 25 
k6 2.15 ± 0.06 2.15 6.9 ± 0.3 6.9 
k-6 463 ± 13 463 946 ± 40 946 
k7 18.4 ± 0.4 18.9 ± 0.2 17.8 ± 0.4 17.8 ± 0.2 
k-7 8.4 ± 0.2 8.6 ± 0.1 9.4 ± 0.2 9.4 ± 0.1 
k8 2410 ± 130 2410 1660 ± 90 1660 
k-8 11.8 ± 0.4 11.8 5.9 ± 0.3 5.9 
(b)  All second order rate constants are given in μM-1s-1, and all first order rate constants are given 
in s-1. 
 
Table 3-3: Summary of Keq and KIE data from equilibrium perturbation experiments. 
Substrate Keq dKeq dkchem (c) 
DXP 22.0 ± 0.3 -- -- 
3[2H]-DXP 22.7 ± 0.2 0.97 ± 0.02 1.04 ± 0.02 
(0.04) 
4[2H]-DXP 19.8 ± 0.2 1.11 ± 0.02 1.11 ± 0.02 
(0.04) 
(c)  This is the KIE determined by the equilibrium perturbation experiment, and this value is 
determined by the ratio of k3 to k7, (See Figure 3-7).  The error reported is from the 
simulations when the binding rates are fixed on the values obtained from initially allowing 
them to float, and the error is the parenthesis is the error for when all the rate constants are 





In conclusion, the normal 2° KIE’s observed for 3[2H]-DXP and 4[2H]-DXP are 
the first direct evidence that strongly favor the retroaldol/aldol rearrangement mechanism 
utilized by DXR to catalyze the rearrangement of DXP to the aldehyde intermediate.  
With this information in hand, it is now possible to design inhibitors by focusing only on 
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Chapter 4: Reconfirmation HppE is an Iron and NAD(P)H Dependent 
Epoxidase 
4.1. INTRODUCTION 
Fosfomycin (2) is a clinically useful antibiotic1 for the treatment of lower urinary 
tract infections2 and limb-threatening diabetic foot infections.3  It is also effective against 
methicillin-resistant4 and vancomycin-resistant5 strains of Staphylococcus aureus.  The 
antimicrobial activity of fosfomycin has been attributed to the inactivation of UDP-
GlcNAc-3-O-enolpyruvyltransferase (MurA), which catalyzes the first committed step in 













Figure 4-1: Reaction catalyzed by HppE. 
 
Fosfomycin (2) is a natural product that is made by several species of 
Pseudomonas and Streptomyces,8,9 and it is biosynthetically derived from (S)-2-
hydroxypropylphosphonic acid [1, (S)-HPP].10,11  The conversion of (S)-HPP (1) to 
fosfomycin (2) is catalyzed by HPP epoxidase (HppE), see Figure 4-1.12,13  A 
mononuclear non-heme iron in the HppE active site is essential for enzyme activity.14  
Coordination of the iron in the enzyme from Streptomyces wedmorensis, which is the 
source of the HppE used in this study, is by His138, Glu142, and His180.  The 2-H-1-D/E 
facial triad, was first implied by sequence alignment15 and site-directed mutagenesis 
studies,16 and it was later confirmed by the X-ray crystal structure of this enzyme.17  
Earlier research also demonstrated that molecular oxygen is essential for the reaction.13,14  
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However, no oxygen atoms from O2 are incorporated into the fosfomycin product.11,13,14  
Instead, the oxygen atom of the epoxy ring in 2 is derived from the secondary hydroxyl 
group of (S)-HPP (1).  Thus, the conversion of 1 to 2 by HppE is effectively a 
dehydrogenation reaction, not an oxygenation reaction.  
This unusual epoxidation reaction is NAD(P)H-dependent and involves four-
electron redox chemistry with full reduction of dioxygen to water.13,14  In this process, 
two electrons are generated through epoxide ring formation, and the other two electrons 
are supplied by NAD(P)H.  The use of NAD(P)H as a source of reducing equivalents 
distinguishes HppE from most other mononuclear non-heme iron-dependent oxygenases, 
where the source of electrons is either the substrate or a cosubstrate such as α-
ketoglutarate, ascorbate, or tetrahydropterin.18-21 
Despite the unusual chemistry of its physiological reaction, HppE can also 
function as a typical oxygenase.  In particular, it can self-hydroxylate an active site 
tyrosine to form 3,4-dihydroxyphenylalanine (DOPA).22  The modified residue has been 
identified as Tyr105, on the basis of its proximity to the iron center (8.7 Å)17 and the 
results of site-directed mutagenesis.22  The chelation of DOPA105 with the active site 
ferric ion gives HppE a green color.  This green chromophore has been assigned, on the 
basis of UV-vis and resonance Raman spectral analyses, to a catecholate-to-Fe(III) 
charge transfer complex.22 
Unlike the self-hydroxylation reactions observed for other non-heme iron-
dependent enzymes, such as the ribonucleotide reductase (RNR) R2 F208Y mutant,23 
taurine dioxygenase (TauD),24 and 2,4-dichlorophenoxyacetic acid dioxygenase (TfdA),25 
where the newly introduced oxygen atom in DOPA is derived from H2O, the oxygen 
atom incorporated into DOPA105 of HppE originates from dioxygen.22  The discovery of 
such oxygenase activity for HppE is significant because the same reactive intermediate 
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responsible for self-hydroxylation may also participate in the reaction cycle for the 















































































Figure 4-2: Proposed NAD(P)H and Iron dependent mechanisms for HppE. 
 
The mechanism of HppE-catalyzed HPP epoxidation likely invokes an FeIII-OOH 
intermediate (7) derived from the one-electron reduction of an initial Fe(II)-O2 adduct.  
As shown in Figure 4-2, this peroxo intermediate (7) may either directly abstract a 
hydrogen atom from C-1 of (S)-HPP (1) to generate a transient substrate radical 
intermediate (9) or be converted to a high-valent iron-oxo species (such as 8) that carries 
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out the oxidation (8 10).  A direct attack by the iron-superoxide complex (5) to generate 
radical 6 is also possible.  Evidence for the involvement of an iron-superoxide species in 
the myoinositol oxygenase reaction has been reported.26  The subsequent cyclization to 
yield fosfomycin (2) and concomitant reduction of the metal center is reminiscent of 
oxygen rebound in the hydroxylation of alkanes by cytochrome P45027 and non-heme 









Figure 4-3: Oxygen rebound mechanism. 
 
In a recent study, McLuskey et al. found that purified recombinant HppE, also 
from Streptomyces wedmorensis,  is active when reconstituted with Fe2+ or Zn2+.30  They 
also determined that HppE exhibits modest affinity for FMN which is required for 
activity.  Since Zn2+ is redox inert, these findings suggested that the previously proposed 
mechanism, which relies on metal ion redox chemistry (Figure 4-2), is incorrect.  Hence, 
McLuskey et al. proposed a new mechanism in which the active site-bound divalent 
metal ion (Fe2+ or Zn2+) serves as a Lewis acid to activate the C-2 hydroxyl group, and 
the epoxide ring is formed by the attack of the 2-hydroxyl group at C-1 coupled with the 
transfer of the C-1 hydrogen as a hydride ion to the bound oxidized FMN (11).  This 










































Figure 4-4:  Proposed nucleophilic displacement-hydride transfer mechanism for HppE. 
 
To resolve the mechanistic discrepancies, we characterized the Zn2+-reconstituted 
HppE and re-evaluated the NADH dependence of HppE activity.  We also compared the 
efficiency of various enzyme activity assays and determined the binding affinity of HppE 
for several flavin derivatives.  The results support an exclusive role for iron in HppE 
catalysis.  We also found that FMN is unlikely a hydride acceptor, but an artificial 
electron mediator for the in vitro HppE activity.  It serves the role of accepting a hydride 
from NADH and then passes electrons on to reduce the iron center of HppE.  On the basis 
of these lines of evidence, we conclude that the "iron redox chemistry" mechanism 
(Figure 4-2) stands as the more likely mechanism for the HppE-catalyzed reaction. 
 
4.2. MATERIALS AND METHODS 
4.2.1. GENERAL. Enzyme E3 (AscD, CDP-6-deoxy-L-threo-D-glycero-4-hexulose-3-
dehydrase reductase) used in the assay was purified from the Escherichia coli 
JM105/pOPI culture based on a procedure published earlier.31  Culture medium 
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ingredients were purchased from Difco (Detroit, MI).  Biochemicals, including the 
fosfomycin disodium salt standard (2), were purchased from Sigma-Aldrich Chemical 
Co. (St. Louis, MO).  The substrate, (S)-2-hydroxypropylphosphonic acid [(S)-HPP, 1], 
was chemically synthesized according to a literature procedure.13,14  All other reagents 
and solvents were purchased from commercial sources and were used without further 
purification unless otherwise noted.  Protein concentrations were determined by the 
procedure of Bradford using bovine serum albumin as the standard.32 
 
4.2.2. PURIFICATION OF HPPE WITH AND WITHOUT BOUND METALS. Recombinant 
HppE from Streptomyces wedmorensis was overproduced from E. coli 
BL21(DE3)/pPL1001, and the metal-free HppE (apo-HppE) was purified according to 
the published procedure.14  An overnight culture of E. coli BL21(DE3)/pPL1001 grown 
at 37 °C in LB medium supplemented with kanamycin (50 μg/mL) was used, in a 200-
fold dilution, to inoculate 6 L of the same medium.  When the OD600 reached 0.6, the 
incubation temperature was lowered to 18 °C and IPTG was added to a final 
concentration of 0.1 mM to induce gene expression.  After incubation for an additional 15 
h at 18 °C, cells were harvested by centrifugation (8000g, 5 min) at 4 °C, washed with 
Tris·HCl buffer (20 mM, pH 7.5), collected again by centrifugation (8000g, 5 min), and 
stored at -80 °C for future use.  The typical yield was 6 g of wet cells per liter of culture. 
All purification operations were carried out at 4 °C except for the FPLC step, and 
all buffers were degassed and saturated with nitrogen before use.  Thawed cells were 
resuspended in a 5-fold (w/v) excess of lysis buffer (20 mM Tris·HCl, pH 7.5, 0.1 mM 
DTT; 1 mM EDTA was included to remove trace amounts of iron ion when necessary) 
and subjected to 5 × 40 s ultrasonic bursts, with a 1 min cooling interval between each 
blast. Cellular debris was removed by centrifugation at 15000g for 20 min.  The 
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supernatant was fractionated by ammonium sulfate, and the 30-65% ammonium sulfate 
precipitate was collected.  The protein pellet was resuspended in a minimal amount of 
Tris·HCl buffer (20 mM, pH 7.5).  The resulting protein solution was dialyzed against 1 
L of the same buffer for 4 h with two buffer changes.  
The dialysate was applied to a DEAE-Sepharose CL-6B column (2.5 × 24 cm) 
pre-equilibrated with 20 mM Tris·HCl, pH 7.5.  After loading, the column was washed 
with 500 mL of the wash buffer (20 mM Tris·HCl, pH 7.5, 0.15 M KCl).  The elution was 
then continued with a linear gradient of KCl from 0.15 to 0.35 M in 20 mM Tris·HCl 
buffer, pH 7.5 (2 L total volume).  The flow rate was 2 mL/min, and fractions of 15 mL 
were collected throughout the gradient elution.  The fractions containing the desired HPP 
epoxidase, as determined by SDS-PAGE, were pooled, concentrated to about 10 mL by 
ultrafiltration on an Amicon concentrator using a YM 10 membrane (Millipore, Bedford, 
MA), and desalted by dialyzing against 1 L of 20 mM Tris·HCl buffer, pH 7.5 for 3 h 
with two buffer changes. 
The protein from the last step was further purified at room temperature by FPLC 
equipped with a Mono Q HR 10/10 (GE Healthcare, Piscataway, NJ) using the solvent 
systems A (20 mM Tris·HCl buffer, pH 7.5) and B (A plus 0.6 M NaCl).  The elution 
profile included a linear gradient of 0 to 60% B from 0 to 25 min, followed by a linear 
gradient of 60 to 100% B from 25 to 26 min, and concluded with a 5 min wash at 100% 
B.  The flow rate was 3 mL/min, and the detector was set at 280 nm.  A sharp peak with a 
retention time of about 19 min was collected, concentrated by ultrafiltration as described 
before, desalted with 20 mM Tris·HCl buffer (pH 7.5), and stored at -80 °C. 
 
4.2.3.  BIOAUTOGRAPHY ASSAY. The conversion of (S)-HPP (1) to fosfomycin (2) by 
HppE was monitored by a previously developed bioautography assay, which is based on 
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the ability of fosfomycin to inhibit the biosynthesis of the bacterial cell wall.14  A typical 
assay mixture (200 μL) contained 20 mM (S)-HPP (1), 90 μM apo-HppE, 90 μM FMN, 
22.5 mM NADH, and 150 μM metal ions in 20 mM Tris-HCl buffer (pH 7.5).  The 
reaction was carried out at room temperature for 2 h.  Meanwhile, 20 mL of LB agar 
medium was autoclaved, cooled to 40-45 °C, mixed with 1 mL of E. coli K12 strain 
HW8235 precultivated in LB medium, and poured into a Petri dish.  After the agar 
solidified, sterilized paper disks (10 mm in diameter) were placed on the top of the agar.  
Each reaction mixture was divided into two portions, one of which was filtered through a 
Y-10 membrane to remove HppE.  Subsequently, an aliquot of 20 μL was applied to the 
paper disk, and the plate was incubated at 37 °C for 12-16 h.  The amount of fosfomycin 
produced in the reaction mixture was estimated by measuring the diameter of the 
inhibition zone and comparing it with that of a fosfomycin standard (10 μL of a 5 mg/mL 
solution).  To test the proposed hydride transfer mechanism, a separate set of reaction 
mixtures containing 20 mM (S)-HPP (1), 90 μM apo-HppE, 900 μM FMN, and 150 μM 
metal ions in 200 μL of 20 mM Tris-HCl buffer (pH 7.5) was prepared and incubated at 
room temperature for 2 h.  The subsequent treatment was the same as that described 
above.  These experiments were conducted by Dr. Fang Yan. 
 
4.2.4.  31P NMR SPECTROSCOPY ASSAY.   To directly determine the percentage of 
conversion of (S)-HPP (1) to fosfomycin (2) catalyzed by HppE, a 31P NMR spectroscopy 
assay developed previously was used.13,14  A typical assay mixture (200 μL) contained 20 
mM (S)-HPP (1), 90 μM apo-HppE, 90 μM FMN, 22.5 mM NADH, and 150 μM metal 
ions in 20 mM Tris-HCl buffer (pH 7.5).  The reaction was carried out at room 
temperature for 2 h, followed by rapid freezing with liquid nitrogen.  The frozen sample 
was thawed immediately before 31P NMR analysis.  The amount of fosfomycin produced 
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was determined on the basis of the integration of the appropriate 31P NMR peaks.  To test 
the newly proposed "hydride transfer" mechanism, the assay conditions were modified to 
include 20 mM (S)-HPP (1), 90 μM apo-HppE, 900 μM FMN, and 150 μM metal ions in 
200 μL of 20 mM Tris-HCl buffer (pH 7.5).  The incubation was allowed to proceed at 
room temperature for 2 h and then flash-frozen with liquid nitrogen.  The frozen sample 
was thawed immediately before NMR analysis.  These experiments were conducted by 
Dr. Fang Yan. 
 
4.2.5. NADH STOICHIOMETRY. The NADH dependence of the conversion of (S)-
HPP to fosfomycin was also studied. The reaction mixture (100 μL) contained 4.5 mM 
(S)-HPP (1), 78 μM apo-HppE, 120 M Fe(NH4)2(SO4)2, 156 μM FMN, and various 
amounts of NADH (0-0.9 mM). The incubation was carried out at room temperature for 2 
h, and the reaction was quenched by the addition of EDTA to a final concentration of 100 
mM, followed by freezing with liquid nitrogen. Product formation was assessed by 31P 
NMR spectroscopy. The percentage of conversion was calculated on the basis of the 
integration of the corresponding peaks [fosfomycin vs the sum of fosfomycin and (S)-
HPP] from the spectra.  These experiments were conducted by Dr. Fang Yan. 
 
4.2.6. BINDING AFFINITY OF FLAVIN DERIVATIVES. The binding affinity between 
HppE and various flavin derivatives (11a-c) was determined by the change in 
fluorescence intensity of flavin resulting from binding to HppE.  Since flavin 
fluorescence is linear only up to ~5 μM, HppE was titrated into the flavin solution [1 μM 
flavin in 2 mL of 20 mM Tris-HCl buffer (pH 7.5)], as opposed to the standard method of 
titrating the ligand into the enzyme solution.  The excitation and emission wavelengths 
were 450 and 525 nm, respectively, and the excitation and emission slit widths were set 
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at 1 and 3 nm, respectively.  The titrations were carried out at 25 °C. The fluorescence 
data were adjusted so that the y-axis represented the net decrease in fluorescence.  These 
data were then fit, using Grafit 5.0.1, to Equation 2-1 with Fo, F, and KD as parameters, 
where Fo is the initial fluorescence, ∞F  is the final fluorescence, Eo is the total HppE 
concentration, and So is the total ligand concentration.33 
 
Equation 4-1 

















4.2.7. HPLC ACTIVITY ASSAY. Enzyme assays were carried out in 50 μL of 20 mM 
Tris-HCl buffer (pH 7.5) in triplicate.  The reactions were initiated by the addition of a 
mixture of apo-HppE, Fe(NH4)2(SO4)2, and an electron mediator (flavin cofactors (11a-
c), benzyl viologen (15), methyl viologen (16) or E3) to a mixture of (S)-HPP (1) and 
NADH.  The final concentrations were as follows: 50 μM HppE, 50 μM Fe2+, 75 μM 
flavin cofactors/benzyl viologen/E3, 10 mM (S)-HPP (1), and 15 mM NADH.  The 
reactions were quenched by the addition of 2 M acetic acid (50 μL), and then the 
mixtures centrifuged through a Nanosep centrifugal device with a 10K Omega Membrane 
(Pall Life Sciences, Ann Arbor, MI) to remove protein.  The samples (77 μL each) were 
analyzed with a HPLC system equipped with a Dionex CarboPac PA-1 (4 × 250 mm) 
column.  The fosfomycin product was eluted with a gradient of water as solvent A and 
500 mM NH4OAc as solvent B where the following gradient was used: 5% B for 2 min, 
from 5 to 25% B over 30 min, from 25 to 100% B over 1 min, 100% B for 9 min, from 
100 to 5% B over 2 min, and then 5% B for 13 min.  The flow rate was 1 mL/min.  The 
detector used is the Corona charged aerosol detector (CAD) (ESA, Inc., Chelmsford, 
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MA), which is designed to detect nonvolatile compounds.  The amount of fosfomycin 
produced was determined by peak integration and then converted into micromoles on the 
basis of a calibration curve. 
 
4.3. RESULTS AND DISCUSSION 
4.3.1.  ENZYME ACTIVITY DETERMINED BY BIOAUTOGRAPHY ASSAY.        Two assay 
methods had been developed in our early work to determine the activity of HppE.13,14  
One is the bioautography assay, in which a paper disk soaked with the assay mixture is 
placed in direct contact with a lawn of E. coli K12 HW8235 grown on nutrient (LB) agar.  
When fosfomycin is produced in the assay mixture, an inhibition zone is visible after 
incubation for a few hours.  Using this bioautography assay led to the identification of 
Fe(II) and NAD(P)H as two essential components for HppE activity.13,14  While this 
assay is convenient and sensitive, the same incubation mixture with all of the components 
mentioned above included failed to produce enough fosfomycin that can be discerned by 
NMR analysis.13  It was later found by a 31P NMR assay that the addition of FMN or 
FAD greatly enhanced the production of fosfomycin.13,14  Because this NMR method 
allows direct detection of fosfomycin production in the assay mixture, it has been the 
assay of choice in our subsequent studies.  However, since the conclusions of McLuskey 
et al. about HppE activity and mechanism were based mainly on the bioautography 
results,30 we decided to re-examine the assay conditions using both Fe(II)- and Zn(II)-
reconstituted HppE.  It should be pointed that FMN was introduced into the 
bioautography assay carried out by McLuskey et al. but was not included in our original 
bioautography assay.13,14  
As shown in Figure 4-5, fosfomycin production was detected in the incubation 
mixture containing Zn(II)-HppE (disk 1) and Fe(II)-HppE (disk 4) complexes with excess 
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FMN and (S)-HPP (1). The addition of NADH to the assay mixture led to more 
fosfomycin formation in both cases as indicated by the enlarged diameter of inhibition 
zones (Figure 4-5B, disks 1 and 4). These results are in agreement with those of 
McLuskey et al. 30 showing that the Zn(II)-HppE complex is catalytically active but less 
active than the Fe(II)-HppE complex. However, we were troubled by the positive 
response given by the metal-free apo-HppE sample, which was performed as a negative 
control (disk 3 in Figure 4-5A,B). The fact that the Fe(II)-HppE complex was active in 
the absence of NADH was also puzzling (Figure 4-5A, disk 4).  
 
 
Figure 4-5: Bioautography assay results of unfiltered reaction samples. (A) (1) Apo-
HppE, Zn(II), FMN, and (S)-HPP, (2) fosfomycin standard, (3) apo-HppE, FMN, and (S)-
HPP, and (4) apo-HppE, Fe(II), FMN, and (S)-HPP. (B) (1) Apo-HppE, Zn(II), FMN, (S)-
HPP, and NADH, (2) fosfomycin standard, (3) apo-HppE, FMN, (S)-HPP, and NADH, and 
(4) apo-HppE, Fe(II), FMN, (S)-HPP, and NADH. 
 
Since HppE was not removed prior to application of the reaction mixture to the 
disk, it should still be catalytically active when exposed to the nutrient rich agar media 
where metal ions are plentiful.  This "postincubation activation/activity" may be partially 
responsible for the positive response exhibited by the Zn(II)-HppE and apo-HppE 
samples.  To eliminate this potential complication, the reaction mixture was passed 
through a membrane with a molecular mass cutoff of 10 kDa.  After this treatment, the 
inhibition results should reflect the total amount of fosfomycin produced in the assay 
solution under defined reaction conditions because no HppE is available to make 
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additional fosfomycin during the overnight incubation on the plate.  As expected, no 
inhibition by the reaction mixture containing the Zn(II)-HppE sample was discernible 
(Figure 4-6A,B, disk 1), whereas the inhibitory effect of the Fe(II)-HppE sample 
remained very apparent (Figure 4-6B, disk 3).  The addition of more FMN to the reaction 
mixture containing the Zn(II)-HppE complex (up to 200-fold more than the HppE 
concentration) showed no effect on the autobiography results (data not shown). It is thus 
evident that the Zn(II)-HppE sample is not active and Zn(II) cannot substitute for Fe(II) 
in reconstituting a catalytically active HppE. The activity observed for the unfiltered 
samples shown in Figure 4-5 must be an artifact and may be attributed to the ability of 
HppE on the disk to elicit iron from the LB agar to make fosfomycin. 
 
 
Figure 4-6: Bioautography assay results of filtered reaction samples. (A) (1) Apo-HppE, 
Zn(II), FMN, and (S)-HPP, (2) fosfomycin standard, and (3) apo-HppE, Fe(II), FMN, and 
(S)-HPP. (B) (1) Apo-HppE, Zn(II), FMN, (S)-HPP, and NADH, (2) fosfomycin standard, 
and (3) apo-HppE, Fe(II), FMN, (S)-HPP, and NADH. 
 
While the observations described above clearly ruled out a role for Zn(II) in the 
HppE-catalyzed reaction, the inhibitory effect exhibited by the mixture containing Fe(II) 
and FMN but no NADH was unexpected (Figure 4-5A, disk 4, and Figure 4-6A, disk 3).  
We speculated that the photoreducible properties of FMN could play a role.  This 
speculation was substantiated by the subsequent two parallel reactions, one carried out in 
the dark and another in sunlight.  As for the reaction in the dark without NADH, no 
 116
detectable level of fosfomycin was produced when the incubation mixture was filtered 
prior to being applied to the disk (Figure 4-7, disk 3).  In sharp contrast, the same 
reaction performed in sunlight gave a large inhibition zone (Figure 4-7, disk 2).  Thus, 
photoreduction of FMN is clearly the cause of the complication.  Taken together, enzyme 
activity determined by the bioautography assay should be analyzed with caution, since 
the readout could be misleading if the assay conditions are not properly controlled. 
 
 
Figure 4-7: Bioautography assay results of filtered reaction samples carried out in dark 
and in sunlight: (1) fosfomycin standard, (2) apo-HppE, Fe(II), FMN, and (S)-HPP in 
sunlight, and (3) apo-HppE, Fe(II), FMN, and (S)-HPP in the dark. 
 
4.3.2. ENZYME ACTIVITY DETERMINED BY NMR SPECTROSCOPY. The HppE 
reactions conducted under various conditions as described above were also subjected to 
31P NMR analysis.  In agreement with our previous observation, only the incubation 
mixture containing the Fe(II)-HppE complex in the presence of FMN and NADH 
produced NMR-discernible amounts of fosfomycin from (S)-HPP (1).  The detection 
limit of fosfomycin is estimated to be 1 mM on the basis of 31P NMR peak integration 
and is equivalent to 5% conversion of (S)-HPP (20 mM, total amount used) under our 
assay conditions.  The fact that no fosfomycin formation was detected when the Zn(II)-
HppE complex was used strongly suggested an exclusive role for iron in HppE catalysis.  
In an earlier study, the apo-HppE was reconstituted with various redox active metal ions 
to examine their effects on enzyme activity using the same NMR assay.  Among the 
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divalent metal ions that were examined [Fe(II), Co(II), Ni(II), Cu(II), and Mn(II)], only 
Fe(II) could reconstitute HppE activity.14  Thus, HppE is believed to be iron-dependent.  
Clearly, the direct detection of product formation by NMR spectroscopy is a much more 
reliable activity assay.   
 
4.3.3. ENZYME ACTIVITY DETERMINED BY THE HPLC ASSAY. Although 31P 
NMR spectroscopy is a highly reliable method of measuring fosfomycin production, it is 
not amenable to microanalysis due to its low sensitivity.  To overcome this shortcoming, 
an HPLC assay coupled with a charged aerosol detector (CAD) to detect nonvolatile 
compounds in the eluent was developed.  This HPLC assay allowed us to quantitatively 
analyze the conversion of (S)-HPP (1) to fosfomycin (2), both nonchromophoric, under 
different incubation conditions.  As illustrated in Figure 4-8, baseline resolution of 1 and 
2 was achieved using a Dionex CarboPac PA-1 (4 × 250 mm) column. 
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Figure 4-8: HPLC chromatogram of the HppE-catalyzed conversion of (S)-HPP (1) to 
fosfomycin (2). The inset shows the increase in the fosfomycin peak after 10, 20, 40, 60, and 
80 min (from bottom to top). 
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4.3.4.  NADH DEPENDENCE OF HPPE ACTIVITY. A fundamental distinction between 
the iron-redox mechanism and the nucleophilic displacement-hydride transfer mechanism 
is the NADH dependence of the reaction. As depicted in Figure 4-2, in the iron-redox 
mechanism, NADH plays an essential role by supplying two electrons to prime the iron 
center for oxygen activation and to reduce an iron-oxygen species during catalysis. In 
contrast, no NADH is needed for the nucleophilic displacement-hydride transfer 
mechanism (Figure 4-4) since the transferred hydride is derived from (S)-HPP (1) and 
not from NADH. Although the activity assay results have clearly implicated NADH as 
the source of reducing equivalents, further analysis was performed to determine the 
stoichiometry of NADH required per catalytic turnover to better quantify the NADH 
dependence. As expected, a direct correlation between the percentage of conversion and 
the NADH/(S)-HPP ratio was found (see Figure 4-9). Our data also established that 1 
equiv of NADH is consumed per conversion of 1 equiv of (S)-HPP to fosfomycin. The 
direct involvement of NADH in the HppE reaction supports the iron-redox mechanism 


















Figure 4-9: The NADH-dependence of the conversion of (S)-HPP (1) to fosfomycin (2) 
catalyzed by HppE. 
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4.3.5. BINDING OF FLAVIN COFACTORS. While no flavin cofactor was found in the 
purified HppE, FMN had been shown to be an important component in the HppE activity 
assay.13,14  It serves as an electron mediator in the iron-redox mechanism and has been 
proposed to be the hydride acceptor in the nucleophilic displacement-hydride transfer 
mechanism.30  Since the translated sequence of HppE lacks an ADP βαβ-binding fold 
characteristic of flavin-dependent enzymes and reconstitution failed to incorporate FMN 
in the active site, FMN has not been considered to be a true coenzyme of HppE.13  
Instead, it is believed to function as a surrogate in the iron-redox mechanism for an 
electron transfer protein involved in the catalysis in vivo.  Interestingly, a Kd of 10 μM 
for dissociation of FMN from HppE was determined by McLuskey et al.,30 which was 
cited as an indication of a specific binding of FMN in HppE in support of the proposed 


















































































Figure 4-10: Proposed pterin-dependent hydroxylase-like mechanism for HppE 
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If FMN is indeed a coenzyme of HppE, a non-heme iron pterin-dependent 
hydroxylase-like mechanism found for aromatic amino acid hydroxylase (see Figure 4-
10), where a Fe-O-O-pterin intermediate (13) is involved, may also need to be 
considered.19,20  In this mechanism, the reduced flavin (12), acting as a 
tetrahydrobiopterin mimic, may react with Fe(II)-activated dioxygen to form a Fe-O-O-
flavin intermediate (13).  Subsequent heterolytic breakdown of the O-O bond leads to the 
generation of the reactive Fe(IV)-oxo intermediate (8).  This iron-oxo species, capable of 
hydroxylating the substrate in the aromatic amino acid hydroxylase reaction, may be used 
to abstract the C-1 hydrogen of (S)-HPP (1) in the HppE reaction (8 9).  To gain more 
insight into flavin binding, the affinities of HppE for a series of flavin analogues were 
determined. 
 
Table 4-1: Binding affinity of HppE for flavin derivatives. 
 Apo-HppE Zn(II)-HppE Fe(II)-HppE 
Riboflavin (11a)   N.B. a N.B. N.B. 
FMN (11b) N.B. 3.2 ± 0.9 μM 5.3 ± 0.9 μM 
FAD (11c) N.B. 300 ± 700 μM 50 ± 10 μM 
FMN + (S)-HPP - N.B. N.B. 
aN.B., no binding.  This is based on an estimated upper detection limit of a Kd equal to 1 mM. 
 
In this study, the Kd constants were determined by the change in the fluorescence 
intensity of flavin resulting from binding to HppE (see Figures 4-11 and 4-12), and the 
Kd’s determined are listed in Table 4-1.  The Kd values for binding of FMN (11b) to the 
Zn(II)-HppE and Fe(II)-HppE complexes are 3.2 ± 0.9 and 5.3 ± 0.9 μM, respectively, 
similar to the reported values measured by isothermal titration calorimetry.30  However, 
when metal ions were absent (apo-HppE) or substrate, (S)-HPP (1), was present, no 
binding interaction between FMN and protein was detected (Table 4-1).  These 
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observations suggest that the binding of substrate and the binding of FMN are mutually 
exclusive and do not support specific binding of FMN to HppE.  Interestingly, riboflavin 
(11a), which is an effective FMN (11b) substitute (see Table 4-2), shows no affinity for 
the Zn(II)-HppE or Fe(II)-HppE complex (Table 4-1).  Since the epoxidation reaction 
catalyzed by HppE proceeds at a comparable rate using FMN (11b) or riboflavin (11a) 
(Table 4-2) and if HppE binds FMN in a specific manner, one would expect a similar 
specific binding of riboflavin.  Taken together, the measured binding interactions are 
unlikely catalytically relevant and may result from binding of the phosphate of FMN to 
the metal center.  This would explain why the presence of substrate, which is known to 
bind to the active site metal,17 can block FMN binding and why riboflavin, which has no 
phosphate group, cannot bind to the enzyme.  The probability of a flavoenzyme not 
having a defined flavin binding pocket is low.  The fact that no flavin was found in the 



























Figure 4-11: To examine FMN (11b) binding, A) HppE(Zn2+) and B) HppE(Fe2+) were 



































Figure 4-12:  To examine FAD (11c) binding, A) HppE(Zn2+) and B) HppE(Fe2+) were 
titrated into a 1 μM solution of FAD in 20 mM Tris pH 7.5. 
 
4.3.6. ELECTRON MEDIATORS. Using our newly developed HPLC assay, we 
determined the rates for fosfomycin formation with FMN (11b) and other electron 
mediators (Figure 4-11), including FAD (11c), riboflavin (11a), benzyl viologen (15), 
methyl viologen (16) and an electron transfer protein, E3.  As listed in Table 4-2, the 
rates of these reactions are within the same order of magnitude, suggesting that these 
compounds and/or proteins are all competent to enhance HppE reaction.  As discussed 
above, riboflavin does not bind to HppE, yet it is as effective as FMN which binds to the 
Fe(II)-HppE complex with a Kd of 5.3 ± 0.9 μM (Table 4-1).  This observation is at odds 
with the expectation of a flavin-dependent hydride transfer mechanism, because the lack 
of riboflavin binding should result in a significant reduction in enzyme activity.  
Interestingly, HppE remains active, albeit slightly slower, when FMN (11b) is replaced 
with benzyl viologen (15).  This finding again supports an electron mediator role of FMN 
in catalysis because benzyl viologen is a well-known electron carrier and is not expected 
to bind to the putative FMN binding site due to lack of structural similarity with FMN.  
The reduced rate seen for benzyl viologen may be due to its Em° value of -370 mV which 
A B
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is lower than the midpoint potential of -211 mV for free FMN.34,35  In agreement with 
this analysis, replacing FMN with methyl viologen (16), which has a much lower Em° (-
448 mV),34 failed to reconstitute HppE activity. 
 
Table 4-2: Rates of HppE-catalyzed epoxidation using different electron mediators. 
 Riboflavin 
(11a) 




k (min-1) 0.41 ± 0.03 0.44 ± 0.05 0.22 ± 0.03 1.3 ± 0.2 0.13 ± 0.01  N.A.b 






















R=  a)  - OH
11
b)  - OPO32-
c)   - AMP  
Figure 4-13: Structure of the electron mediators analyzed. 
 
The results obtained with E3, an NADH-dependent [2Fe-2S]-containing 
flavoenzyme from Yersinia pseudotuberculosis,36,37 provide further support for the 
assigned electron mediator role of FMN in HppE catalysis.  E3, along with E1 (CDP-6-
deoxy-L-threo-D-glycero-4-hexulose-3-dehydrase), catalyzes the C-3 deoxygenation 
reaction in the biosynthesis of 3,6-dideoxyhexoses.38  During turnover, the reducing 
equivalents are relayed from the E3-bound NADH to the active site of E1 via a chain of 
redox-active cofactors, including FAD and the iron-sulfur center in E3.37  The 
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involvement of an iron-sulfur cluster, an obligatory one-electron carrier, defines E3 as an 
electron transfer protein.  No change in function is expected for E3 in the HppE reaction 
where the FAD in E3 is the immediate recipient of hydride from NADH and serves as a 
two-electron (hydride)/one-electron switch in the subsequent electron relay to reduce the 
ferric center in HppE.  The fact that E3 is more effective than any flavin analogues that 
were tested (Table 4-2) implies that the physiological electron mediator is likely a 
protein reductase.  However, since no reductase gene exists in the two known fosfomycin 
biosynthetic gene clusters of Streptomyces wedmorensis12 and Pseudomonas syringae,39 
the electron transfer in the HppE reaction may not be mediated by a specific reductase 
but may rely on a promiscuous reductase within the cell. 
 
4.4. CONCLUSION 
Literature precedence for epoxide formation via a nucleophilic substitution 
mechanism comes from the halohydrin dehalogenase reaction in which the leaving group 
is a chloride (or a bromide) anion that is intramolecularly displaced by a vicinal hydroxyl 
group to yield the corresponding epoxide.40  A similar mechanism has recently been 
proposed for HppE where a divalent metal ion [Zn(II) or Fe(II)] acts as a Lewis acid and 
enhances the nucleophilicity of the attacking 2-hydroxyl group, and an active site-bound 
flavin coenzyme (FMN) receives the departing hydride to complete this energetically 
challenging epoxidation reaction (Figure 4-4).30  However, in this study, we have 
demonstrated that the Zn(II)-reconstituted HppE is catalytically inactive, and FMN 
cannot bind to the HppE-substrate binary complex.  Both observations fail to support the 
nucleophilic displacement-hydride transfer mechanism.  Likewise, a non-heme iron 
pterin-dependent hydroxylase-like mechanism (Figure 4-10) can be ruled out on the 
basis of the preclusion of binding of FMN to the HppE-substrate complex and the 
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competence of non-flavin electron mediators in the catalysis.  Our results also confirmed 
that Fe(II) is the only metal ion examined that is effective in reconstituting HppE activity, 
and NADH is an exogenous electron donor which is necessary for multiple turnovers by 
the Fe(II)-HppE complex.  The requirement of an electron mediator, either an electron 
transfer protein or a small molecule electron carrier, for HppE activity is also firmly 
established.  All of these results strongly support the iron-redox mechanism (Figure 4-2).  
Clearly, the reaction catalyzed by HppE is beyond the scope encompassed by common 
biological epoxidation and C-O bond formation reactions.  More studies aimed at 
uncovering details of the mechanism of HppE-catalyzed epoxidation are in progress.  
Insight gained from study of this unique non-heme iron-dependent enzyme will certainly 
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CHAPTER 5: PURIFICATION, CHARACTERIZATION AND A 
KINETIC ISOTOPE EFFECT ANALYSIS OF THE HPPE FROM 
PSEUDOMONAS SYRINGAE 
5.1. INTRODUCTION 
Fosfomycin (6) is a clinically useful antibiotic1 for the treatment of limb-
threatening diabetic foot infections2 and lower urinary tract infections.3  It has been 
shown to be effective against ciprofloxacin-resistant E. coli,4 as well as methicillin-
resistant5 and vancomycin-resistant6 strains of Staphylococcus aureus.  The antimicrobial 
activity of fosfomycin results from the inactivation of UDP-GlcNAc-3-O-
enolpyruvyltransferase (MurA), which catalyzes the first committed step in the 
biosynthesis of peptidoglycan, the main component of the cell wall.7,8 
Fosfomycin belongs to a steadily growing family of natural products containing a 
C-P bond.9  Members of this family, such as fosfomycin,10 fosmidomycin,11 and 
bialaphos,12 are all derived from phosphoenolpyruvate (1, PEP).  The C-P bonds in these 
compounds are formed through an intramolecular rearrangement reaction catalyzed by 
PEP mutase resulting in the conversion of PEP (1) to phosphopyruvate (2, PnPy) (Figure 
1).13-15  Since the equilibrium between PEP and PnPy highly favors PEP, the 
decarboxylation catalyzed by the second enzyme, Fom2 (PnPy decarboxylase), provides 
the driving force to shift the equilibrium in favor of C-P bond formation.16  The next two 
steps in the biosynthesis have not been explicitly demonstrated, but it is believed to be the 
reduction of the aldehyde (3) to generate hydroxyethylphosphonic acid (4), followed by a 
methyl transfer reaction to generate (S)-2-hydroxypropylphosphonic acid (5, (S)-HPP).17  
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The final step of the pathway is the conversion of (S)-HPP (5) to fosfomycin (6) 
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Figure 5-1: Fosfomycin biosynthetic pathway. 
 
Previous investigations of HppE from Streptomyces wedmorensis (Sw-HppE) 
revealed that this enzyme is a mononuclear non-heme iron-containing catalyst, and unlike 
most other enzymes in the same class, its activity is α-ketoglutarate-independent.18  For 
activity, HppE does require NADH, FMN and O2.19   In nature, most epoxide rings are 
generated via oxidation of the corresponding alkenes by either heme-dependent 
cytochrome P450s20,21 or non-heme iron-dependent monooxygenases.22  However, 
isotope labeling experiments with Sw-HppE revealed that no oxygen atoms from O2 are 
incorporated into fosfomycin, and instead, the oxygen atom of the epoxy ring in 6 is 
derived from the secondary hydroxyl group of (S)-HPP (5).18,19  Thus the conversion of 5 
to 6 by Sw-HppE is effectively a dehydrogenation reaction, not an oxygenation reaction.   
The mechanism of HppE epoxidation (Figure 5-2) has been proposed to parallel 
alkane hydroxylation catalyzed by cytochrome P45021 and non-heme iron-dependent 
oxygenases.23,24  The reaction likely begins with hydrogen abstraction from the C-1 
position by an activated oxygen species.  In a manner similar to the oxygen rebound 
mechanism for cytochrome P450s, the C-1 centered radical intermediate can then cyclize 
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to form fosfomycin and the reduced iron center.  The reactive oxygen species can be one 
of three species.  The reactive species can be Fe(III)-superoxide (9), which forms upon 
dioxygen binding to the ferrous iron center, similar to what has been proposed for 
isopenicillin N synthase (IPNS).25,26  The Fe(III)-superoxide species can be reduced by 
one electron and protonated to form Fe(III)-hydroperoxide (11), which can also abstract 
the C-1 hydrogen atom.  The Fe(III)-hydroperoxide species can be further reduced by a 
second single electron transfer with concurrent cleavage of the O-O bond to form Fe(IV)-
oxo (12), as proposed for α-ketoglutarate dependent TauD27 and for tyrosine 
















































































Figure 5-2: Proposed NAD(P)H and Iron dependent mechanisms for HppE. 
 
Clearly, Sw-HppE is unique with respect to all other mononuclear non-heme iron-
dependent enzymes regarding the required components for activity, and it is also unique 
among epoxidase enzymes in that the net transformation is a dehydrogenation reaction 
and not an oxygen insertion across a carbon-carbon double bond.  Interestingly, an 
homologous enzyme has been identified in the fosfomycin producing Pseudomonas 
syringae PB-5123.29  This HppE (Ps-HppE) has not been investigated to determine if it is 
a functional mimic of Sw-HppE, acting as an iron-dependent enzyme and catalyzing the 
analogous epoxidation reaction.  Reported herein is an account of the biochemical and 
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spectroscopic characterization of the Ps-HppE enzyme and the implications of its mode 
of action. 
In order to obtain a more intimate understanding of how Ps-HppE, and 
presumably Sw-HppE, activates molecular oxygen and possibly to determine the identity 
of the reactive oxygen species, an [18O]-KIE analysis was conducted in collaboration 
with Prof. Judith P. Klinman at the University of California at Berkeley.  The 18O in the 
experiments is from the natural abundance in air, which is ~0.2%.30  Due to the low level 
of abundance, the isotope effect determined is for 16,16O2 versus 16,18O2.30,31  As described 
in Chapter 3, a KIE arises from differences in the zero-point energies (ZPE), mass 
moments of inertia (MMI) and excited vibrational states (EXC) between the reactant state 
and the transition state.  This is also true for an equilibrium isotope effect (EIE), except 
the difference is then between the reactant state and the product state.  Unlike the 
deuterium KIE, the [18O]-KIE and EIE is not necessarily dominated by differences in 
ZPE.  However, for the single electron reduction of molecular oxygen to superoxide (see 
Table 5-1)30 the difference in ZPE does dominate the EIE, and a reaction coordinate 
diagram depicting the EIE (see Figure 5-3) can be drawn as in Chapter 3. 
 
Table 5-1: Calculated EIEs for the reduction of molecular oxygen.30 
Reaction ΔBO ZPE EXC MMI 18Kcalc 
O2 O2-
1e-
 0.5 1.03309 .99921 1.00004 1.03309 
O2 O22-
2e-
















Figure 5-3: Reaction coordinate diagram displaying the origin of the 18O KIE for the 
single electron reduction of molecular oxygen to superoxide. 
 
The 2° [2H]-KIE in Chapter 3 was described as arising from changes in the 
hybridization state of the carbon center.  This rehybridization results is a difference in the 
frequency for the out-of-plane bending vibration of the reacting carbon center in the 
reactant state versus in the transition state, which in turn produces an isotope effect.  For 
18O isotope effects, it is most easily to envision them arising from changes in bond order; 
however, this is not always true when metal ions or protons are involved.30  For the single 
electron reduction of dioxygen to superoxide, there is a decrease in bond order of 0.5 (see 
Table 5-1).  As seen in Figure 5-4, this results because the additional electron enters one 
of the π* molecular orbitals, which is an antibonding orbital.  Such a decrease in bond 






Table 5-2: Vibration frequencies of molecular oxygen and reduced forms.31 
Molecule ν16,16 (cm-1) ν16,18 (cm-1) 
O2 1556.3 1512.5 
•O2¯ 1064.8 1034.8 
















Figure 5-4: Molecular orbital diagram for A) O2 and B) •O2¯ 
 
Using either calculated or experimentally determined frequencies for all the 
stretching and bending vibrations, the isotope effect from the difference in ZPE, EXC and 
MMI can be calculated.  The product of the three terms is the EIE (see Equation 5-1).  
These frequencies are not easy to obtain for the transition state, so it is not typically 
calculated.32  Instead, the EIE is calculated and is used as an upper boundary for the KIE, 
assuming a negligible isotope effect contribution from the reaction coordinate 
frequency.30,32,33  To probe the identity of the oxygen species that forms in the rate-
limiting step of the enzymatic reaction, the experimentally determined KIE can be 
compared to a list of calculated EIEs of possible oxygen intermediates.  Due to the [18O]-
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KIEs being determined by competition between 16,16O2 and 16,18O2, the experimental 
[18O]-KIEs are on kcat/KM.  KIEs on kcat/KM only take in to account the enzymatic steps up 
to and including the first irreversible step; therefore, any steps after the first irreversible 
step will not affect the [18O]-KIE. 
 
Equation 5-1 
MMIEXCZPEEIE ××=  
 
In the proposed HppE mechanism in Figure 5-2, the first irreversible step differs 
based on the reactive oxygen species used to abstract the C-1 hydrogen atom.  If Fe(III)-
superoxide (9) is the reactive species, then the first irreversible step will be the electron 
transfer from reduced FMN to the active site iron (10→13).  If the reactive species is 
either Fe(III)-hydroperoxide (11) or Fe(IV)-oxo (12), then the first irreversible step will 
also be the electron transfer from reduced FMN to the active site iron (9→11).  For all 
three possible reactive species, the resulting [18O]-KIE will be too similar to discriminate 
between the three.  The mechanisms differ in if the hydrogen atom abstraction occurs 
before or after the first irreversible step.  For the reaction with Fe(III)-superoxide (9) as 
the reactive species, hydrogen atom abstraction (9→10) occurs before the first 
irreversible step, and with Fe(III)-hydroperoxide (11) or Fe(IV)-oxo (12) as the reactive 
species, abstraction occurs after the first irreversible step (11→13 and 12→14, 
respectively).  If the hydrogen that is abstracted is replaced with deuterium, there will be 
a 1° [2H]-KIE on its abstraction.  If the [18O]-KIE is determined with the deuterium 
labeled (S)-HPP, it may or may not affect the [18O]-KIE value, depending on whether or 
not hydrogen atom abstraction occurs before or after the first irreversible step.  Therefore, 
if Fe(III)-hydroperoxide or Fe(IV)-oxo is the reactive species, then the [2H]-KIE will 
have no effect on the [18O]-KIE, but if Fe(III)-superoxide (9) is the reactive species, then 
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abstraction (9→10) will occur before the first irreversible step and could possibly affect 
the [18O]-KIE. 
 
5.2. MATERIALS AND METHODS 
5.2.1. GENERAL. Protein concentrations were determined by the procedure of 
Bradford using bovine serum albumin as the standard.34  The NMR spectra were acquired 
on a Varian Unity 300 spectrometer, and chemical shifts (δ in ppm) are given relative to 
those for Me4Si (for 1H and 13C) and aqueous 85% H3PO4 (external, for 31P), with 
coupling constants reported in hertz (Hz).  The UV-vis absorption spectra were recorded 
on the Agilent 8453A Diode Array Spectrophotometer.  The HPLC assays were 
conducted with the Beckman Coulter System Gold 125 Solvent Module coupled with the 
System Gold 508 Autosampler.  The Corona charged aerosol detector (CAD) from ESA 
(Chelmsford, MA) was used as the HPLC detector. 
 
5.2.2. MATERIALS. Culture medium ingredients were purchased from Difco (Detroit, 
MI).  DNA minipreps were performed using QIA Spin Miniprep Kit from Qiagen 
(Valencia, CA).  All oligonucleotide primers for PCR amplification of the desired inserts 
were customly prepared by Integrated DNA Technologies (Coralville, IA) and used 
without further purification.  Restriction endonucleases were acquired from New England 
Biolabs (Ipswich, MA).  The pET24b(+) vector and the overexpression host strain 
Escherichia coli BL21(DE3) were obtained from Novagen Inc. (Madison, WI).  All 
electrophoresis materials were products of Gibco BRL or Bio-Rad (Hercules, CA).  All 
chemicals were analytical grade or the highest quality commercially available.  
Biochemicals, including fosfomycin disodium salt (6) standard, were purchased from 
Sigma-Aldrich (St. Louis, MO), unless noted otherwise.  The natural substrate, (S)-2-
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hydroxypropylphosphonic acid (5, (S)-HPP) and its enantiomer (7, (R)-HPP) were 
chemically synthesized according to reported proceedures.18,19,35 
 
5.2.3. SYNTHESIS OF DEUTERIUM LABELED HPP ANALOGUES. The deuterium 
labeled HPP analogues, (R)-2-[2H]-HPP (20), (1R,2S)-1-[2H]-HPP (31) and (S)-1,1-[2H]2-
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Figure 5-7: Synthetic scheme for (S)-1,1-[2H]2-HPP (35). 
 
5.2.4. CONSTRUCTION OF EXPRESSION PLASMID FOR THE PS-HPPE GENE. A 
clone of the Ps-HppE gene (orf3) in pUC118 was generously provided by Dr. Tomohisa 
Kuzuyama, the University of Tokyo.  The Ps-HppE gene was PCR amplified from this 
plasmid and ligated into pET24b(+) to generate pLH01.  The resulting plasmid was used 
to transform Escherichia coli BL21(DE3).  The general methods and protocols for 
recombinant DNA manipulations were as described by Sambrook et al.36  This was 
conducted by Dr. Lin Hong. 
 
5.2.5. GROWTH OF E. COLI BL21(DE3)/PLH01 CELLS. An overnight culture of E. 
coli BL21(DE3)/pLH01 grown at 37 °C in Luria-Bertani (LB) medium supplemented 
with kanamycin (50 μg/mL) was used, in a 250-fold dilution, to inoculate 6 L of the same 
medium.  The culture grew at 37 °C until the OD600 reached 0.6.  The incubation 
temperature was then lowered to 18 °C, and isopropyl β-D-thiogalactoside (IPTG) was 
added to a final concentration of 0.5 mM.  After incubation for an additional 16 h at 18 
°C, cells were harvested by centrifugation (7000g, 8 min) at 4 °C and washed with the 
lysis buffer (20 mM Tris·HCl, pH 7.5, 0.1 mM DTT, 10 mM EDTA).  The washed cells 
were again centrifugated (7000g, 8 min) and stored at -80 °C until future use. 
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5.2.6. PURIFICATION OF RECOMBINANT APO- PS-HPPE.            All purification 
operations were carried out at 4 °C except for the fast protein liquid chromatography 
(FPLC) step.  All buffers were degassed and saturated with nitrogen before use.  Thawed 
cells were resuspended in a 5-fold (w/v) excess of lysis buffer (see above) and subjected 
to 14 × 30 s ultrasonic bursts, with a 50 s cooling interval between each blast.  Cellular 
debris was removed by centrifugation at 17000g for 25 min.  The supernatant was 
fractionated by ammonium sulfate, and the 10-65% ammonium sulfate precipitate was 
collected.  The protein pellet was resuspended in a minimal amount of buffer A (20 mM 
Tris·HCl, pH 7.5, 0.1 mM DTT, 0.1 mM EDTA).  The resulting protein solution was 
dialyzed against 1 L of the same buffer for 3 h with two buffer changes.  
The dialysate was applied to a DEAE-Sepharose CL-6B column (6 × 18 cm) pre-
equilibrated with buffer A.  After loading, the column was washed with 300 mL of buffer 
A containing 180 mM NaCl.  The elution was then continued with a linear gradient of 
NaCl from 180 to 300 mM in the same buffer (2 L total volume).  The flow rate was 1.5 
mL/min, and fractions of 20 mL were collected throughout the gradient elution. The 
fractions containing HppE, as determined by SDS-PAGE, were pooled, concentrated to 
about 15 mL by ultrafiltration on an Amicon concentrator using a YM 10 membrane 
(Millipore, Bedford, MA), and desalted by dialyzing against 1 L of buffer A for 1 h, 
followed by 1 L of 20 mM Tris·HCl buffer (pH 7.5) for 2 h with one buffer change.  The 
concentrated protein from the last step was further purified at room temperature by FPLC 
equipped with a Mono Q HR 16/10 column (GE Healthcare, Piscataway, NJ) using the 
solvent systems B (20 mM Tris·HCl buffer, pH 7.5) and C (B plus 0.6 M NaCl).  The 
elution profile included a linear gradient of 0 to 35% C over 40 mL, followed by a linear 
gradient of 35 to 60% C over 160 mL, and concluded with a 40 mL wash at 100% C.  
The flow rate was 7 mL/min, and the detector was set at 280 nm.  A peak with a retention 
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time of approximately 19 min was collected, concentrated by ultrafiltration as described 
before, and dialyzed against 1 L of 20 mM Tris·HCl buffer (pH 7.5) for 3 h with two 
buffer changes.  The purified protein was then aliquoted, flash frozen, and stored at -80 
°C. 
 
5.2.7. MOLECULAR MASS DETERMINATION. The molecular mass of Ps-HppE was 
determined by size exclusion chromatography performed on a FPLC Superdex 200 HR 
10/300 column (GE Healthcare, Piscataway, NJ) with an eluent of 20 mM Tris·HCl, 0.15 
M NaCl, pH 7.5, at a flow rate of 1 mL/min.  Calibration of the column was achieved 
using the following protein standards (Aldrich): cytochrome C (14.2 kDa), carbonic 
anhydrase (29 kDa), bovine serum albumin (66 kDa), alcohol dehydrogenase (150 kDa), 
and β-amylase (200 kDa).  The void volume (V0) of the column was measured using blue 
dextran (2000 kDa).  A linear fit to a plot of the Log molecular weight versus Ve/V0 was 
used to estimate the native molecular mass (Mr) of the protein sample.37  This experiment 
was conducted by Dr. Svetlana Borisova. 
 
5.2.8. NBT STAINING OF PS-HPPE. Detection of the presence of quinoid 
structure in the protein was performed according to a published procedure.38,39  The wild-
type HppE and its mutants were subjected to 15% SDS-PAGE and transblotted onto a 
nitro-cellulose membrane at 100 V for 1 h using a transfer buffer (25 mM Tris base, 192 
mM glycine, 20% methanol).  Detection of the presence of quinoid structure was 
performed according to a procedure of Paz et al.38 by immersing the membrane in a 
solution of 0.24 mM nitroblue tetrazolium and 2 M potassium glycinate, pH 10, for 45 
min.  After the membrane was rinsed with H2O, the stained bands were recorded. 
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5.2.9. ENZYME ACTIVITY ASSAYS. The enzyme activity was determined by an 
HPLC assay, which was conducted as previously described in Chapter 4.  Due to the 
slower rate of turnover of Ps-HppE compared to that of Sw-HppE, the concentrations of 
Ps-HppE, iron, and FMN used in the assays were doubled.  The final concentration of 
each reagent in a 50 μL assay was 100 μM Ps-HppE, 100 μM Fe(NH4)2(SO4)2, 150 μM 
FMN, 10 mM HPP, and  16 mM NADH  in 20 mM Tris•HCl buffer (pH 7.5).  To 
compare the activity of Ps-HppE to Sw-HppE, the assays were carried out on the same 
day and with the same stock of reagents for Sw-HppE.  The final concentrations in the 50 
μL Sw-HppE reactions were 50 μM Sw-HppE, 50 μM Fe(NH4)2(SO4)2, 75 μM FMN, 10 
mM HPP, and 16 mM NADH  in 20 mM Tris•HCl buffer (pH 7.5).  The amount of 
product formed was normalized by dividing by the concentration of HppE, which was 
then plotted versus time to determine kobs.  With the assumption that substrate is 
saturating, kobs is kcat.  Over the time scale used in all assays, the product formation was 
linear with respect to time. 
 
5.2.10. PRIMARY [2H] KINETIC ISOTOPE EFFECT.  The catalytic rate of HppE 
increases with increasing concentration of FMN.  To determine the ratio of FMN:Ps-
HppE where the increase in rate plateaus, the reaction with (R)-HPP (38) was conducted 
at increasing ratios of FMN:Ps-HPP by varying the concentration of FMN at a fixed 
concentration of Ps-HppE.  The final concentrations in the 50 μL reactions were 100 μM 
Ps-HppE, 100 μM Fe(NH4)2(SO4)2, 0.01-12.9 mM FMN, 10 mM (R)-HPP, and 16 mM 
NADH  in 20 mM Tris•HCl buffer (pH 7.5).  At each ratio, each reaction was incubated 
at room temperature for 20 min before being quenched with 50 μL of 2 M acetic acid and 
analyzed by HPLC as previously described.  The concentration of ketone (39) formed 
was plotted versus the FMN:Ps-HppE ratio to determine the saturating ratio.  It was 
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assumed that the saturating FMN:Ps-HppE ratio for the (R)-HPP (38) reaction is the same 
as the (S)-HPP (5) reaction.  To determine the 1° [2H]-KIE for hydrogen atom 
abstraction, the kobs was measured by the HPLC assay for (S)-HPP (5), (1R,2S)-1-[2H]-
HPP (31), (S)-1,1-[2H]2-HPP (35), (R)-HPP (38) and (R)-2-[2H]-HPP (20) at specified 
ratios of FMN to Ps-HppE.  The final concentrations in the 50 μL reactions to determine 
the KIE were 100 μM Ps-HppE, 100 μM Fe(NH4)2(SO4)2, 0.11-5 mM FMN, 10 mM 
HPP, and 16 mM NADH  in 20 mM Tris•HCl buffer (pH 7.5). 
 
5.2.11. NMR CHARACTERIZATION OF THE PS-HPPE’S PRODUCTS. 1H and 31P 
NMR’s were used to characterize the products of the reaction catalyzed by Ps-HppE with 
(S)-HPP (5) and (R)-HPP (38) as the substrates.  The conditions used were 150 μM Ps-
HppE, 150 μM Fe(NH4)2(SO4)2, 370 μM FMN, 40 mM (S)-HPP (5) or (R)-HPP (38), and 
40 mM NADH in 200 μL of 20 mM Tris•HCl buffer (pH 7.5).  The reactions were 
incubated at room temperature for 15 h.  The samples were then lyophilized to dryness 
and redissolved in 600 μL of D2O.  Spectral data of fosfomycin (6):1H NMR (300 MHz, 
D2O) δ 3.11 (1H, m, J = 5.4, 2-H), 2.66 (1H, d, J = 5.3, 18.6, 1-H), 1.33 (3H, d, J = 5.4, 
3-H); 31P NMR (D2O, 121 MHz) δ 10.9 (s).  Spectral data for 2-oxopropylphosphonic 
acid (39): 1H NMR (300 MHz, D2O) δ 2.81 (2H, d, J = 21.0 Hz), 2.16 ppm (3H, s); 31P 
NMR (D2O) δ 11.1 (s). 
 
5.2.12. EFFECTS OF METAL IONS ON THE ACTIVITY OF PS-HPPE. A systematic 
investigation to determine the metal ion(s) requirement for the activity of Ps-HppE was 
performed by including different redox-active metals, such as iron (Fe(NH4)2(SO4)2), 
copper (CuSO4), cobalt (CoCl2), and manganese (MnCl2), and the non-redox active 
metal, zinc (ZnSO4), in the reaction mixture, and assessing their effects on enzyme 
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activity.  A typical 50 μL reaction mixture contained 16 mM NADH, 10 mM (S)-HPP 
(5), 100 μM Ps-HppE, 150 μM FMN, and 100 μM of the investigate metal in 20 mM 
Tris·HCl buffer (pH 7.5).  After incubating at room temperature for 1.5 h, the reaction 
was quenched with 2 M acetic acid, and the relative activity of each sample was 
determined by the HPLC assay described above.  To further assess the metal ion 
requirement for the enzyme activity, the effect of the metal chelator, EDTA, on the 
catalysis of Ps-HppE was also examined.  In this case, the activity assay with Ps-HppE 
reconstituted with ferrous iron was repeated in the presence of 5 mM EDTA. 
 
5.2.13. THE DEPENDENCE OF PS-HPPE ACTIVITY ON OXYGEN.  In a sealed vessel, an 
assay mixture (1 mL) containing 200 μM Ps-HppE and 200 μM Fe(NH4)2(SO4)2 in 20 
mM Tris·HCl, pH 7.5, was made anaerobic by 15 repeated cycles of subjecting the 
mixture to vacuum and purging with argon. The mixture was kept under argon for 20 min 
followed by another 15 cycles of vacuum and argon purging to ensure anaerobic 
conditions. In a separate sealed vessel, a solution of 32 mM NADH, 300 μM FMN, and 
20 mM (S)-HPP (5) in the same buffer was made anaerobic by the same procedure.  The 
vessels were transferred to an anaerobic glove box, where 25 μL of each mixture was 
combined to start the assay.  The final concentrations of the reagents in 50 μL were 100 
μM Ps-HppE, 100 μM Fe(NH4)2(SO4)2, 150 μM FMN, 10 mM (S)-HPP, and 16 mM 
NADH.  After incubating for 1.5 h at room temperature, the reaction was quenched with 
50 μL of 2 M acetic acid.  The activity was then analyzed by the HPLC assay described 
above. 
 
5.2.14. DFT CALCULATIONS OF BOND DISSOCIATION ENERGIES.             To gain 
insight into the distinct regiospecificity observed in the reactions of HppE with (R)- and 
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(S)-HPP (38 and 5, respectively), electronic structure calculations were performed to 
estimate the bond dissociation enthalpies of the C1-H and C2-H bonds of HPP.  All 
calculations were performed using Gaussian98.40  Geometry optimizations were 
performed using Becke-style 3-Parameter Density Functional Theory (DFT) with the 
Lee-Yang-Parr correlation functional (B3LYP) and Pople’s diffuse polarized triple-ζ 6-
311+G(d,p) basis set with the Opt = Tight and Int = Ultrafine keywords.  The initial 
geometry of the heavy atoms of the substrate was taken from the crystal structure of Fe2+-
HppE in complex with (S)-HPP (5) (PDB accession number 1ZZ8).41  Vibration 
frequency calculations were then performed on the optimized geometries based on the 
same B3LYP/6-311+G(d,p) scheme at 25 °C and 1.0 Atm, using a scale factor of 0.9877 
to correct the zero-point vibrational energies.42  These calculations were performed by 
Dr. Steven O. Mansoorabadi. 
 
5.2.15. EPR SPECTROSCOPY. EPR first derivative spectra of Ps-HppE were 
collected at X-band microwave frequency with 100-kHz field modulation using a Bruker 
(Billerica, MA) EMX spectrometer with a 4119HS high-sensitivity resonator.  Sample 
temperature was maintained with an ITC503S temperature controller, an ESR910 liquid 
helium cryostat, and LLT650/13 liquid helium transfer tube (Oxford Instruments, 
Concord, MA).  The EPR parameters were obtained by simulation of the experimental 
spectra using an EPR program written by Dr. Frank Neese43 and were further verified in 
Bruker SimFonia.  The as-isolated Ps-HppE was made anaerobic by repeated cycles of 
evacuation and flushing with argon.  A molar equivalent of Fe(NH4)2(SO4)2 from an 
anaerobic stock solution was added to Ps-HppE to reconstitute it under anaerobic 
conditions.  For the sample with (S)-HPP bound, ten molar equivalents of anaerobic (S)-
HPP (5) were incubated with the ferrous reconstituted Ps-HppE in the EPR tube.  Nitric 
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oxide gas was passed over NaOH pellets to remove any acid impurities and then 
introduced into the substrate-bound enzyme samples through a gas-tight Hamilton 
syringe under argon.  The samples were frozen by slow immersion in liquid nitrogen for 
later EPR analysis.  Spin quantification was performed by double integration of the EPR 
spectra recorded under nonsaturating conditions at 20 K for comparison with a Cu-EDTA 
standard (0.5 mM).  The EPR samples were prepared by myself, and Dr. Aimin Liu 
helped with the analysis of the signal. 
 
5.2.16.  [18O] KINETIC ISOTOPE EFFECTS MEASUREMENTS. [18O]-KIEs were 
measured competitively as described previously.31,44  The 18O/16O ratios were measured 
using isotopic ratio mass spectrometry (Laboratory for Environmental and Sedimentary 
Geochemistry, Department of Earth and Planetary Science, UC Berkeley, CA).  The 
[18O]-KIEs were obtained by fitting the 18O/16O ratio of ratios versus fractional 
conversion according to Equation 5-2, where Rf is the 18O/16O isotopic ratio at f 
fractional conversion, and R0 is the isotopic ratio prior to the enzymatic reaction.  All 











The [18O]-KIE experiments were carried out in 20 mM Tris-HCl buffer (pH 7.5), 
in the presence of 1 mM (S)-HPP (5) or (S)-1,1-[2H]2-HPP (35), 1.5 mM NADH, and 
0.4–0.6 mM O2.  Reactions were initiated by the addition of 3 μL of apo-Ps-HppE 
reconstituted with equimolar Fe(NH4)2(SO4)2, followed by the addition of FMN to 
minimize the background oxygen consumption.  Final concentrations were typically 8–12 
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μM HppE and 9–13 μM FMN.  The fractional conversions used for the [18O]-KIE 
measurements were between 20 and 60%.  The amount of O2 consumed was corrected for 
the background O2 consumption due to FMN, NADH and/or Fe(II) in the absence of 
enzyme.  In all experiments, the O2 consumed in non-enzymatic reactions accounted for 
less than 10% of the total O2 consumed.  The [18O]-KIE was also measured for the 
background oxygen consumption (at 11 μM FMN and 1.5 mM NADH), for comparison 
with the enzymatic reaction.  The [18O]-KIE experiments were conducted by Dr. Liviu 
Mirica in the lab of Prof. Judith Klinman at the University of California at Berkeley. 
 
5.2.17. CALCULATION OF 18O EQUILIBIUM ISOTOPE EFFECTS. The [18O]-EIEs for 
the reactions with O2 were determined as the product of three terms, ZPE, EXC and 
MMI, see Equation 5-1.45,46  All three terms are related to vibrational frequencies (ν) of 
18O– and 16O–containing reactants (R ≡ O2) and products (P), as shown in Equations 5-3, 
5-4 and 5-5, where the asterisk denotes the 18O-containing reactants or products, T is 
temperature in K, h is Planck’s constant, and k is Boltzmann’s constant.31  
Experimentally determined frequencies for Fe(III)-OO•, Fe(III)-OOH,47,48 and Fe(IV)=O 
species49 were used for calculation of the [18O]-EIE (Table 5-3).  For the asymmetric 
Fe(III)-O2• and Fe(III)-OOH, species, the 18O label can be at either the central or terminal 
position.  The populations of the two isotopic products are expected to be close to each 
other, hence the [18O]-EIE was calculated using the formula: [18O]-EIEcalc = 2/(18,16K–1 + 
16,18K–1).  The [18O]-EIE calculations were conducted by Dr. Liviu Mirica in the lab of 




































































































































Table 5-3: Vibrational frequencies (cm–1) of O2, H2O, and Fe/O2 species. 
Frequency (cm-1) Molecule Mode 
ν16-16a ν18-18a ν18-16a ν16-18a 
O2 O–Ob 1556 1467 1512 1512 
H2O H–Ob 3824 -c 3824 - 
 H–Ob 3939 - 3922 - 
 H-O-Hb 1654 - 1644 - 
Fe(III)-OO• Fe–Od 555 526 526 555 
 O–Od 1136 1066 1100e 1100e 
Fe(III)-OOH Fe–Of 621 599 599 621 
 O–Of 844 796 820e 820e 
 O–Hb 3539 - 3527 3539 
 O-O-Hb 1205 1199 1199 1204 
Fe(IV)=O Fe–Og 821 - 787 - 
a) Frequencies νx-x represent the modes for the species derived from x,xO2, the first label 
corresponding to the O atom closest to the metal center; b) Ref 31; c) Not applicable; d) Ref 50; 
e) ν18-16 was calculated as follows: ν18-16 = (ν16-16 ν18-18)½; f) Ref 48; g) Ref 49. 
 
5.3. RESULTS AND DISCUSSION 
5.3.1. CLONING, OVEREXPRESSION, AND PURIFICATION OF PS-HPPE.  The 
gene, orf3, coding for Ps-HppE which catalyzes the last step of fosfomycin biosynthesis 
in Pseudomonas syringae PB-5123, was amplified by PCR and cloned into the 
expression vector pET24b(+).  The resulting construct, pLH01, was used to transform E. 
coli BL21(DE3) cells.  The induction of orf3 expression by IPTG was conducted at 18 °C 
to minimize the formation of inclusion bodies. 
As shown in SDS-PAGE (Figure 5-5), the desired protein was isolated in nearly 
homogeneous form after ammonium sulfate fractionation and two anion exchange 
chromatographic steps (DEAE-Sepharose and MonoQ).  The subunit molecular mass of 
21 kDa, assessed by SDS-PAGE, correlates well with the predicted value of 21,315 Da 
calculated from the deduced amino acid sequence.  As determined by size exclusion 
chromatography, the purified recombinant Ps-HppE has a mass of 73 kDa in solution.  
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When Sw-HppE, which has a mass of 21,210 Da as a monomer, was analyzed under the 
same conditions, it yielded a mass of 95 kDa.  Based on the results of  X-ray 
crystallography, Sw-HppE has been determined to exist as a homotetramer.41  Since the 
observed mass for Sw-HppE is 11 kDa higher than the predicted mass for a 
homotetramer, and the Ps-HppE is 10 kDa higher than the predicted mass for a 
homotrimer, Ps-HppE likely exists as a homotrimer instead of homotetramer.  
Determination of the crystal structure for Ps-HppE is in progress, and the results will 






Figure 5-8: SDS-PAGE gel of as-purified (apo) Ps-HppE. 
 
5.3.2. SEQUENCE ANALYSIS. The epoxidation reaction catalyzed by Ps-HppE is 
identical to that catalyzed by Sw-HppE and is the final step in the biosynthesis of 
fosfomycin.  Interestingly, amino acid sequence alignment showed that the two enzymes 
share only 27% identity (Figure 5-6).  However, the residues that have been determined 
to be crucial for Sw-HppE are conserved in Ps-HppE.  These include Lys21, Tyr92, 
Tyr93, Tyr95, His128, Glu132, and His171 (the numbering given is based on the Ps-
HppE sequence).  His128, Glu132, and His171 are assigned to be the ligands responsible 
for iron binding in Ps-HppE, since the corresponding residues; His138, Glu142, and 
His180; in Sw-HppE have been determined to be the metal binding residues.41,51  The 
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proposed role for Lys21 in Ps-HppE is to stabilize the negative charge on the iron-peroxo 
intermediate generated during oxygen activation.  A similar function has been assigned to 
its counterpart, Lys23, in Sw-HppE based on the crystal structure as well as the 
mutagenesis results.41  The three conserved tyrosine residues; Tyr92, Tyr93, and Tyr95; 
are proposed to be part of a relay for shuttling electrons derived from NADH from the 
protein surface to reduce the active site iron.  This is based on the observation from the 
crystal structure of Sw-HppE, which undergoes a significant conformational change upon 
(S)-HPP binding.  It was noted that the three conserved tyrosine residues in the enzyme-
substrate complex align themselves in a row constituting a pathway extending from the 
surface of the protein to the active site.41 
 
Sw-HppE      1     MSNTKTASTGFAELLKDRREQVKMDHAALASLLGETPETVAAWENGEGGELTLTQLGRIA
Ps-HppE      1     M-DVRTLAVGKAHLEA-LLATRKMT---LEHLQDVRHDATQVYFDG------LEHLQNVA
Consensus               T   G A L        KM    L  L             G      L  L   A
Sw-HppE     61     HVLGTSIGALTP-PAGNDLDDGVIIQMPDERPILKGVRDNVDYYVYNCLVRTKRAPSLVP 
Ps-HppE     50     QYLAIPLSEFFVGQTQSDLDDGVKIARRNGGFKREEIRGGVHYYTYEHLVTTNQDPGLMA 
Consensus            L              DLDDGV I            R  V YY Y  LV T   P L  
Sw-HppE    120     LVVDVLTDNPDDAKFNSGHAGNEFLFVLEGEIHMKWG-DKENPKEALLPTGASMFVEEHV 
Ps-HppE    110     LRLDLHSDDEQPLRLNGGHGSREIVYVTRGAVRVRWVGDNDELKEDVLNEGDSIFILPNV 
Consensus          L  D   D       N GH   E   V  G     W  D    KE  L  G S F    V
Sw-HppE    179     PHAFTAAKGTGSAKLIAVNF-
Ps-HppE    170     PHSFTNHVGGAKSEIIAINYG
Consensus          PH FT   G      IA N
 
Figure 5-9: Protein sequence alignment of Ps-HppE and Sw-HppE. 
 
5.3.3. RECONSTITUTION OF EPOXIDASE ACTIVITY. As described above, Ps-HppE 
and Sw-HppE catalyze the same reaction, and the residues important for catalysis are 
conserved in both enzymes.  Thus, it is very likely that Ps-HppE utilizes the same 
chemistry as Sw-HppE to catalyze the epoxide formation.  To verify this contention, the 
as-purified Ps-HppE was reconstituted using the same procedures developed for Sw-
HppE with ferrous iron and assayed under aerobic conditions in the presence of FMN, 
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NADH and (S)-HPP.19  Formation of the product, fosfomycin (6), was detected by 
HPLC, and its chemical identity verified by 1H and 31P NMR.  If either iron, FMN or 
NADH was omitted from the reaction mixture, no product formation was discernible by 
HPLC.  Our results showed that NADH is essential and is consistent with its role to 
provide two of the four electrons needed for oxygen activation and the conversion of 
molecular oxygen to water (Figure 5-2).  FMN is also required.  This requirement may 
be ascribed to its role as an electron mediator in the reduction of the metal center by 
NADH.  Since oxygen is used to activate the iron center, when the incubation was carried 
out under an anaerobic environment, no epoxidase activity could be detected by the 
HPLC-based enzyme assay. 
 It was reported in a recent publication that Sw-HppE was not strictly iron-
dependent, because the zinc reconstituted enzyme retained reduced but measurable 
activity.52  Since zinc ion is redox-inert, a new mechanism that does not involve the 
reductive activation of molecular oxygen was proposed.  In this mechanism (Figure 5-7), 
the divalent metal ion acts as a Lewis acid to activate the C-2 hydroxyl group, which 
attacks C-1 with concurrent transfer of the pro-R hydrogen as a hydride to FMN.  It was 
later determined that the observed activity with the zinc Sw-HppE was an artifact.53  This 
“nucleophilic displacement-hydride transfer” mechanism could also be ruled out for Ps-
HppE, since no epoxidase activity could be detected with zinc reconstituted Ps-HppE.  
To explore if other redox active metals could substitute iron in the epoxidase assay, the 
catalytic property of Ps-HppE reconstituted with cobalt, copper and manganese was 
investigated.  No turnover could be detected using Ps-HppE carrying any of these metals.  
The fact that the addition of 5 mM EDTA abolished the activity of the iron reconstituted 










































Figure 5-10: Proposed nucleophilic displacement-hydride transfer mechanism for HppE. 
When using (R)-HPP (38) as the substrate, Sw-HppE catalyzed the conversion of 
the C-2 hydroxyl group to a ketone to yield 2-oxopropylphosphonic acid (39) as the 
product (Figure 5-8).54  Further investigation indicated that the stereochemistry at the C-
2 position of HPP determines the regiospecificity of the initial hydrogen atom 
abstraction.  In the mechanism depicted in Figure 5-2, when (S)-HPP binds to Sw-HppE, 
the C-1 pro-R hydrogen atom is abstracted, which leads to the production of fosfomycin.  
However, when (R)-HPP binds to Sw-HppE, it is believed that the C-2 hydrogen atom is 
abstracted, which leads to the formation of 2-oxopropylphosphonic acid (39).  It was 
investigated if Ps-HppE utilizes this method to control the regiospecificity of the initial 
hydrogen atom abstraction.  When the above activity assays for Ps-HppE where 
conducted using (R)-HPP as the substrate, the product 2-oxopropylphosphonic acid (39) 
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Figure 5-11: The HppE catalyzed reaction with (R)-HPP as the substrate. 
 
5.3.4. ACTIVITY FOR (S)-HPP AND (R)-HPP. To determine how the activity of Ps-
HppE compares to Sw-HppE, the rate of catalysis was determined separately using (S)-
HPP (5) and (R)-HPP (38) at saturating concentration.  To determine the optimal 
substrate concentration for the assay, the amount of product formation was measured 
after 20 min incubation using 5, 10, 15 and 20 mM substrate.  Since all four substrate 
concentrations resulted in the same amount of product formation, 10 mM substrate was 
set as the saturating concentration.  Due to the reduced activity of Ps-HppE with respect 
to Sw-HppE, the concentrations of Ps-HppE, Fe(NH4)2SO4 and FMN were doubled.  The 
ratio of 1:1:1.5 for HppE to Fe(NH4)2SO4 to FMN was held constant for all assays. 
 
Table 5-4:  Rate constants for reactions at 1.5:1 FMN to HppE ratio. 
Substrate Ps-HppE Sw-HppE 
(S)-HPP (5) 
kobs (min-1) 
0.17 ± 0.02 0.31 ± 0.06 
(R)-HPP (38) 
kobs (min-1) 
0.33 ± 0.04 0.58 ± 0.02 
 
As seen in Table 5-4, the observed rate constants for both enzymes with both 
substrates are of similar magnitudes.  Two observations are worthy of comments.  The 
first is that the Sw-HppE is roughly 1.8 times faster than Ps-HppE for both (S)-HPP and 
(R)-HPP.  It appears that Sw-HppE is a more effective epoxidase.  Secondly, the reaction 
rate for (R)-HPP (38) is 1.9 times faster than that for (S)-HPP (5) using either Sw-HppE 
or Ps-HppE.   
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To determine how rate-limiting hydrogen atom abstraction is for the (S)-HPP (5) 
and (R)-HPP (38) reactions, the 1° [2H]-KIE was determined for both.  It has previously 
been demonstrated that the C-1 pro-R hydrogen atom is abstracted in the conversion of 
(S)-HPP to fosfomycin,55 and for the turnover of (R)-HPP to 39, it is the C-2 hydrogen 
atom that is abstracted.54  When the [2H]-KIE was determined for the (S)-HPP reaction, 
using (S)-1,1-[2H]2-HPP (35) as the labeled substrate and at a FMN to Ps-HppE ratio of 
1.1:1, a [2H]-KIE of 1.10 ± 0.04 was measured.  Since this [2H]-KIE was determined with 
(S)-1,1-[2H]2-HPP (35), it results from the 1° [2H]-KIE on hydrogen atom abstraction and 
from the 2° [2H]-KIE on radical formation (sp3 to sp2) and ring-closure (sp2 to sp3).   The 
2° [2H]-KIE on radical formation will be small and normal, while the 2° [2H]-KIE on 
ring-closure will be small and inverse.  Since ring-closure is not expected to be 
significantly rate-limiting, the impact of the inverse isotope effect should be small.  
Either way, due to the difference in magnitude of a 1° [2H]-KIE versus a 2° [2H]-KIE; the 
measured [2H]-KIE will be dominated by the 1° [2H]-KIE.  The 1° [2H]-KIE for the (R)-
HPP (38) reaction was determined with (R)-2-[2H]-HPP (20) as the labeled substrate and 
at an FMN to Ps-HppE ratio of 1.5:1.  The measured 1° [2H]-KIE was 1.07 ± 0.07.  The 
observed [2H]-KIEs for both reactions are smaller than is expected for a 1° [2H]-KIE; 
therefore, a step other than hydrogen atom abstraction is rate-limiting, presumably 
electron transfer to the active site iron. 
It is known that the rate of reaction increases with increasing FMN, presumably 
due to an increased rate in electron transfer to the active site iron.  In order to reduce the 
commitments to catalysis, which could have masked the previous 1° [2H]-KIEs, the [2H]-
KIEs were re-measured at an FMN:Ps-HppE  ratio where the rate enhancement of FMN 
is saturated.  To determine this saturating FMN:Ps-HppE  ratio, the (R)-HPP reaction was 
conducted at varying ratios of FMN:Ps-HppE.  At each ratio, the reaction incubated for 
 157
20 min before being quenched and analyzed by HPLC.  The amount of product (39) 
formed was plotted versus the respective FMN:Ps-HppE  ratio.  From the plot in Figure 
5-12, an FMN to Ps-HppE ratio of 50:1 was chosen.  It was assumed that this ratio is 
saturating for the (S)-HPP reaction as well.  For the (S)-HPP [2H]-KIE measurement at 
this FMN ratio, (1R,2S)-1-[2H]-HPP (31) was used as the labeled substrate; therefore 
there is no 2° [2H]-KIE to complicate the analysis.  From the results in Table 5-5, it is 
evident that hydrogen atom abstraction does become more rate-limiting for the (S)-HPP.  
The measured 1° [2H]-KIE is smaller than what would be expected for an intrinsic 1° 
[2H]-KIE.  Thus the hydrogen abstraction step is believed to be partially rate-limiting, 
and electron transfer may still be the predominant rate-limiting step.  For the (R)-HPP 




















Figure 5-12: Plot of the product (39) from the reaction of (R)-HPP (38) with Ps-HppE at 
varying ratios of FMN to Ps-HppE. 
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Table 5-5: Summary of 1° [2H]-KIE results at a different FMN to Ps-HppE ratios. 





Substrate kobs dkobs kobs dkobs kobs dkobs 






0.03 1.5 ± 0.2 ND ND ND ND 
(S)-1,1-[2H]2-HPP 





(R)-HPP (38) 1.12 ± 0.1 -- 0.45 ± 0.03 -- ND -- 




0.07 ND ND 
 
The reduced rate for the Ps-HppE reaction with (S)-HPP compared to with (R)-
HPP reaction and the small but significant 1° [2H]-KIE for (S)-HPP versus the KIE of 
unity for (R)-HPP implies that hydrogen atom abstraction is slower and more rate-
limiting for (S)-HPP than (R)-HPP.  There are two possible explanations for the 
difference in rates for C-2 hydrogen atom abstraction in the (R)-HPP reaction versus C-1 
hydrogen atom abstraction in the (S)-HPP reaction.  It is possible that the C-2 hydrogen 
for bound (R)-HPP is closer to the reactive oxygen species than the C-1 hydrogen for the 
bound (S)-HPP, thus reducing the barrier for abstraction.56  The rate difference is likely 
due to the difference in the energetics of the hydrogen being abstracted and the stability 
of the resulting substrate radical.  Based on DFT calculations, the bond dissociation 
energies (BDE) for the C-1 hydrogen and the C-2 hydrogen are 96.5 and 89.0 kcal/mol, 
respectively.  Thus, the thermodynamic energy barrier for hydrogen atom abstraction in 
the (R)-HPP reaction is 7.5 kcal/mol lower than in the (S)-HPP reaction.  This may 
account for the observed rate difference of the two substrates. 
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5.3.5. EPR CHARACTERIZATION OF PS-HPPE.  EPR spectra of Ps-HppE-
Fe(II) nitrosyl complexes, in the presence and absence of substrate, are shown in Figure 
5-13.  The corresponding EPR spectra of Sw-HppE-Fe(II) are also shown in this figure in 
dashed traces for comparison.  In the absence of (S)-HPP (5), the EPR spectrum of the 
Ps-HppE-NO complex consists of two sets of axial EPR signals of the Fe-nitrosyl 
complexes in an 88:12 ratio.  The major axial species exhibits an isotropic resonance 
component at g = 3.96 and a V-shaped resonance at 2.00 (not shown).  This is typical for 
an S = 3/2 non-heme {Fe-NO}7 species with  an E/D value of 0.01 and D > 0.  The minor 
species is also an S = 3/2 {Fe-NO}7 complex, but less axial, with principal g values of 
4.30, 3.69, and 2.00 (E/D value of 0.05).  In contrast, an apparent heterogeneity is 
observed for Sw-HppE, with two similar species present in a 3:7 ratio.19  Thus, the Fe(II) 






Figure 5-13: EPR spectra of reduced HppE-Fe(II) nitrosyl complexes at 4 K: (A) 250 μM 
Ps-HppE (solid trace) or Sw-HppE (dashed trace) in the presence of NO; (B) 
the ternary complex of substrate-HppE- NO (Ps-HppE, solid trace; Sw-
HppE, dashed trace).  Substrate was present in 10-fold excess. The spectrum 
shown also contains a minor species (ca. 5%) due to a denatured protein-
bound Fe-NO complex (g = 4.07) which was previously characterized.19  
Instrumental conditions: microwave power, 0.5 mW; modulation amplitude, 
5 G; time constant, 0.02 s; and sweep rate: 50 G/s. The g-scale is plotted on 
the top of the spectra. 
 
Although the ferrous center of Sw-HppE can react with NO and form two 
spectroscopically distinguishable complexes, we have previously found that only a 
uniform substrate-Fe-NO complex of Sw-HppE (g = 4.42, 3.63, and 1.97, E/D = 0.066) is 
formed in the presence of substrate (S)-HPP (5).19  These results suggested that the 
substrate likely binds to the active site iron center first, and as such organizes the center 
to bind NO, an O2 analogue, only in one conformation.  In contrast, in the presence of 
(S)-HPP, the EPR spectrum of the nitrosyl complex of Ps-HppE-Fe(II) presents apparent 
heterogeneity.  Two sets of EPR signals are observed (in a 3:7 ratio); both can be 
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attributed to the substrate-enzyme-NO ternary complexes.  This is opposite to the prior 
Sw-HppE result.  The minor ternary complex (30%) observed for Ps-HppE exhibits the 
same EPR parameters as those previously observed for Sw-HppE (g = 4.42, 3.63, and 
1.97, E/D = 0.066).  The major ternary complex (70%) having g = 4.33, 3.74, and 2.00, 
E/D = 0.059, is less rhombic. 
The above results indicate that substrate and NO could bind to the ferrous center 
of the reduced Ps-HppE enzyme to form a stable complex.  But the heterogeneity EPR 
signals observed for the ternary complex of Ps-HppE suggest that substrate binding to the 
active site Fe(II) ion may lead to two different conformations.  Our recent isotope 
labeling study showed that the uniform EPR signal for the ternary complex of Sw-HppE 
is a result of the substrate coordination to the Fe(II) ion in a bidentate fashion.57  This 
same species is also seen in the Ps-HppE ternary complex, albeit it represents only 30% 
of the total iron.  The remaining 70% of the ternary complex may be in a form of 
monodentate coordination of substrate onto the metal center.  This is an intermediate step 
towards the bidentate binding to the active site Fe ion. 
 
5.3.6. POST-TRANSLATIONAL HYDROXYLATION OF PS-HPPE.  The reconstituted 
ferrous form of Ps-HppE is colorless.  However, when the protein is exposed to air, it 
slowly turns green in color. The optical spectrum of this green protein exhibits a broad 
band around 600-750 nm having a λmax at 672 nm with a molar absorption coefficient of 
approximately 409 (M of Fe)-1·cm-1 (Figure 5-14).  A similar peak formed with a λmax at 
680 nm and a molar extinction coefficient of 450 (M of Fe)-1·cm-1 was previously 
observed when the reconstituted ferrous form of Sw-HppE was exposed to air.19  Further 
investigation showed that the color change in Sw-HppE is due to a post-translational 
hydroxylation of Tyr105 to DOPA.39  The green chromophore arises from a ligand to 
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metal charge transfer transition of a bidentate catecholate-iron (III) complex formed 
between the active-site iron center and the modified tyrosine.  A similar post-
translationally hydroxylate ion of Tyr95 (the Tyr105 equivalent in Ps-HppE) to DOPA, 
may also occur when ferrous reconstituted Ps-HppE is exposed to air leading to the 
formation of the bidentate catecholate-iron (III) complex. 
 
 
Figure 5-14: Electronic absorption spectrum of as-purified Ps-HppE that has been 
reconstituted with 1.1 equivalents of Fe(NH4)2(SO4)2.  
 
To verify the occurrence of the catecholate residue, the isolated Ps-HppE was 
subjected to the Paz’s quinone staining reagents including glycine and nitroblue 
tetrazolium (NBT).38  If a quinone is present, it can oxidize the glycine in solution.  The 
reduced quinone then reacts with dioxygen to generate superoxide, which oxidizes NBT 
to generate a blue-purple compound.  As shown in Figure 5-15, the stain produced a 
positive result indicating the presence of quinone in Ps-HppE.  It is therefore highly 
likely that Tyr95 is post-translationally hydroxylated to DOPA.  The significance of this 






















Figure 5-15: As-purified Ps-HppE was run on SDS-PAGE gel and transfered 
electrophoritically to nitrocellulose membrane.  The membrane is then 
temporarily stained for proteins with Ponccaus (left) and then NBT stained 
(right) to detect the presence of quinone. 
5.3.7. [18O]-KIE Analysis of Ps-HppE. 
1-fraction conversion









Figure 5-16: Isotope fractionation plots for (S)-HPP (5) (●) and (S)-1,1-[2H]2-HPP (35) 
(■).  The fits for obtaining [18O]-KIEs are shown in solid for (S)-HPP (5) and 
dashed for (S)-1,1-[2H]2-HPP (35). Conditions: Ps-HppE: 10 μM HppE, 0.4–
0.6 mM O2, 1 mM (S)-HPP or (S)-1,1-[2H]2-HPP, 11 μM FMN, 1.5 mM 
NADH, 20 mM Tris-HCl (pH 7.5), 25 ºC. 
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The [18O]-KIE was determined from the data in Figure 5-16 for the Ps-HppE 
reaction with (S)-HPP and separately with (S)-1,1-[2H]2-HPP (35), and these values are 
reported in Table 5-6.  As described above, the values in Table 5-6 are [18O]-KIEs on 
kcat/KM(O2), which reflect changes in the oxygen bond order that occur in all steps from 
initial O2 binding up to and including the first irreversible step.44  To help interpret the 
measured [18O]-KIEs, [18O]-EIEs were calculated from vibrational frequencies from 
Table 5-3 of the reactants and possible oxygen products, following the formalism 
developed by Bigeleisen and Mayer.45  These calculated [18O]-EIEs (see Table 5-7) can 
be used as upper limits for the measured [18O]-KIEs,30,32,33 allowing a direct comparison 
between model reactions and experimental values. 
 
Table 5-6: Summary of experimental [18O]-KIEs 
Substrate [18O]-KIE 
(S)-HPP (5) 1.0120 ± 0.0002 
(S)-1,1-[2H]2-HPP (35) 1.0136 ± 0.0002 
 
Table 5-7: Calculated [18O]-EIEs using vibrational frequencies. 
Reaction ZPE EXC MMI [18O]-EIEcalc [18O]-EIEneta 
Fe(II) O2 Fe(III)-O2+       
Fe-18O-16O• 0.9493 0.9887 1.0590 0.9939  
Fe-16O-18O• 1.0193 0.9994 1.0037 1.0224 1.0080 
      
Fe(II) O2 Fe(III)-OOH+
e-, H+
      
FeIII-18O16OH 0.9947 0.9921 1.0370 1.0234  
FeIII-16O18OH 1.0044 0.9979 1.0087 1.0110 1.0172 
      
Fe(II) O2 Fe(IV)=O + H2O+
2e-, 2H+
 
     
FeIV=18O, H216O 1.0239 0.9967 1.0138 1.0347  
FeIV=16O, H218O 1.0414 1.0001 0.9820 1.0228 1.0287 
a The net 18O EIE was calculated using the formula: 18EIEnet = 2/(18,16EIE–1 + 16,18EIE–1).31 
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Comparing the measured [18O]-KIE for (S)-HPP (5) of 1.0120 ± 0.0002 with the 
calculated [18O]-EIEs, the oxygen product formed in the rate-limiting step appears to be 
Fe(III)-hydroperoxide, which would be either species 10 or 11 in Figure 5-2.  The [18O]-
KIE is slightly lower than the calculated [18O]-EIE for Fe(III)-hydroperoxide of 1.0172; 
however, it is similar to the experimentally determined [18O]-EIE of 1.0113 ± 0.0005 for 
Hr, which does form a Fe(III)-OOH as its product.31  From the [18O]-KIE measured with 
(S)-1,1-[2H]2-HPP (35) as the substrate (1.0136 ± 0.0002), it can be concluded that the 
[18O]-KIE is mechanistic in origin.  If the [18O]-KIE was dominated by O2 binding, the 
[18O]-KIE would not change when measured with a deuterated substrate.  The fact that 
the [18O]-KIE did increase when (S)-1,1-[2H]2-HPP (35) was the substrate also implies 
that the step giving rise to the [18O]-KIE becomes more rate-limiting with the deuterated 
substrate.  The change in [18O]-KIE with (S)-1,1-[2H]2-HPP (35) as the substrate also 
requires that hydrogen atom abstraction occurs before or in the first irreversible step.  The 
first irreversible step is believed to be the first electron transfer from reduced FMN to the 
active site iron.  If Fe(III)-superoxide (9) (path a in Figure 5-2) is the reactive species, 
the first irreversible step will be 10→13, and if either Fe(III)-hydroperoxide (11) or 
Fe(IV)-oxo (12) (paths b and c in Figure 5-2, respectively), then the first irreversible 
step will be 9→11.  If the reactive species was either Fe(III)-hydroperoxide (11) or 
Fe(IV)-oxo (12) is the reactive species, hydrogen atom abstraction will occur after the 
first irreversible step; thus there would be no change in the [18O]-KIE when using the 
deuterated substrate.  Of the different mechanisms depicted in Figure 5-2, only in path a, 
where Fe(III)-superoxide (9) is the reactive species, does hydrogen atom abstraction 
occur before or in the first irreversible step. Therefore, based on the increase in the [18O]-
KIE when using the deuterated substrate, (S)-1,1-[2H]2-HPP (35), versus (S)-HPP; the 
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reactive oxygen species in the Ps-HppE reaction, and presumably the Sw-HppE reaction, 
is Fe(III)-superoxide (9). 
Superoxide has been proposed as the reactive oxygen species in the copper-
dependent enzymes, dopamine β-monooxygenase (DβM)58 and peptidylglycine α-
amidating monooxygenase (PHM),59 in the binuclear non-heme iron dependent, myo-
inositol oxygenase (MIOX),60 and in the mononuclear non-heme iron-dependent, 
isopenicillin N-synthase (IPNS).25  The mechanism of IPNS is displayed in Figure 5-17.  
The IPNS reaction begins with the binding of the substrate, δ-(L-α-aminoadipoyl)-L-
cysteinyl-D-valine (ACV, see 41).25,61  The binding of the thiolate group of ACV to the 
active site iron produces a five-coordinate iron, which leaves the sixth site open for 
oxygen binding.  Dioxygen now binds to the ferrous iron at the available coordination 
site, where it is reduced by an inner-sphere electron transfer from iron(II) to yield Fe(III)-
superoxide (42).  The reactive species for the first oxidative ring closure, formation of the 
β-lactam ring, is believed to be this Fe(III)-superoxide (42); however, it has not been 
experimentally verified.  The Fe(III)-superoxide (42) is believed to abstract a hydrogen 
atom from the cysteine β-carbon to form the substrate radical and Fe(III)-hydroperoxide 
(43).  The substrate is then further oxidized by a second single electron transfer to the 
iron to form the thioketone and Fe(II)-hydroperoxide (44).  The O-O bond of the 
peroxide is then cleaved heterolytically to generate Fe(IV)-oxo (45), which abstracts the 
unactivated hydrogen atom from the valine β-carbon.  Similar in fashion to the oxygen 
rebound mechanism of cytochrome P450 and the ring-closure reaction proposed for 
HppE (Figure 5-2), the resulting substrate radical attacks the thiolate to close the 
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Figure 5-17: Proposed mechanism of isopenicillin N-synthase (IPNS). 
 
Fe(III)-superoxide (42) has not been experimentally verified as the reactive 
species for IPNS, as it has for MIOX60 and DβM.58  Through the use of semi-empirical 
density functional theory (DFT) calculations that were guided by variable-temperature, 
variable-field magnetic circular dichroism (VTVH-MCD) experiments, the labs of Profs. 
Lipscomb and Solomon were able to determine Fe(III)-superoxide (42) to be an 
energetically accessible reactive species for the IPNS reaction.26  The formation of an 
Fe(III)-superoxide species is not typically a favored reaction.  In other mononuclear non-
heme iron-dependent enzymes, this is overcome by distal oxygen inserting itself into 
either the substrate, as in extradiol catechol dioxygenases, or co-substrate, as in the α-
KG- and pterin-dependent enzymes.  They determined that the charge donation from the 
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thiolate of ACV stabilizes the oxidation Fe(II) to Fe(III), which allows the IPNS-ACV 
complex to form a now energetically favorable Fe(III)-superoxide complex (42). 
It is possible that HppE utilizes a similar strategy to stabilize the HppE-Fe(III)-
superoxide complex (9) from charge donation.  From EPR and X-ray crystallography 
results with Sw-HppE, it is known that (S)-HPP (5) binds the iron in a bidentate manner 
(8) through the hydroxyl group and a phosphonate oxygen.41,57  Thus, there could be 
stabilizing charge donation from the C-2 oxygen, assuming it is deprotonated when 
bound to iron, and/or from the phosphonate oxygen.  It is also possible that the positively 
charged Lys21 (Lys23 in Sw-HppE) stabilizes the negative charge that develops on 
oxygen in the superoxide complex.  Thus HppE could stabilize the Fe(III)-superoxide 
species (9) in a push-pull type manner.  This Fe(III)-superoxide stabilizing mechanism 
will also prevent the formation of a reactive oxygen species that could possibly damage 
the enzyme if the substrate is not present.  Compared to other metaloenzymes where a 
metal-superoxide is believed to be the reactive species that abstracts a hydrogen atom 
from the substrate, the BDEs of the abstracted hydrogen atom in those cases are all lower 
than the BDE of the hydrogen atom that is abstracted in the (S)-HPP (5) reaction (see 
Table 5-8).  The closest in energy is the β-C-H bond in the IPNS reaction, the only other 
mononuclear non-heme iron enzyme proposed to utilize metal-superoxide as the reactive 
species.  Thus the C-1 hydrogen of (S)-HPP (5) has the highest thermodynamic energy 






Table 5-8: Summary of BDEs of the different hydrogen atoms abstracted by a metal-
superoxide. 
Enzyme BDE of H-atom abstracted (kcal/mol) 
HppE ((S)-HPP, 5) 96.5 




IPNS (β-C-H bond) 93d 
a) Ref. 62; b) Ref. 63; c) Ref. 64; d) Ref. 65. 
 
5.4 CONCLUSION 
In this study, the newly isolated Ps-HppE was established to be an iron dependent 
enzyme, which catalyzes the same reactions and requires the same components; iron, 
FMN, NADH, and O2; as Sw-HppE.   As implicated by the EPR results, dioxygen is 
activated in the reaction with the aid of ferrous iron, to a reactive species in order to 
abstract a hydrogen atom from the substrate.  To complete the oxygen activation cycle, 
four electrons are consumed.  Two of the electrons are supplied by the substrate, and the 
remaining two are provided by NADH.  Due to the fact that reduction of iron requires 
single electron transfer and NADH is incapable of single electron transfer, FMN is 
needed to mediate the two single electron transfers from NADH to reduce the active site 
iron.  Since no suitable reductase gene can be found in the S. wedmorensis and P. 
syringae fosfomycin biosynthetic gene clusters, a promiscuous reductase may serve the 
role as electron mediator in vivo. 
On the basis of sequence comparison with Sw-HppE, Ps-HppE utilizes two 
histidines and one glutamate residue as ligands to bind the active site iron.  Thus, Ps-
HppE is a new member of the growing superfamily of non-heme iron-dependent enzymes 
that contain the 2-His-1-carboxylate facial triad to bind and activate iron.  This family of 
enzymes have proven to be remarkably versatile in the types of reactions they catalyze.20  
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According to Koehntop et al., this superfamily of enzymes can be devided into five 
classes: extradiol cleaving catechol dioxygenases, Rieske dioxygenases, α-ketoglutarate-
dependent enzymes, pterin-dependent enzymes, and “other” oxidases.66  The fifth family 
of enzymes is described as a “catch all” for the unique enzymes that can not be included 
in one of the other four families.  The “other” family includes IPNS, 1-
aminocyclopropane-1-carboxylic acid oxidase and Sw-HppE.  From the results reported 
herein, Ps-HppE has been demonstrated to require the same components for activity and 
catalyze the same unique reaction as Sw-HppE.  Ps-HppE is therefore a second example 
of a member in the superfamily of enzymes that utilize the 2-His-1-carboxlyate facial 
triad that catalyzes this unusual epoxidation reaction, and it can be further subdivided as a 
member of the “other” division in this superfamily. 
Based on the comparison of the measured [18O]-KIE to the calculated [18O]-EIEs, 
Ps-HppE forms Fe(III)-hydroperoxide (10) in the rate-limiting step (looking up to and 
including the first irreversible step).  When the [18O]-KIE was measured using a 
deuterated (S)-HPP that would produce a 1° [2H]-KIE on hydrogen atom abstraction, the 
[18O]-KIE increased.  Since the [18O]-KIE only takes into account the steps up to and 
including the first irreversible step, the hydrogen atom abstraction must occur before or 
be part of the first irreversible step to have an effect on the [18O]-KIE.  When the 
proposed mechanisms for the different possible reactive oxygen species (see Figure 5-2) 
were examined for when hydrogen atom abstraction occurred in relation to the first 
irreversible step, only in the mechanism with Fe(III)-superoxide (9) as the reactive 
species did hydrogen atom abstraction occur before or in the first irreversible step.  
Therefore, the reactive oxygen species that abstract the C-1-hydrogen of (S)-HPP (5), and 
presumably the C-2 hydrogen of (R)-HPP (38), in the HppE reaction is Fe(III)-superoxide 
 171
(9).  This is the first experimental evidence of Fe(III)-superoxide as the reactive oxygen 
species in a mononuclear non-heme iron-dependent enzyme. 
The method of C-O bond formation catalyzed by Sw-HppE was believed to be 
unique among Nature; however, with the characterization reported herein of Ps-HppE, it 
is evident that there is another example.  In these two reactions, an important factor is 
believed to be the coordination of the reacting oxygen to the active site iron.  There are 
two α-KG dependent enzymes, hyoscyamine 6β-hydroxylase (H6H)67 and clavaminic 
acid  synthase (CAS),68 that catalyze similar C-O bond formations (see Figure 5-18); 
however, for the standard oxygen activation mechanism in α-KG dependent enzymes,24 
there is no available coordination site for the reacting oxygen.  It will be interesting to 
determine if the chemistry utilized by Sw-HppE and Ps-HppE for C-O bond formation is 
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